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ABSTRACT
The RecQ family of helicases has been termed the “Caretakers of the Genome,”
and rightfully so. These proteins are highly conserved from bacteria to humans and
have been implicated in functions from homologous recombinatorial repair to damage
checkpoint response to telomere maintenance and more. Mutant genes of three of the
human RecQ helicases lead to syndromes characterized by a high incidence of cancer,
premature aging and early death. Despite their implications in several biological
functions and importance to the integrity of the human genome and suppression of
cancer, many aspects of the RecQ family structure and function remain unknown. To
date, much is known about the catalytic function of the helicase domain and
accompanying domains, but considerably less is known about the non-catalytic Nterminus in these proteins, which, in many cases, including those human orthologs
involved in disease, can make up about half of the total protein length. While
experiments have been able to identify protein partners that interact with the N-terminal
region, few are able to narrow the binding sites to minimally functional parts and fewer
still describe any detail regarding the structural features of these binding areas. In fact,
some reviews have generally described the N-terminus as “featureless,” a concept we
challenge in our studies.
Many of the N-termini of these RecQs have long been known to contain large
stretches of acidic residues, a feature of intrinsically disordered regions. These
xii

regions/proteins are rich in charged and polar residues, lack compactness that makes
crystallography possible, and have flexible and dynamic conformations that are
prevalent in “high specificity, low affinity” interactions. Disordered proteins are wellknown to be hot spots for protein/protein interactions and post-translational
modifications, amongst other functions. Considering these facts, and recognizing the
ties between these and what we know about the N-termini of the RecQs, we
hypothesized that these proteins likely have long disordered termini. In Chapter 3, we
confirm the presence of disorder at the Top3/Rmi1 binding site on Sgs1, the
Saccharomyces cerevisiae RecQ helicase. We show that even in a disordered state,
this binding region is not “featureless,” but in fact contains a transient alpha-helical
molecular recognition element that is necessary to facilitate complex formation between
Sgs1, Top3 and Rmi1. Loss of helical structure at this site leads to increased genomic
instability and sensitivity to DNA damaging agents. Based on these results, we suggest
that there are likely many more such elements in the N-terminus that that are important
for other Sgs1 protein/protein interactions and provide an estimate for the number of
interactions in this region.
In Chapter 4, we evaluate the prevalence of disorder in a set of Chromatin
Processes proteins in an effort to establish a role for disorder with regards to
maintaining chromatin integrity. In our bioinformatics study, we found that disorder is
overrepresented in the Chromatin Processes proteins, and that a major driving force for
disorder in these proteins is protein/protein interaction and post-translational
modification. We also show a biological connection to disorder and increased
protein/protein interaction by investigating these parameters in the context of the DNA
xiii

damage checkpoint response and in complex formations. Mediators between highly
structured kinases in the checkpoint were the most interactive proteins and over half of
all predicted interaction sites occurred in disordered areas. Complexed proteins often
contained one protein with a high number of disordered sites and a high number of
predicted interactions, while the rest were considerably more ordered.
Chapter 5 explores a Sgs1 interaction partner, Rmi1 and uses bioinformatics to
design structurally-based point mutations in an effort to further elucidate Rmi1 function
in yeast, which remains largely unknown outside of its enhancement of Top3/Sgs1
catalytic function. Using AGADIR, which predicts alpha-helical structure and is
particularly useful in our hands for guided-mutagenesis in disordered regions, we
identified several point mutations that lead to Δrmi1 phenotypes or intermediate growth
on hydroxyurea. We hypothesize that these mutants are important in maintaining Rmi1
stability.
Together, these studies suggest an important change in how the field
approaches further studies into the RecQ helicases; traditional methods of primary
sequence comparisons and crystal structures limit the study of disordered regions that
are still functionally important. Future care should be given to consider the conservation
of structure or structural elements in the RecQs over strict alignments when comparing
functional regions between orthologs. Our studies also suggest that it is highly likely that
structural motifs for important protein interactions in RecQs are being overlooked
because they are not readily obvious using traditional methods. By understanding these
motifs and the interactions they facilitate, we may be able to more easily identify
polymorphisms in patients with genomically unstable conditions like cancer and, having
xiv

better understood the biological process these structures facilitate, design drugs to
counteract detrimental effects.

xv

CHAPTER ONE:
INTRODUCTION

The RecQ family of helicases is highly conserved from bacteria to humans and
functions at the interface of DNA replication and repair [1]. It is instrumental in
maintaining genomic stability by directing homologous recombinatorial repair and
preventing crossover events with non-sister chromatids during repair [2]. Some
organisms like Saccharomyces cerevisiae and Schizosaccharomyces pombe contain
only one RecQ helicase, while others can contain many--like the human WRN, BLM,
RecQL4, RecQL1, and RecQL5 homologs--with a maximum of seven homologs
discovered in Arabidopsis [3]. Homology arises from the similarity of the catalytic
domains [4]; differences in protein primary sequence usually arises in extended Nterminal regions of the protein, most of which are predicted to have an appreciable
degree of protein disorder.

Founding Member of the RecQ Family of Helicases
RecQ was first identified in E. coli as a mutated gene in the RecF pathway that
imparts death-resistance in thymineless media, but makes the organism more sensitive
to UV damage and results in a deficiency in recombination [5]. Purification efforts of the
gene product found that the gene produces a helicase with 3’ to 5’ unwinding activity
and DNA-dependent ATPase activity [6]. This activity is sensitive to ATP and Mg+2
1

levels, to the presence of single-stranded DNA (ssDNA) and is facilitated by the
presence of single stranded DNA binding (SSB) protein and [7]. RecQ promotes and
disrupts recombinatorial events, and thus is an important mediator in preventing
aberrant recombination events (i.e. Between homeologous sequences) [8].

RecQ Helicase Structure and Function
Structurally, all RecQ family members contain a C-terminal helicase region with a
DEAD/H motif that spans about 400 residues with seven sequence motifs common in
most DNA and RNA helicases, including the Walker-A motif, which is required for the
binding and hydrolysis of ATP [9]. Crystallography has revealed that the helicase region
of RecQ consists of two lobes separated by a cleft lined with highly conserved amino
acid residues that bind ATP and potentially ssDNA [10]. Single point mutations in and
around this cleft in the human RecQ variant, BLM, have been found to lead to either fullor partial-loss-of-function of the helicase [11].
Many RecQ helicases also contain domains that are essential for the protein’s
catalytic activity including a RecQ conserved (RQC) domain and a helicase and
RNaseD C-terminal (HRDC) domain [12]. The RQC domain, while not present in all
members, is exclusive to the RecQ family. The function of this domain is not fully
understood, but it has been implicated as an important region for DNA binding and
processing. Crystallography reveals that the region has two subdomains. One
subdomain is crucial for Zn+2 binding via a set of four conserved cysteines; this domain
was also found to be essential for proper BLM core folding and ATPase activity [13].
The second subdomain is a winged-helix domain, which has been shown to bind DNA
2

in the human WRN homolog [10, 14]. NMR structural analysis of this region in the
human BLM protein reveals that it is comprised of 4 alpha helices and 4 beta strands
with a flexible loop between the first and second helices not present in other RecQs,
implying that the full functionality of this winged helix domain may vary between
orthologs [15]. In WRN, this domain also contains a nucleolar targeting sequence [16].
The functionality of the HRDC domain has been implicated through biophysical
studies; the structure of this domain has been resolved via NMR and crystallography,
and has been shown to resemble DNA binding domains from other helicase and DNAbinding proteins [17, 18]. This domain in the S. cerevisiae ortholog was found to be
comprised of 5 helices, and, since the hydrophobic residues responsible for packing
these helices into a functional core are conserved, it is hypothesized that the structure is
likely similar in other orthologs with this domain. On the surface of this core are a series
of positively-charged residues that can facilitate binding to negatively-charged DNA [17].
The HRDC domain is required for dissolution of double Holliday junctions (dHJs) in BLM
protein, and can bind DNA in the RecQ protein [18, 19].
A study has suggested that the RecQ helicases be divided into two classes,
depending on the length of the protein and overall structure (Figure 1.1) [9]. One class,
called the ‘long-form’ RecQ helicases, contains a large N-terminal stretches of acidic
amino acids and/or extended C-terminal regions of poorly described function, or, in the
case of WRN, an exonuclease domain. Members of the RecQ family included in this
class include BLM, WRN, Sgs1, D.m.BLM, and RecQL4. The ‘short-form’ of RecQ
helicases is missing this long N-terminal region but still contains the typical helicase
domain and may contain the RQC and HRDC domains. An example of this class
3

includes E. coli RecQ. Opresko et al suggests that the presence or absence of this
additional protein sequence on either the N- or C-terminal end may reflect the nature of
DNA substrate-binding specificities in the RecQ family; in general, E. coli RecQ is the
least structurally complex member but preferentially binds the broadest number of DNA
duplex types. Sgs1, BLM and WRN, with their long stretches of additional sequence on
both the N- and C-termini, tend to unwind mostly those DNA duplexes containing
junctions, such as Y-structures and HJs [20]. It is probably more likely that the extended
domains in the N-terminus are to serve as protein/protein interaction sites and
modifications sites, as discussed at length below.

Figure 1.1: Domain comparison of long- and short-form RecQ helicases. Data for
H. sapiens sand S. cerevisiae come from genetic studies; C. albicans domains are
estimated by a CD search on NCBI BLASTp.

4

RecQ Helicase in S. cerevisiae, Sgs1
Sgs1 is the only RecQ helicase in the budding yeast Saccharomyces cerevisiae;
it contains 1447 amino acid residues with a helicase domain (residues 674-1017), an
RQC domain (residues 1017-1085) and an HRDC domain (residues 1272-1351) [21].
Purification of residues 400-1268 (including the helicase and RQC domain) showed a
protein able to hydrolyze ATP, but only in the presence of DNA substrates of various
forms [22]. This fragment is able to bind DNA, with a preference for ssDNA over dsDNA,
particularly forked substrates. This same fragment is capable of unwinding G4
quadruplex structures [23]. Full-length Sgs1 is capable of binding Y-structure, ssDNA, 3’
overhang, 5’ overhang, HJs, and dsDNA. The binding of substrates with 5’ and 3’
overhangs was found to be similar, unlike the results found in the 400-1268 fragment.
This implies that the N-terminal and C-terminal domains of the protein, including the
HRDC and mostly undefined N-terminus, may facilitate the binding of a wider array of
substrates

[24]. Like the founding family member, Sgs1 unwinds DNA in a 3’-5’

direction and requires ATP (and preferably, Mg +2) [22]. The rate of ATPase activity of
Sgs1 is approximately 10 fold greater than RecQ and is inhibited by the presence of
RPA, possibly as a function of competition between the two proteins for ssDNA [24].
The first 674 amino acids lack any well-defined or well-conserved domains, but do
contain two extended regions of acidic residues (residues 400-474 and 510-596; [12])
that are present in other yeast homologs and in human BLM. Deletion of these regions
can suppress Δtop3 slow growth like a Δsgs1 mutant, but are mostly like wildtype
growth on hydroxyurea (HU) and methylmethanesulfonate (MMS), implying that there is
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a separation of function in this region, though the specific function of these regions
remains to be discovered [12].

Characterization of the Δsgs1 Phenotype
Sgs1 was first classified by Gangloff et al. in 1994 during a search for
suppressors of the slow-growth phenotype common to strains lacking Topoisomerase 3
(Top3). The importance of Sgs1 in maintaining genomic stability is apparent as cells
lacking Sgs1 show an increase in mitotic recombination in the form of interchromosomal
homologous recombination, intrachromosomal excision recombination, and ectopic
recombination [25, 26]. This recombination has been found to be improperly induced
and concluded in Δsgs1 cell lines, as cells lacking Sgs1 have been found to have an
increase in gross chromosomal rearrangements (GCRs), most notably in the form of
translocation/deletions and telomere additions [27]. Meiotically, Δsgs1 cells are also
abnormal, as an increased number of multichromatid molecules and an increase in
homeologous recombination between non-identical sequences (though not homologous
recombination) have been observed [25, 28, 29]. Cells lacking Sgs1 were found to
undergo more synapsis in meiosis and have an increased number of crossing over
events over wildtype cells [30]. Exposure of Δsgs1 cells to a diverse range of DNA
damage has revealed several sensitivities, including UV light, hydroxyurea and MMS
[31-33]. In addition to being sensitive to damage, sgs1Δ cells are overall unhealthy
under normal conditions, and have an average life span only 40% that of wildtype cells.
In older Δsgs1 cells, the nucleoli appear to age faster than wildtype cells as well [34].

6

Role of Sgs1 in DNA Repair
Catalytically, Sgs1 acts in many steps in DNA repair (Figure 2). At the beginning
of double strand break processing, Sgs1 works in tandem with Dna2 and Exo1 to resect
the ends of the break beyond the actions of the MRX complex, which is needed to
produce a length of ssDNA long enough for Sgs1 to work on [35, 36]. Sgs1 is needed in
order to achieve resection efficiency needed for further steps in the repair process; in
cells missing Sgs1, only a fraction of cells are able to achieve the same degree of
resection as wildtype cells [37]. The ends produced by Sgs1 and partners are then
acted upon by Rad51, which is able to invade a homologous sequence and use it as a
template for error-free recombinatorial repair. Sgs1 later works in conjunction with the
topoisomerase Top3 and accessory protein Rmi1 to dissolve double dHJs in a noncrossover event [38]. The result is a repaired gap that is error-free. Loss of Sgs1 results
in a greater percentage of these breaks being repaired in an alternative pathway that
promotes crossing over by allowing HR to occur between homologous chromosomes
rather than sister chromatids [39]. This may result in a loss of heterozygosity (LOH). In
addition to properly processing ends in the first steps and resolving branched structures
in the last steps of recombination, Sgs1 has been found to be instrumental in preventing
homeologous recombination by acting as an anti-recombinase [27]. Because there is an
increase in recombination between sequences of less than perfect homology in cells
lacking Sgs1, it is hypothesized that Sgs1 plays a role in dismantling the d-loop created
by Rad51 during strand invasion if the site of recombination on the donor strand is not
homologous. Though the method of divergent strand rejection is not fully known, it has
been shown that mismatch repair proteins often drive the suppression of homeologous
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recombination, and that helicase activity is likely a necessary addition to the proteins
that mediate the dissolution [27, 29, 40].
Sgs1 has also been shown to be required in the intra-S-phase checkpoint that
activates in response to stalled DNA replication. This checkpoint is activated in part by
the phosphorylation of Rad53, and cells that were lacking Sgs1 were found to have
substantially lower amounts of phosphorylated Rad53 in S-phase under damaging
conditions [41]. This implies that, in addition to its role in the physical repair of DNA
damage, Sgs1 has been found to promote genome integrity by activating replication
checkpoints that allow for sound repair of DNA damage and by stabilizing DNA
polymerase ε at these stalled forks along with Mec1 [42-44]. Sgs1 has also been
implicated in the phosphorylation of Rad53 in conjunction with Exo1 in G1 cells, and
both are needed to induce a checkpoint delay at G1 in the presence of irradiating
damage [45]. Sgs1 interaction with Rad53 has been confirmed via mutagenic coimmunoprecipitation and is believed to be reliant on the phosphorylation of Sgs1 at
residue T451; this gives support to Sgs1 working as an upstream element of Rad53 in
the checkpoint cascade, a theory supported by the experiments in G1 cells described
above [46].
Sgs1 has also been implicated in telomere maintenance, since in cells that lack
telomerase (Δtlc1, the gene for telomerase RNA) loss of Sgs1 results in more rapid
aging, an increased rate of telomere shortening, and arrest in G2/M phase. Though the
exact nature of Sgs1’s role in telomere maintenance is still unknown, it is hypothesized
that the phenotypes observed in Δtlc Δsgs1 cells may be the result of a) formation of
DNA quadruplex structures at shortened telomere ends that require Sgs1 to be
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resolved, b) the loss of S-phase checkpoint ability that results in the delayed G2/M
arrest seen in these cells, c) Sgs1 playing an active, yet unknown role in telomeraseindependent repair pathways (ALT pathway) as it was shown to co-localize with a few
proteins in this pathway, or a combination of the above [47]. Deletion of SGS1 in a
Δest2 background (a catalytic subunit of telomerase) also saw rapid senescence
beyond the deletion of EST2 alone. The double mutant also exhibited the increased rate
of telomere loss found in the Δtlc1 Δsgs1 strain, and this loss was further exacerbated
by the loss of another protein in the recombination pathway, Rad52. When senescent
cells were allowed to recover via recombination-mediated telomere lengthening, Δsgs1
Δest2 cells were unable to recover wildtype growth rates like the Δest2 mutant, implying
a role for recombination and, subsequently, Sgs1 in telomere lengthening as a means of
maintenance. Indeed, evaluation of the telomere structure of Δest2 versus Δest2 Δsgs1
cells found that the former contained longer type II structures with Y’ elements followed
by extended tracts of C1-3A/TG1-3 repeats, while the latter contained shorter type I
structures, which contains tandem Y’ elements followed by a short tract of repeats [48].
It has been shown that cells with type II structures tend to eventually reach a wildtype
growth rate, while type I cells never recover wildtype growth. The findings imply a role
for Sgs1 in suppressing preference for type I structure formation in the absence of
telomerase [49, 50]. Part of Sgs1’s role in maintaining type II telomere structure is due
to a sumoylation event at K621, as mutation of this residue to an arginine incapable of
being sumoylated shows the increase in type I telomere structure found in strains
lacking telomerase and full-length Sgs1 [51].
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Recently, Sgs1 has also been implicated in single strand annealing (SSA) and
strand exchange (SE) activities [52]. The region in the N-terminus spanning residues
103-322 has been identified as the minimum domain for SSA and SE. In vivo assays
have shown that in a sgs1 mutant lacking this region, recombination rates are elevated
on par with a Δsgs1 strain, implicating this region in suppressing hyperrecombination,
though the mechanism, and whether or not deletion of the domain inactivates the whole
protein, is unknown. Loss of this region also leads to a greater amount of homeologous
annealing in vivo, implying that the region is needed in order to reject duplex DNA
formation between mismatched sequences. In vitro, a peptide containing this region can
perform SA with homeologous DNA, but not SE, implying that the SE function of this
region in Sgs1 is what is used to prevent aberrant recombination between
nonhomologous sequences in vivo [52].

Figure 1.2: Roles for STR complex in yeast.
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N-Terminal and Putative N-terminal Sgs1 Protein/Protein Interactions
While the catalytic core serves as the driver for the catalytic functions of Sgs1,
only half of the protein is actually dedicated to helicase and helicase-related activities.
The entire N-terminus of Sgs1 has no known activity outside of SE/SSA, but has been
implicated in several protein/protein interactions; the diversity of these interacting
proteins illustrates the numerous pathways and steps Sgs1 has been implicated in with
regards to DNA repair (Figure 1.3).

Figure 1.3: Putative domains of Sgs1 binding partners. Domains of selected
partners important in DNA repair are present over whole protein, but are preferentially
located in the N-terminus.

Topoisomerase 2 (Top2) is a type II topoisomerase responsible for DNA
decatenation events in both mitosis and meiosis; loss of Top2 can result in failure to
complete mitosis and meiosis [53].

Because of this, Top2 has been described as the

only essential topoisomerase in yeast. Top2 has been shown to interact with full-length
Sgs1 via co-immunoprecipitation, and yeast-two-hybrid assays have narrowed down the
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minimal binding area for Top2 on Sgs1 from residues 466-746 and for Sgs1 on Top2 to
residues 1109-1163, a potential leucine zipper [53, 54].
Rad16 was also discovered via yeast two-hybrid to bind with the N-terminal
region between residues 421-792 [55].

This region overlaps the Top2 binding domain.

Rad 16 has been implicated in nucleotide excision repair (NER) in conjunction with
Rad7; the two form the NEF4 complex, which is an ATP-dependent DNA damage
sensor [56]. It is instrumental in repairing UV damage, specifically pyrimidine dimers
induced in transcriptionally inactive DNA. Yeast cells lacking Rad16 cannot perform
NER but retain transcription-coupled repair [55]. Loss of Sgs1 in a Δrad16 background
leads to increased sensitivity to UV damage, implying that the two proteins may work in
redundant repair pathways, despite the fact that they interact physically. Because of this
evidence of physical interaction, the authors of the primary study of the Sgs1/Rad16
interaction suggest that in addition to the several functions of Sgs1 outlined above, it
may also play a role in repairing specific DNA damage with Rad16, thus making Sgs1
an important protein in the absence of Rad16 [55].
Srs2 is a second 3’-5’ helicase present in S. cerevisiae. It has similarities to
bacterial UvrD/Rep helicases and is implicated in early-stage recombinatorial regulation
[57, 58]. Though Srs2 and Sgs1 have been shown to physically interact [59], the double
mutant is inviable unless upstream recombination elements are also knocked out,
implying that in the absence of these helicases, lethal recombination events occur. The
area mapped to Sgs1 for Srs2 binding spans residues 422-722, an overlap with both the
proposed domains for Top2 and Rad16 binding. It should be considered, also, that
Sgs1, Srs2 and Mre11 form a complex, though the interaction between Sgs1 and Mre11
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alone has not been elaborated on; it is possible that the binding region for Srs2 also
houses a binding domain for Mre11 [59].
Deletion of Sgs1 contributes to a decrease in Rad53 phosphorylation [41].
Interaction with Sgs1 via Rad53’s FHA1 domain has been localized to Sgs1 residues
292-661 [44, 60]. Mutagenesis of four phosphorylation sites in this regions to
unphosphorylatable residues shows an approximately 50% reduction in Rad53
activation [60]. The authors of the study suggest that interaction between Rad53 and
Sgs1 at these sites in the acidic region is necessary for Rad53 recruitment and
activation.
Rpa70 binding to the acidic region of the N-terminus was recently identified using
beta-galactosidase binding assays; the binding area is between residues 292-661 on
Sgs1--the same binding site proposed for Rad53. Isothermal titration calorimetry further
narrowed this region to residues 404-560 [46]. Interestingly, the presence of Rpa70
controls the nuclease/helicase functions of another Sgs1 binding partner, Dna2. Dna2
and Sgs1 work together in conjunction with Exo1 to resect DNA at double strand breaks
[61]. The authors of the study found that the presence of RPA enhances 5’-3’ Dna2
resection, and impairs 3’-5’ resection. It is possible, then, that the Rpa70 interaction on
Sgs1 serves, in part, to regulate strand selection of the Dna2/Sgs1 interaction at breaks.
Physical interaction between Sgs1 and Dna2 has been confirmed [61], but it is yet
unknown where the interaction occurs on Sgs1. Considering the role of Rpa70 in
resection activity of Sgs1/Dna2, and considering where Rpa70 has been confirmed to
interact, it is plausible that the N-terminus contains a binding site for Dna2 as well.
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The RTR Complex: RecQ Interaction with Top3 and Rmi1
The most well-studied interaction with Sgs1 involves the formation of a
RecQ/Topoisomerase/Rmi protein (RTR) complex, an assembly that is conserved in
many of the other RecQ homologs. In S.cerevisiae, Top3 and Rmi1 partner with Sgs1 to
perform the catalytic functions necessary to facilitate early and late stage DNA repair.

Role and Interaction of Topoisomerase III (Top3) in the RTR complex
Top3 was first purified and classified in a 1992 study as a type IA topoisomerase
[62]. Strains lacking Top3 suffer from a slow-growth phenotype under normal conditions,
hyperrecombination, inability to form asci, and an increased GCR rate [27, 63, 64].
Structurally, the yeast Top3 has not been solved, but as the human variety, Top3α, is
said to closely resemble the canonical topoisomerase IA structure, it stands to reason
that S. cerevisiae Top3 likely contains the domains I-IV, Toprim, and acidic cluster
found in other orthologs [65, 66].

Top3 is responsible for resolving negatively

supercoiled DNA structures in the cell, and has been implicated in resolving
recombination-dependent X-shaped molecules (HJs) in an Sgs1-dependent manner
[67]. This topoisomerase dependency on RecQ function has also been seen in bacterial
systems, as E. coli RecQ has been found to stimulate catenation of dsDNA via TopoIII
[68]. The first yeast two-hybrid study implicated the first 282 amino acids of Sgs1 in
Top3 binding [54], and the minimum functional binding area has been further narrowed
down to the first 158 amino acid residues via co-immunoprecipitation and ELISA assay
[69].

Yeast mutants lacking the N-terminal 158 residues of Sgs1 demonstrate

hyperrecombination and a greater DNA damage sensitivity as compared to a Δtop3
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mutant.

It has been hypothesized that the loss of the N-terminus results in a

“hyperactive” Sgs1 helicase which introduces more chromosomal instability than a
wildtype Sgs1 in this same background [70]. This effect is described by the authors as a
“toxic effect” that is specific to a Sgs1 lacking the interaction domain for Top3 but still
catalytically active. The nature of this toxic effect, however, is still unknown. The
phenotype observed in these mutants can be overcome by increasing the concentration
of Top3 in the cell or by fusing the Top3 open reading frame to the N-terminus of Sgs1
[69, 71]; as Sgs1/Top3 interaction has been shown to be independent of DNA binding, it
has been implied that Sgs1 may be responsible for recruiting Top3 to areas of DNA it
needs to act upon [72].

Role and Interaction of Rmi1 in the RTR Complex
Rmi1 was first discovered in a screen for genes that, like Sgs1, were required for
viability of cells that lacked Mus81, with hopes that this would lead them to other
candidates for genes in the Sgs1-Top3 pathway [73]. RMI1 deletion produced a
synthetically lethal phenotype in a Δmus81 mutant that could be rescued when RAD51
was also deleted; as this lethality could also be repeated in conjunction with deletion of
several other genes with roles in replication fork restarting (RRM3, SLX1, SLX4, etc.),
and that this lethality could also be rescued when genes responsible for homologous
recombination were also deleted (RAD51, RAD52, RAD54), a role for Rmi1 in
homologous recombination was proposed [74]. Strains lacking Rmi1 are slow-growing
and sensitive to HU and MMS; these phenotypes could be suppressed by also deleting
SGS1, similar to Δtop3. Rmi1 strains are also genetically unstable; Δrmi1 strains have
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an increased recombination rate over both wildtype and Δsgs1 cells. Rad52 foci are
increased in response to a loss of Rmi1, implying that there is an increased rate of
spontaneous damage in Δrmi1 cells that likely explains the elevated GCR rates [73, 74].
A role for Rmi1 in checkpoint response has been suggested as well, as Rad53
phosphorylation is incomplete in the presence of HU or MMS when Rmi1 is absent [74].
Rmi1 has been co-precipitated with both Top3 and Sgs1, but Sgs1/Rmi1 and
Sgs1/Top3 interaction appears to require the third partner to bind stably [73, 75]. Rmi1
has no known catalytic function, but has been implicated in binding small amounts of
DNA, particularly dHJs [76]. Rmi1 is a known enhancer of Top3 DNA relaxation and
has been found to stimulate the decatenation of dHJs by Sgs1 and Top3, particularly at
late stages of junction dissolution, a function retained in the human complex [24, 76,
77]. Interestingly, yeast cells lacking Sgs1, Top3, or Sgs1 and Top3 have been found to
retain DNA resection ability (albeit slow and inefficient compared to wildtype), but
strains lacking Rmi1 lack the ability to resect at all, perhaps suggesting an important
supporting role for Rmi1 in resection function both in the presence and absence of Sgs1
[37]. Rmi1 may also play a role in sister chromatid cohesion in conjunction with Top3,
as cells lacking either of these proteins show an increase in separated chromatids over
wildtype cells [78]. Notably, Δsgs1 mutants did not appear to have a cohesion defect;
the authors suggest that, because Δrad51 and Δsgs1 in conjunction with Δrmi1 and
Δtop3 alleviated the cohesion defect, Rad51 and Sgs1 act upstream in a pathway that
drives Top3 and Rmi1 to facilitate cohesion.
The structure of the yeast ortholog of Rmi1 is still unknown, but alignment of the
human N-terminal portion of the protein best approximates the yeast structure. Human
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Rmi1 contains a cluster of three alpha helices at the far N-terminus that are predicted to
stabilize a central β-barrel structure containing an OB-fold [79]. This barrel affixes to
Top3α in domain II, with the alpha helices facing away from the domain. From this
barrel extends a 23-residue loop with no appreciable structure; this loop is believed to
be a functional region for modulating Top3α activity by controlling the mechanistics of
the catalytic “gate” of the topoisomerase, and is necessary for Top3α/Rmi1 interaction
[65, 79]. Studies with the human Rmi1/Top3α found that this loop is needed for the
enhancement of Top3α dissolution of dHJs and helps facilitate interaction between the
two proteins, lending support to the gatekeeper model [79]. In human RTR, this process
may be more complicated, as the Rmi1 protein is double the size of the yeast variety
and the complex contains a fourth member, Rmi2, which binds to the C-terminal portion
of the human Rmi1 protein and to RPA [79, 80]. Rmi1-/- models in mammalian systems
reveal similar phenotypes to those found in yeast, as rmi1 -/- mice stop developing in the
embryonic stage due to a decrease in cell proliferation and decrease in replication and
accumulate genomic instability in the form of aneuploidy and fragmented chromosomes
[81].

RTR Complex Member in Humans: Rmi2
The human RTR complex contains a fourth member in Rmi2, a protein with no
known homolog in yeast. Considering the fact that Rmi2 interaction in the complex is
due at least in part to interaction with the C-terminal OB fold of Rmi1, which has no
equivalent in yeast, it is unlikely that this protein exists at all in yeast, and could be a
function of the more complex RecQ network in humans [82]. Disrupting the interface
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that is responsible for Rmi1/Rmi2 binding contributes to an increase in sister chromatid
exchange (SCE) in human cells, a sign of genomic instability [82]. Deleting Rmi2 leads
to an overall decrease in both Top3α and Rmi1 levels, sensitivity to MMS, and an
increase in chromosome breaks [83]. The role for Rmi2, like the role for Rmi1, is still
being fully discovered, but it has been suggested that Rmi2 is responsible for proper
Rmi1 folding, RTR complex stability, and enhancement of dHJ dissolution via RTR [82,
83].

RecQ Orthologs in Humans
Unlike yeast, humans have five known RecQs, [84], all with activity in different
pathways, interactions with different proteins, and, in the case of three of the five,
different syndromes that result from mutation in one of the RecQ genes. This part of the
introduction will discuss the five human homologs, starting with the two not known to
cause syndromes, and following with the clinically-relevant homologs.

RecQL1
RecQL1 is the most robustly expressed of all of the RecQs in humans, and is
most prevalent in the heart, lungs, skeletal muscles and kidney [85]. It is capable of
unwinding forked substrates in an ATP-dependent manner and of single strand
annealing in the absence of ATP [86]. Deficiency in RecQL1 has no known disease
phenotype, but cells lacking the protein have decreased replication origin firing and
replication fork rates. Since RecQL1 is recruited to origins at the G1/S border, it is
reasonable to assume that the protein plays some role in modulating proper DNA
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replication in vivo [87]. RecQL1 interacts with PARP1 [88], a protein implicated in
responding to replication stress, and mutants lacking RecQL1 are sensitive to agents
that impair replication via inhibition of topoisomerase activity. RecQL1 has the capability
of restoring synthetically-created replication fork structures from regressed “chickenfoot” structures, implying that the protein is needed to restore forks undergoing repair
and restart proper replication [89]. Mouse fibroblast cells lacking RecQL1 also have
increased sensitivity to IR damage, an increase in spontaneous γH2AX foci (an
indicator of DNA damage), aneuploidy, and an increase in SCEs, all indicators of
genomic instability [90].

RecQL5
The human RecQL5 gene locus encodes for three isomers, generated via
alternative splicing. The α- and γ-isoforms are largely understudied, but a study into one
of the Drosophila small-form isomers shows that it shares the catalytic characteristics of
the other RecQs [91]. The small isomers, however, lack any nuclear localization signal,
and are thus not present in the nucleus [92]. The sub-cellular localization of these
isoforms and specific function has yet to be explained. The most commonly-studied
variant is RecQL5β, a 991 amino acid protein present in both the nucleus and
cytoplasm. It is expressed in many different tissue types in appreciable amounts, with
strong expression in the testis [92, 93]. Cells lines lacking RecQL5 are enriched in
γH2AX and Rad51 foci, have an increased number of broken chromatids/chromosomes,
tri- and quadriradials, and other aberrations, and are associated with an increase in HRmediated DSB repair [94]. While deletion of RecQL5 does not lead to an increase in
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spontaneous SCEs, the deficient cells are campothecin (CPT)-sensitive and have an
increase in SCEs when treated versus wildtype cell lines [95]. It is suggested that the
cause of RecQL5 CPT sensitivity is due to the inability of the cells to restart forks posttreatment, leading to apoptosis [96]. RecQL5 is a 3’-5’ helicase found to interact with the
MRN complex in vivo and in vitro. RecQL5 co-localizes with the complex at the site of
DNA double strand breaks, and requires the complex in vivo for recruitment to damage.
RecQL5 has been implicated in regulating MRN exonuclease activity by impeding
resection of break ends [97]. The helicase also interacts with RNA polymerase II via its
RPBI subunit; because the interaction occurs only when the mapped interaction site on
RPBI is phosphorylated, and because this phosphorylation is indicative of transcript
elongation, it has been proposed that RecQL5 also plays a role in transcription [98]. The
most fully studied interaction is between Rad51 and RecQL5, where the interaction site
of RecQL5 on Rad51 at the stretch between residues 654-725 is needed for RecQL5
prevention of d-loop formation by displacing Rad51 on ssDNA [94, 99]. This prevention
is believed to be an active mechanism for regulating Rad51 activity preventing HR in
wildtype cells, a parallel function to the anti-recombinase function seen in Sgs1. While
no known human disease is connected to RecQL5 mutation, RecQL5 deficient mice
were found to be more prone to cancer than their wildtype counterparts, with 46% of
those tested developing a cancer by 22 months of age [94]. The most common cancers
in this study were lymphomas, and the most common solid tumor was lung
adenocarcinoma. In a study of RecQ homolog levels in primary colorectal cancer,
RecQL5 mRNA expression and protein levels were found to be reduced in tumors,
particularly in those tissues described to be microsatellite instable [100]. Overall, this
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implies that RecQL5 may be tumor-suppressing in the colon, so while there may not be
a specific syndrome equated to mutant RecQL5, it is feasible that the protein levels are
misregulated in other cancer types as well.

RecQL4
RecQL4 displays the same ATPase and single strand annealing properties as
other RecQs, but compared to some of the other human members, it is not particularly
robust as a helicase since it is unable to efficiently unwind the diversity of DNA
structures found from BLM or WRN protein [101, 102]. Unlike these other helicases,
however, RecQL4 seems to be adept at unwinding long duplex DNA, suggesting a
specialized biological function [103]. Structurally, RecQL4 is also remarkably different
from other “long” human RecQs in that it does not contain the RQC or HRDC accessory
domains typical of this family of proteins. Instead, it is the only member to feature a
domain with similarities to S. cerevisiae Sld2, a protein necessary for proper DNA
replication [104, 105]. The ortholog in Xenopus laevis, xRTS, has been found to be
recruited to DNA early in replication initiation and deficient cells are delayed in DNA
replication [104]. Drosophila RecQ4 also has replication defects, including loss of DNA
polymerase alpha on chromatin and S-phase arrest; the Sld2 domain has been found to
be necessary to rescue RecQ4 deficient cells from replication defects [106]. These
findings suggest a role for RecQL4 in maintaining proper replication fidelity in the cell.
Interestingly, RecQL4 has also been detected in the mitochondria and is necessary for
proper mtDNA replication [106, 107]. RecQL4-deficient fibroblasts are sensitive to HU,
CPT, and doxorubicin (DOX), but are not significantly sensitive to UV, IR, and cisplatin
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damage. Since HU, CPT, and DOX are primarily harmful during S-phase, this further
strengthens the suggestion that RecQL4 plays a functional role in replication (Figure
1.4) [108] . A role for RecQL4 in telomere maintenance has also been proposed, since
interaction with TRF2, a protein in this process, has been confirmed [109]. The authors
of this study also found that RecQL4 associates with TRF1 foci at telomeres during Sphase and deficient cell lines display greater telomere fragility than wildtype cells. What
role RecQL4 actively plays at the telomeres, however, has yet to be discovered.

Figure 1.4: Proposed roles for RecQL4.

RecQL4 is predominantly expressed in the thymus and testis, with low-level
expression also detected in the heart, brain, placenta, pancreas, small intestine, and
colon; peak expression is detected in G1/S, consistent with a role in early replication
[110]. Given the pattern of expression, it is unsurprising that RecQL4 deficient mice
models have been found to have hypoplasia of the thymus; this finding perhaps
explains the frequency of infections some patients of RecQL4-deficient syndromes
incur. The same mice are also prone to embryonic growth retardation and death, low
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birth weight, hair loss, skin lesions, sclerotic tails and premature greying, symptoms of
aging, growth and skin problems similar to those seen in some human patients [111].
Perhaps suggestive of the diversity of its suggested roles, humans deficient in RecQL4
suffer from one of three syndromes: Rothmund-Thomson Syndrome (RTS),
RAPADILINO syndrome, or Baller-Gerold syndrome.
Rothmund-Thomson

syndrome

was

first

described

in

1868,

by

an

ophthalmologist who observed children with poikiloderma and cataracts [112]. Patients
with RTS can exhibit any of a myriad of symptoms, including short stature, bone
deformations, poikiloderma, early aging, photosensitivity and neoplasia predisposition,
particularly lymphomas and osteosarcomas; variability of symptoms between patients is
often great, as indicated in several patient case studies where no two patients showed
the same phenotype and no patient showed all of the possible symptoms associated
with the syndrome (Figure 1.5) [112-115]. The mutation responsible for the disease
varies from patient to patient, but all known mutations are exclusive to the helicase core
and C-terminus of the protein [115]. RAPADILINO syndrome is characterized by radial
deformations, patellae malformation/lack of formation, diarrhea, skeletal abnormalities
including high or cleft palates, and short stature [116]. There are fewer than 20 reported
cases of the syndrome as of 2009, but they are overwhelmingly occurring in Finland,
implying the presence of a founder mutation. Cancer status is as high as 40% in
patients with RAPADILINO, with osteosarcomas and lymphomas being the most
common cancer types in the populations studied, particularly in those with dual A420
and A463 deletion genotypes [115].

Baller-Gerold syndrome patients exhibit bone

deformities similar to those seen in RAPADILINO, and have anomalies including cranial
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malformations, imperforate anus, rectovaginal fistulas, poor prenatal growth, and mental
retardation [117].

Figure 1.5: Rothmund-Thomson patients. The patient on the left shows the
poikiloderma and bone malformations characteristic of the syndrome. The patient on the
right shows a closer look at poikiloderma [118, 119].

WRN
The Werner’s helicase is much like other RecQ homologs in that it easily
unwinds a diverse spectrum of DNA structures, including G4 quadruplex, bubbled
duplex, 3’-overhang, synthetic x-junction, and forked duplexes; long-range unwinding is
stimulated by the presence of RPA, which physically interacts with WRN [120, 121].
However, it presents another original case with regards to human “long form” RecQs in
that it contains a 3’-5’ exonuclease domain in the far N-terminus of the protein that is
active particularly on forked DNA [122, 123]. Roles for WRN are summarized below
(Figure 1.6). Phenotypically, cells which lack a functional WRN protein have a growth
deficit, decreased survival rate, and sensitivity to HU, MMS, CPT and crosslinking
agents [124-128]. A study with WRN-deficient mice found that embryos have a
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decreased rate of survival versus wildtype mice; mice that survive embryogenesis show
early evidence of myocardial fibrosis and higher incidence of cancer than mice that are
wildtype or heterozygous at the WRN locus [129].

Cell lines derived from patients

lacking WRN exhibit an increase in mutation rates over normal cell lines, especially in
deletions [130]. Cells have an increased number of chromosome aberrations, including
chromatid breaks and gaps in general and at fragile sites, both spontaneously and when
treated with DNA-damaging agents.

These cells have an increase in DSBs as

evidenced by an increased level in γH2AX phosphorylation, both in untreated cells and
in cells arrested in replication by HU [131]; the authors of the study suggest that this
may be due to increased PCNA dissociation from chromatin at stalled forks in these cell
lines and subsequent fork collapse, as PCNA levels in chromatin fractions are reduced
in HU-treated Werner’s syndrome cell lines. Whether this mechanism is true, however,
remains unknown. WRN-deficient cells also have an increase in Rad51 foci, suggesting
an increase in HR in these cell lines, possibly as a result of increased DSBs [131, 132].
Wildtype WRN protein interacts with a bevy of proteins from different biological
pathways, suggesting a diverse role for both of its catalytic domains. The C-terminus of
WRN interacts with the C-terminus of the oncoprotein p53, and WRN-deficient cells
have been found to have a decrease in p53-mediated apoptosis and increase in
senescence, implying a regulatory role for p53 with regards to WRN function [133, 134].
Indeed, p53 has been found to inhibit WRN exonuclease function, as well as helicase
function on X-shaped junctions [135, 136].
WRN co-localizes with Mre11 after replication fork arrest in mid- to late- S phase
and syndromes that are deficient in members of the MRN (Mre11/Rad50/Nbs1)
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complex, including Nijmegen breakage syndrome, have a decrease in WRN
relocalization to nuclear foci, suggesting that WRN may be recruited to breaks via MRN
and this recruitment is needed for proper DNA repair via HR [137]. Physical interaction
with Nbs1 and WRN has been confirmed, and the two proteins co-localize in response
to IR and mitomycin C [138]. In addition to possibly recruiting WRN to the site of breaks
being initially processed by MRN, the complex has also been found to enhance the
activity of WRN helicase function in vitro [138]. In support of WRN’s role in DSB repair
via HR, WRN has also been found to co-localize with Rad51, Rad54, and Rad54b at
sites of mitomycin C-induced damage [139].
In addition to being needed in HR-mediated DSB repair, WRN has been found to
interact with, and unwind DNA intermediates from base excision repair (BER) [140].
This unwinding activity is regulated by Ape1, a protein active in BER that WRN
physically interacts with. Ape1 inhibits the helicase function of WRN unless the complex
is acted on by polβ; the suggested model for WRN’s role in BER is that Ape1 binds a
lesion that requires BER, and recruits WRN to the lesion. Polβ “takes” the DNA from
WRN-bound Ape1, and the now catalytically-active WRN helps stimulate polβ-driven
DNA repair of the lesion. Though this model is yet unconfirmed, it is clear that WRN
plays some role in efficient BER repair.
WRN may also play a role in nucleotide-excision repair (NER) and base-excision
repair (BER) as co-IPs have shown that the RQC domain of WRN interacts with NEIL1,
a protein that repairs bases damaged by oxidation, and this interaction is most strong
under conditions of oxidative stress. NEIL1 interaction inhibits both the exonuclease and
helicase function of WRN, while WRN stimulates the glycosylase activity of NEIL1. The
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exact role of WRN in NER is still unknown, but there is a significant increase in oxidative
damage-derived base modifications in cells lacking WRN, and no additive increase in
modification in cells lacking both NEIL1 and WRN, implying that NEIL1 and WRN work
in the same NER pathway to prevent the persistence of damaged bases [141].
WRN’s role in non-homologous end-joining (NHEJ) has also been described,
though no further investigation into this role has been conducted in the last decade. It
had been found that the N-terminus of WRN interacts physically with NHEJ protein
Ku70, and the C-terminus interacts with Ku80 [142]. This interaction stimulates WRN
exonuclease, but not helicase activity [142-144]. WRN also interacts with DNA-PKcs,
which phosphorylates WRN in an unclear role and inhibits WRN helicase function in a
manner that can be blocked by the Ku complex. It is suggested that WRN and DNAPKcs form a complex where WRN is inactive until it binds Ku-bound DNA, after which
WRN’s helicase activity becomes active and helps process broken DNA ends for NHEJ
[145]. The authors of this study also found interaction between DNA-PKcs and WRN is
important at telomeric D-loops, as DNA-PKcs actually stimulates WRN helicase activity
at telomeric D-loops. In vitro, DNA-PKcs also stimulates WRN D-loop dissolution in nontelomeric regions, though it cannot stimulate WRN-mediated dissolution of forked DNA,
HJs, or G-tailed substrates. In agreement with this role at telomeric D-loops, WRN
deficient cells have shorter telomeric G-tails [146].
A study in mice deficient for both WRN and Terc, which codes for telomerase
RNA, also supports a role for WRN in telomere maintenance. Mutant mice exhibited
aging symptoms more readily than mice expressing WRN in a Terc deficient
background. Affected mice appeared to be normal in young adulthood, but began to
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rapidly age shortly thereafter; these symptoms became more severe as subsequent
generations ended up with shorter telomeres, implying that symptoms are due at least
in part to insufficient telomere maintenance [147].

Figure 1.6: Proposed roles for WRN protein.

The WRN protein is prone to modification, the most-studied of which is
phosphorylation. Phosphorylation of the protein occurs in response to replication fork
blocks, and both ATR and ATM kinases have been implicated in modification of the
protein in the presence of HU-stalled forks [148]. Interaction with the Abl kinase, which
is active in response to genotoxic stress, has been detected in peptides containing the
exonuclease and helicase domains. Abl phosphorylates tyrosine on WRN in response
to bleomycin, and this phosphorylation inhibits exonuclease and helicase activities
[149]. Phosphorylation by an unknown kinase also occurs at residues S440 and S467 in
response to bleomycin. These residues are not in a catalytic region, and thus have not
yet been found to influence the catalytic activity of the protein, but phosphomutants at
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these sites are unable to relocalize WRN to the nucleoli post-damage, and repair DSBs
more slowly following etoposide treatment [146].

Figure 1.7: Werner's syndrome patient at various ages. Tracking of a Werner's
patient show the normal aging to age 21, followed by rapid aging characteristic of the
disease. Image from University of Washington.

Given the wide range of pathways and modifications of WRN, it is perhaps
unsurprising those patients with Werner’s Syndrome (WS) --who lack WRN-- have a
range of symptoms that are the result of increased cell senescence and cancersusceptibility. WS patients are different from sufferers of other RecQ-related syndromes
in that they live relatively healthy lives for approximately the first 20 years of life, but age
quickly thereafter and become more prone to age-related disease at a younger-thanexpected ages, including bilateral cataracts, dermatological problems, premature
greying/hair thinning, diabetes mellitus, hypogonadism, osteoporosis, premature
atherosclerosis, and neoplasms (Figure 1.7) [150]. The mean age of first neoplasm in
WS patients is 43 years, and patients have an excess in rare cancer types versus the
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normal population, with an increase in soft-tissue sarcomas, osteosarcomas, and
follicular thyroid carcinoma, amongst others [151]. These rare neoplasms are some of
the most commonly encountered in the small patient pool, along with melanoma,
meningioma and leukemia. The gross diversity of cancer types is perhaps reflective of
the multiple pathways in which WRN is implicated.

BLM
BLM was first identified as a RecQ Helicase in 1995, when cDNA mapping
verified that it contained the motifs common to the RecQ family [152]. Analysis of the
gene product of this cDNA also confirmed its ATP and 3’-5’ helicase activity present in
the other family members [153]. Since then, many in vitro and in vivo studies of human
BLM and other mammalian orthologs have tried to establish the role of BLM in
maintaining genomic stability (Figure 1.8). Human and other mammalian cells lacking
BLM have reduced survival in response to crosslinking agents, sensitivity to HU, MMS,
etoposide, CPT, 4-NQO and UV-C irradiation, increased rates of homologous
recombination resulting in non-crossovers, reduced NHEJ repair, and an increased
numbers of SCEs [154-158].

Mice with mutant BLM have an increased rate in

spontaneous tumor incidence, and this occurrence appears to be dosage-dependent, as
homozygous mutants suffer they greatest occurrence, and heterozygous mice have a
slightly elevated rate over wildtype mice [156]. Mitotic recombination in BLM-deficient
mice was found to be increased in a separate study, and, as a result, an 18-fold
increase in loss of heterozygosity (LOH) [159]. The effect of LOH became apparent in
combination with APC-/+ mice, which become prone to intestinal cancer if they become
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APC-/- through aberrant crossing over between homologous chromosomes rather than
sister chromatids. These mutants lose the tumor-suppressing effects of APC; mice
lacking BLM in this background accumulated cancers at a greater rate than mice with
WT BLM [159]. Embryogenesis of BLM-deficient mice is also impaired, as these
embryos are developmentally delayed and small compared to their WT counterparts.
Red cell production in these mutants is also impaired, and mutant fibroblasts incur an
increased number of SCEs compared to fibroblasts from WT embryos [160].
Protein levels of BLM peak in S-phase and persist through G2/M before
decreasing dramatically in G1, where repair by NHEJ takes over [161-163]. BLM protein
can be found all over the nucleus, but form foci in response to damage and has been
shown to co-localize with RPA, PMLs, and the nucleolus [163]. BLM catalyzes the
branch migration of recombination intermediates, including dHJs, and has affinity for Xshaped DNA junctions, 3’-tailed duplex DNA, ssDNA, and G4 quadruplexes [153, 164166]. It is also capable of resecting DNA in concert with Dna2, a function which requires
helicase ability, is regulated by RPA, and enhanced by MRN, which acts upstream of
BLM to resect short tracts of DNA at breaks [167, 168]. BLM catalysis is perhaps the
most closely related to S. cerevisiae Sgs1 as it also harbors an interaction with Top3(α)
and Rmi1 in the far N-terminus and is found to co-localize with these proteins in vivo
[169, 170]. This interaction enhances BLM unwinding of dHJs, but does not affect the
rate of ATP hydrolysis by BLM. Even in the presence of synthetic substrates that do not
require the DNA-relaxing activity of Top3α, BLM unwinding activity of this DNA is
enhanced, implying that the binding event between proteins itself may have some sort
of effect on BLM processivity [170, 171].
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Like WRN and other long-form RecQ helicases, BLM has been shown to interact
with a bevy of different proteins acting in different pathways, implying a diverse cellular
role. BLM has been shown to localize to the telomeres in cells lacking telomerase, and
FRET analysis confirms interaction between BLM and telomeric protein Trf2 [172]. The
same study found that overexpression of BLM in telomerase-deficient cells has been
shown to increase telomere DNA synthesis, dampening the telomere-shortening effect
seen in the telomerase-defective strains. This result, paired with the fact that telomere
defects and shortened telomeres increase in BLM-deficient cells, suggests a role for
BLM in the alternative lengthening of telomeres (ALT) pathway and general telomere
maintenance [161, 172].
BLM has been detected in two large proteins complexes. The BRCA1-associated
genome surveillance complex (BASC) contains Msh2, Msh6, Mlh1, ATM, BLM and the
MRN complex proteins [173]. Co-localization between BRCA1 and BLM after HU
exposure and partial co-localization after IR damage has been observed, implying this
complex of proteins is needed to respond to DNA damage, but the functionality of this
complex is yet unknown. BLM has also been found to work in complex with Top3α,
RPA, Mlh1 and the Fanconi Anemia proteins FANCG, FANCC, FANCE, FANCF, and
FANCA, and has been shown to co-localize and co-immunoprecipitate with FANCD2
[157]. Cells lacking the Fanconi core complex show a decrease in subnuclear
relocalization of BLM to γH2AX foci following interstrand crosslink damage; this colocalization is driven by BLM phosphorylation, which is abolished when the FANC
complex is absent. Cells derived from mice deficient in FANCD2 and both FANCD2 and
BLM show equivalent sensitivity to crosslinking agents, suggesting a pathway overlap
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for the proteins with regards to crosslink repair [174]. Deletion of both genes is not
epistatic with regards to SCEs, however, suggesting that the overlap in FANC and BLM
repair pathways are limited to certain types of regulation [174]. BLM has also been
known to localize at ultrafine anaphase bridges and is proposed to be necessary for
dissolving these bridges in anaphase to prevent chromosome fragmentation [175].
FANCD2 has also been detected on chromosomes during anaphase, and these
ultrafine bridges were found to associate with FANCD2 spots, suggesting a role for the
two proteins in faithful chromosome segregation [176]. While the exact relation between
BLM and the FANC proteins has yet to be elucidated, it is clear that the interaction of
these proteins is necessary for proper BLM response to DNA damage [157, 173].
Protein-protein interactions have also been detected with other singular proteins.
SPIDR, a scaffolding protein that co-localizes and binds to BLM in response to DNA
damage is required to formation of BLM foci [177]. The oncoprotein p53 physically
interacts with BLM residues 1-431 between its own residues 155-393, and the
localization of BLM to PML bodies in the nucleus has been found to be dependent on
p53 [178, 179]. BLM and p53 have also been shown to co-localize at the site of stalled
DNA replication forks and cells lacking BLM have a decrease in p53 recruited to these
forks, implying that BLM is needed for p53 transport to these stalls. Thus, both play a
role in regulating the location of the other in the cell [180]. Yeast-two-hybrid analysis has
mapped an interaction between BLM and MLH1 to the BLM C-terminus, but cells
lacking BLM have no difference in mismatch repair versus WT cells, suggesting that the
interaction is not due to a role in mismatch repair, but rather a yet undescribed more
specific repair [181]. Co-localization of BLM, Top3α, and Rmi1 with the PICH helicase
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on ultrafine anaphase DNA bridges has been detected, and these bridges, indicative of
defective sister chromatid separation, are increased in cell lines lacking BLM. The role
of BLM at these bridges is unknown, but may reflect the need for the protein at
unresolved DNA replication structures [175].

Figure 1.8: Proposed roles for BLM protein.

Like WRN, BLM is subject to extensive post-translational modification. BLM has
been found to be phosphorylated by ATM in response to IR damage and by Chk1 and
Chk2 in response to HU damage [154, 182]. Phosphorylation of residue T99 is
increased in response to CPT and HU-induced damage, and occurs in a DNA
replication-dependent manner by ATM and ATR. It is believed that this phosphorylation
regulates the association of BLM with Top3α; when phosphorylated, BLM association
with Top3α and PML bodies decreases, and association with γH2AX at breaks
increases. This function suggests a potential role for BLM as a signaling molecule
independent of its function with Top3α [183]. Residue S144 is phosphorylated by SAC
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kinase MPS1; modification peaks in G2/M, suggesting a role for this modification in
mitosis. Indeed, mutant S144A cells do not properly delay in mitosis in response to
nocodazole and have an increase in multinucleated cells. S144A cells also have an
increase in chromosome instability as illustrated by a broad distribution of chromosome
number/cell vs. WT [184]. In S-phase, S338 is phosphorylated in an effort to enhance
interaction with the protein TopBP1, which maintains BLM levels in the cell through
G2/M before residue K3 is ubiquitinated by Mib1 in G1 to facilitate degradation of BLM
in an effort to favor NHEJ DNA repair over HR [185]. A second study suggests that not
S338, but S304 mediates this interaction [186]. In either case, a phosphorylation event
is necessary to mediate at least one protein/protein interaction in BLM.
In humans, deficiency in BLM protein results in Bloom’s syndrome, first described
by dermatologist Dr. David Bloom when he described several patients with symptoms
including telangiectatic erythema on the cheeks, nose, eyelid margins, lips, forehead,
and ears, sun sensitivity, and stunted growth (Figure 1.9). Considering that some
patients were related, he suggested that the disease has a genetic component [187,
188]. Case studies into patients listed in the Bloom’s Syndrome Registry reveal that low
birth weight at full term, café au lait spots, bone abnormalities, underdeveloped testes in
males, irregular menses and early menopause in females, early onset diabetes (median
age 24.8 years), high-pitched voices, and learning disabilities are also common
symptoms [189, 190]. Of the 150 persons in the 1993 study, 118 had incidence of
neoplasms; 86 of these were malignant, and mean age onset of these neoplasias was
24.4 years. Leukemias tended to predominate in children, and carcinomas in adults;
lymphomas were prevalent in both age groups. Immune deficiency is also reported in
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most patients [190]. In a survey of 134 persons with Bloom’s Syndrome, 64 different
mutations were found in 125 of them; 54 of these are premature stops, and 10 are
missense mutations. Premature stops exist over the length of the protein from residue
104 to 1283. While there is no single mutation responsible for the disease, the most
common mutation is the BLMAsh mutation, a frame shift mutation at tyrosine 736 and
prevalent in the Ashkenazi Jewish population [191]. Bloom’s Syndrome is an autosomal
recessive disease, suggesting a ¼ chance in inheritance from two carrier parents, but
the observed rate in afflicted families is actually lower than this; the prevailing
hypothesis is that BLM recessive homozygotes are prone to greater loss in
embryogenesis, thus making the disease yet more rare and restricted to the 265
reported registered cases as of 2009 [189]. While heterozygotes do not have Bloom’s
Syndrome, it has been suggested that this genetic status results in an increased risk of
cancer; a study of heterozygotes for BLMAsh found that they were twice as prone to
colorectal cancer than those without the mutant allele [192]. However, a human study of
Jewish individuals with colorectal cancer found no significant relationship between
cancer incidence and BLMAsh heterozygosity [193]. A study in a functional BLM chimera
in diploid yeast shows that non-Bloom’s causing loss-of-function mutants in
heterozygotic carriers have HU sensitivity intermediate to the wildtype and loss-offunction homozygotes [11]. This finding suggests that combination of a non-functional
allele with a wildtype BLM allele could in fact impact cell survival in the presence of
chronic DNA damage. This could have potential consequences for human patients with
a heterozygotic loss-of-function BLM status, particularly with regards to long-term DNA
damage (e.g. chemotherapy).

A frameshift mutation in a polyadenine tract in BLM in
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genetically unstable cancers prone to microsatellite instability was also discovered
[194], and intronic SNPs in Rmi1, Top3α, and BLM have all been found to be associated
with increased risk of acute myelogenous leukemia/myelodysplastic syndrome and
melanoma (Rmi1 and Top3α) and bladder cancer (BLM) [194, 195]. This suggests an
importance for BLM in maintaining genomic stability in the body, and that a degree of
haploinsuffciency may exist with regards to certain kinds of cancer.

Figure 1.9: Patients with Bloom's syndrome. Patient on the left exhibits the classic
facial telangiectasias of the disease. The middle and right patients exhibit the short
stature of the disease. The middle patient grew to 138 cm in adulthood and the patient
in the right photograph (147 cm) is next to his brother (183 cm), who does not have the
disease. Photographs from Bloom’s syndrome registry, Weill Cornell Medical College.

Intrinsically Disordered Proteins/Regions (IDP/Rs)
As the RecQ helicases participate in a wide range of functions, and, as shown in
the case of Sgs1, many of the protein/protein interactions that regulate these functions
are N-terminal, it is perhaps striking that little research has been done in defining the
structure of the first half of these proteins as has been done for the catalytic regions. It
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is well-known that the N-termini of many of the long-form RecQs contain acidic domains
and that they are home to both protein interaction and modification sites, but the termini
have been described as being “featureless [196].” Classically, shape and folding was
believed to be the cornerstone in understanding protein function, and the so-called
"lock-and-key" models were used to describe the biochemistry behind most proteinsubstrate interactions. While secondary and tertiary structures are still indicators of
protein function for many proteins, this somewhat stringent view of structural science is
moot for a rising class of proteins and protein domains. For many important proteins,
including those used in cell cycle control, transcriptional and translational regulation,
and protein phosphorylation, a low degree of even secondary structure is evident.
These proteins are called "intrinsically disordered proteins (IDP)" or "natively unfolded"
proteins [197].

Characteristics of IDPs
Many IDPs are characterized by a high degree of flexibility, low hydrophobicity,
little sequence complexity, a low degree of compactness, and a large net charge. IDPs
are generally rich in polar molecules (R, G, Q, E, S, P, K), two of which (P and G) have
been shown to break secondary structures like alpha helices and beta sheets [197,
198]. In general, they tend to lack large hydrophobic or aromatic residues, as well as
residues that promote tertiary structure (i.e. through disulfide bonds). These proteins
therefore lack the sequence complexity of a more structured protein as they are
depleted in several amino acids (I, L, V, W, Y, F, C, N). Because of this specialized
composition, disordered proteins tend to be highly soluble in water and are generally
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more heat-soluble than ordered proteins [199]. Even within the disordered proteins,
there are proposed “flavors” of protein, and the composition of the different flavors (V,
C, and S) vary slightly from one another [200]; type C are more enriched in H, M, and A
than the others, type S has the least amount of H, and type V contain the greatest
percentage of inflexible residues C, F, I, and Y versus the other types of disordered
proteins. Interestingly, the role of these classes tend to differ as well, with C-type
containing the most protein modification sites, S-type proteins being mostly proteinprotein interactors, and V-type being mostly ribosomal proteins, thus implying a role for
primary structure in protein function [200, 201]. Secondary structure in these proteins is
typically confined to short segments, often helical and transient.

As a whole, the

“shape” of these proteins is classified as an ensemble of conformations which vary in
their degree of transient secondary and tertiary structure. The protein will continuously
shift between different conformations, and it is from these conformations that protein
function(s) can arise [202-206]. In general, these disordered regions and proteins are
believed to exist within a “structural continuum” along with folded proteins, and can
generally be described as being “molten globules,” collapsed structure with no firm
tertiary structure but developed secondary structure that is in a relatively fixed position;
“multi-domain proteins,” which have ordered domains tied together by disordered linkers
(also referred to as “beads on a string”), and “intrinsic coils,” which are mostly unfolded
and have little secondary structure, if any [202, 207]. For disordered regions within
proteins that have clusters of defined, folded structure, functionally disordered regions
may be very short, such as 4-8 residue linkers and transient helices; they could also be
large, being 10% of the protein in consecutive residues or longer [200]. Given depletion
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in aromatic and hydrophobic residues that result in the lack of a folded structure,
traditional techniques like X-ray crystallography are not available to IDPs. As such,
alternative techniques, including NMR spectroscopy, small angle x-ray scattering
(SAXS), circular dichroism, infared spectroscopy and atomic force microscopy are
employed in order to determine the ensemble-averaged structures obtained from
disordered proteins.

Prevalence of IDPs
A high percentage of eukaryotic proteins contain regions that are predicted to
have a long stretch (greater than 30 residues) of disorder; in S. cerevisiae, 50-60% of
the proteome is predicted to have these disordered domains, nearly three times as
many disordered regions as predicted in E. coli [208]. Within the three kingdoms, these
long stretches are predicted in 2% of Archea, 4.2% of Eubacteria, and 33% of
Eukaryotic proteins. In mammals, up to 25% of the total number of proteins is predicted
to be composed of completely unfolded proteins, such as Securin, Calpastatin, and Tau
[209, 210], which makes study of IDP function and characteristics an important topic
[200].

Thermodynamic Characteristics of IDPs
If one were to visualize the energy profile of a folded protein graphically, it could
generally be described as an energy landscape ranging from conformations with high
energy, to an energy minimum of the folded state in the pit of the graphical
representation (Figure 1.10). Unfolded proteins represent a dense population of
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conformational possibilities--transition from one disordered conformation to another
incurs little energy penalty [211]. In ordered proteins, however, the transition from
unfolded to folded protein is stepwise, and the energy landscape is “funnel-like.” As the
protein reaches conformations of ever decreasing free energy, the conformational
possibilities become less dense, as reversal from a lower energy state incurs an
entropic penalty much greater than those seen in the disordered ensemble. Thus, the
structural possibilities for a folded protein decrease as the folds approach the local
energy minima. Upon binding, disordered proteins lose a degree of entropy, particularly
if they undergo an induced-folding event; appropriate enthalpy compensation from
modifications like phosphorylation can also counteract entropy loss from folding. It has
also been inferred through experiments with the disordered interaction between pKID
and KIX proteins that IDPs may have a lower energy barrier to overcome than an
order/order interaction, as it is easier for disordered proteins to reach transitional states
in the binding reaction; this also lowers the need for high entropy loss compensation
[197, 212-214].

Functional Advantage of IDPs
IDPs are great for transient interactions, but given their high prevalence,
particularly in higher eukaryotes, benefits beyond the transient nature likely exist.
Indeed, there are several theories to the benefits of a fully- or largely-disordered protein.
One potential scenario is that an ordered protein of importance in several protein
pathways (i.e. kinases) has several downstream partners with disordered regions [213];
this allows the kinase to bind several partners with one single structure. On the other
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hand, a disordered protein/region may have many ordered partners that it can support
along the length of the disorder. The shape of the protein may change differently based
on the partner being bound (or may even stay disordered, forming a “fuzzy complex
[215]”). Beyond this, even these same proteins can bind different partners in the same
region, using small molecular recognition motifs (MoRFs) as docking points to
specifically recognize each different partner. By nature of its extended conformation,
disordered proteins may also allow for a much larger interaction area with its partner
than a folded partner affords; indeed, a disordered protein may well surround some or
all of an ordered protein [213, 216, 217]. Beyond this variety of binding events, termed
“promiscuous binding [210],” disordered proteins/regions also provide open access to
post-translational modification of residues, can serve as flexible linkers that modulate
the distance/position between two ordered domains, can be a stimulus for protein
degradation (for transient protein expression), can contribute to molecular assemblies of
proteins into large complexes, and can act as an area of rapid evolution that will not
disrupt a protein’s catalytic or structural function (Figure 1.11) [200, 217-219]. A study
into the putative roles and advantages of IDPs in yeast Chromatin Processes proteins
can be found in chapter 4 of this dissertation.
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Figure 1.10: Free energy of proteins. Unfolded proteins tend to have high free energy
that reaches no minimum energy conformation, while ordered proteins have a lowenergy conformation termed "native." Proteins with small degrees of secondary
structure vary between the energy extremes [220].

Figure 1.11: Potential roles of disorder in protein binding. Adapted from Dunker et
al, 2002 [219].
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Evolutionary Advantage of IDPs
IDPs present an interesting case in the study of the evolution of proteins. There
are three definitions of structural conservation with regards to IDPs: flexible disorder,
which conserves the disorder in orthologs but not the primary sequence, constrained
disorder, which conserves both the disorder and the primary sequence, and nonconserved disorder [221]. Specific examples of flexible disorder evolution have been
investigated where dynamic properties of disordered regions like linkers are conserved
between orthologs, but primary sequence alignment is poor [222].

As such, it is

important to consider evaluation beyond primary sequence alignments with regards to
these regions; the different levels of disorder conservation are prevalent in different cell
functions, with flexible disorder being most enriched in cell signaling and regulatory
proteins and constrained disorder being most prevalent in proteins involving ribosome
biogenesis, RNA binding, and protein folding [221]. Thus, the degree of primary
sequence conservation may or may not be an important tool depending on the function
of a group of orthologs. Also, while primary sequence in a great deal of IDPs tends to be
poorly conserved in comparison to ordered proteins, a large percentage of them tend to
conserve overall chemical composition; this allows a certain degree of flexibility in these
regions with regards to acquisition of mutations and indels in these regions; function of
these regions may still be retained if the mutagenesis does not affect overall chemistry
[223, 224]. Indeed, long indels in homologous eukaryotic proteins have been confined
mostly to the termini and disordered regions of the protein, and further disorder usually
arises from disordered areas, which can more easily tolerate the modification of
sequence [225, 226]. Conservation of disordered regions is particularly important with
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regards to areas of post-translational modification, and the density of phosphosites in a
protein highly correlates with disorder conservation (and less so with amino acid
conservation) [221].
With regards to evolutionary time, it has been suggested that disorder tends to
evolve more quickly than ordered regions [227]. An investigation into the evolution of
disordered and ordered protein sets found that disordered proteins are generally more
tolerant of evolution than ordered proteins, and evolution of individual residues tolerates
a broader range of substitutions. Interestingly, this is not true of all residues in disorder;
glutamine and asparagine are more prone to change in order than disorder, and
tryptophan and tyrosine are often highly conserved in disordered domains [228].
Because protein/protein interaction events are also often driven by MoRFs that are not
large, folded structures, interactions between partner proteins can be conserved so long
as the MoRF remains, allowing for greater evolutionary change in the areas surrounding
the MoRF [223]. It should be unsurprising, then, that disorder is more prevalent in
eukaryotes than prokaryotes; over evolutionary time, disorder present in prokaryotes
can add on more disorder to accommodate for further protein function in higher
organisms. Indeed, length of disorder very closely correlates with the super-kingdoms,
with eukaryota exhibiting much larger percentages of proteins with 80 or more
consecutive residues in a disordered region than prokaryota and archea [229].

Examples of Intrinsic Disorder
The oncoprotein p53 has been shown to have disordered N- and C-termini that
modulate several protein-protein interactions and house the majority of the protein’s
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PTMs, including acetylation, phosphorylation, and methylation events [230]. p53 is
modulated by Mdm2 via its disordered transcription activation domain; binding regulates
p53 interaction with transcriptional factors and targets p53 for destruction. As proper
p53 function is important for suppressing cancer, the impact of mutated disordered
regions on the ability of p53 to regulate downstream elements is in ongoing
investigation [231]. Mutation of the disordered domain in the p53 transactivation domain
showed that a simple P27A substitution increased binding to E3 ligase Mdm2, a result
that lead to lowered expression of p53 target genes; this clearly exhibits the need for a
degree of conserved disorder in proteins like p53 [232].
Tau protein in mammalian brain cells is a microtubule-associated protein that has
been detected in neurofibrillary tangles in the brains of Alzheimer’s Disease (AD)
patients. In the normal brain, Tau protein is mostly a random coil; Tau has been found
to be abnormally hyperphosphorylated in AD cases, and this modified protein is more
prone to a stiffer, more partially folded conformation that tends to form the observed
tangles [233-235]. Though it is currently unknown what mechanism this aggregation
plays in AD onset and progression (if any), it remains a hallmark sign of the disease and
the advancement of dementia in AD has been highly correlated with the degree of
tangles present [236].
In yeast, ADR1, a regulator of alcohol dehydrogenase ADH2, contains a DNAbinding domain with an N-terminal disordered accessory domain and two zinc finger
domains; overall, the unbound protein resembles a “beads on a string” model, where
the two structured zinc finger domains lie on the disordered “string” that makes up the
rest of the domain. Upon DNA binding, the region undergoes more extensive folding,
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and the whole domain becomes structured. It is hypothesized that this increased folding
around the fingers may increase the affinity of the region for DNA and is a good
example of functional disorder in transcriptional regulation [237].

Disorder in S. cerevisiae
Studies in the S. cerevisiae proteome have estimated the percentage of proteins
containing at least 30 consecutive disordered residues is between 31-54%, at least 50
consecutive disordered residues is between 19-30%, and wholly disordered proteins are
up to 6% of the total proteome [209, 238]. With regards to the types of protein in the
yeast genome that contain disorder, proteins are often found in the nucleus and are
associated with transcription, protein modification (kinases), and binding activity,
including DNA binding [238]. Disorder was also found to be a characteristic of “hub”
proteins in yeast--proteins that act as a docker of several different partner proteins.
Yeast hubs are enriched in wholly disordered proteins and depleted in ordered proteins,
with hubs involved in protein binding being most strongly associated with predicted
disorder, supporting the hypothesis that they are acting as “promiscuous binders” of
several downstream protein elements; a study in promiscuous transcriptional hubs show
that this specific class of protein reflects this model [239, 240].

Disorder in RecQ Helicases
Though there has been talk about the acidic domains of Sgs1 and BLM, implying
consideration of the role of disorder in the RecQ family, the topic remains overall
understudied. Using IUPRED prediction software [241], it is evident that the long-form
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RecQs in humans and the yeast Sgs1 all contain a degree of long disorder in the Nterminus (Figure 1.12). Given that the RecQ helicases function in several different
pathways as described above, and are subject to a wide array of protein/protein
interactions and post-translational modifications in these N-termini, and, since these are
major function of disordered proteins, disorder and other structural study in the RecQ
helicases require more attention going forward. Thinking about the RecQs with regard
to disorder, both flexible and non-conserved rather than traditional primary sequence
alignments could potentially help elucidate some of the questions still surrounding these
proteins. Chapter 3 reports a study we conducted on the N-terminal region of Sgs1 at
the Top3 binding site, confirming predictions that this area is in fact, disordered. It is
suggested, then, that disorder be taken into consideration when studying the RecQ
proteins and their binding partner interactions. While NMR is the basis for study of
disorder in that chapter, chapter 5 suggests a method for using site-directed
mutagenesis as a means for targeting MoRFs in otherwise disordered regions. This can
allow for the identification of important small/transient structure in these areas that may
help mediate protein function and stability. Indeed, helical prediction of the first 250
residues of BLM using a bioinformatics tool for predicting alpha-helical structure, Agadir
[242], reveals several putative helical regions that, based on our findings with Sgs1,
may be transient helices facilitating the interaction of BLM with Top3α, Rmi1 and Rmi2
(Figure 1.13). Further study into this region may highlight areas of interest to look for
SNPs in the general population that may contribute to an understanding of increased
cancer risk.
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Figure 1.12: IUPRED predictions for BLM, WRN, RECQL4, and Sgs1. IUPRED [241]
profiles show that long-form RecQs in humans have some degree of predicted disorder,
particularly in protein/protein interaction domains.
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residues of the BLM protein (Top3/Rmi1/Rmi2 interaction) reveals several putative
areas of predicted alpha-helical structure for site-directed mutagenesis-based structural
studies.
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CHAPTER 2:
MATERIALS AND METHODS

Note to the reader: Experiment-specific methods are included in the chapter they apply
to. Please refer to those chapters for these protocols. Below are detailed protocols for
techniques used for several different experiments or for protocols only briefly outlined in
publications.

Site-Directed Mutagenesis
Protocol was adapted from the Agilent Technologies protocol manual for Quick
Change Mutagenesis. Primer numbers used in all site-directed mutagenesis
experiments in the table 2.1 below and were designed as 35-mers with the mutation of
interest in the center of the primer; the codon choice was determined by the least
amount of nucleotide changes that could be made from original sequence to mutant,
with consideration for codon commonality. All mutagenesis was conducted with a twelve
and a half minute extension time at 68°C
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Table 2.1: Site-Directed Mutagenesis Primer List
Primer Name
1877-sgs1-F30P-F

Gene
SGS1

Mutation
F30P

1878-sgs1-F30P-R

SGS1

F30P

1879-sgs1-N80STOP-F

SGS1

1880-sgs1-N80STOP-R

SGS1

1881-sgs1-L93P-F

SGS1

Stop at residue
80
Stop at residue
80
L93P

1882-sgs1-L93P-R

SGS1

L93P

1923-W92PF

SGS1

W92P

1924-W92PR

SGS1

W92P

1987-K26P-F

SGS1

K26P

1988-K26P-R

SGS1

K26P

1989-Q34P-F

SGS1

Q34P

1990-Q34P-R

SGS1

Q34P

2014-Sgs1V29PF

SGS1

V29P

2015-Sgs1V29PR

SGS1

V29P

2016-Sgs1I33PF

SGS1

I33P

2017-Sgs1I33PR

SGS1

I33P

2061- Sgs1K17P F

SGS1

K17P

2062- Sgs1K17P R

SGS1

K17P

2063- Sgs1 T21P F

SGS1

T21P

2064-Sgs1 T21P R

SGS1

T21P

2065-Sgs1 D25P F

SGS1

D25P
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Sequence
AGACAAAGATTTCGTACCCCA
GGCTATCCAAAAGC
GCTTTTGGATAGCCTGGGGTA
CGAAATCTTTGTCT
TGCTACGAAACAACATTAAGT
CATGCAAACTTTGT
ACAAAGTTTGCATGACTTAATG
TTGTTTCGTAGCA
GAACGATACAGAATGGCTCTC
GTACACTGCCACAT
ATGTGGCAGTGTACGAGGGC
CATTCTGTATCGTTC
GTCGAACGATACAGAACCGCC
CTCGTACACTGCCA
TGGCAGTGTACGAGGGCGGT
TCTGTATCGTTCGAC
GACTTTACAGGAAGACCCAGA
TTTCGTATTCCAGG
CCTGGAATACGAAATCTGGGT
CTTCCTGTAAAGTC
CGTATTCCAGGCTATCCCAAA
GCACATCGCGAACA
TGTTCGCGATGTGCTTTGGGA
TAGCCTGGAATACG
GGAAGACAAAGATTTCCCATT
CCAGGCTATCCAAA
TTTGGATAGCCTGGAATGGGA
AATCTTTGTCTTCC
TTTCGTATTCCAGGCTCCCCA
AAAGCACATCGCGA
TCGCGATGTGCTTTTGGGGAG
CCTGGAATACGAAA
GGAGCACAAATGGTTAccGGA
AACGGCGACTTTAC
GTAAAGTCGCCGTTTCCggTAA
CCATTTGTGCTCC
GTTAAAGGAAACGGCGcCTTT
ACAGGAAGACAAAG
CTTTGTCTTCCTGTAAAGgCGC
CGTTTCCTTTAAC
GGCGACTTTACAGGAAccCAA
AGATTTCGTATTCC

Table 2.1: Site-Directed Mutagenesis Primer List (continued)
Primer Name
2066-Sgs1D25P R

Gene
SGS1

Mutation
D25P

2067-Sgs1 I37P F

SGS1

I37P

2068-Sgs1 I37P R

SGS1

I37P

2069-Sgs1T61P F

SGS1

T61P

2070-Sgs1T61P R

SGS1

T61P

2098-Sgs1D25A F

SGS1

D25A

2099-Sgs1D25A R

SGS1

D25A

2100-Sgs1D25K F

SGS1

D25K

2101-Sgs1D25K R

SGS1

D25K

2102-Sgs1I33A F

SGS1

I33A

2103-Sgs1I33A R

SGS1

I33A

2104-Sgs1I33K F

SGS1

I33K

2105-Sgs1I33K R

SGS1

I33K

2273-Sgs1 L9P F

SGS1

L9P

2274-Sgs1 L9P R

SGS1

L9P

2275-Sgs1H13P F

SGS1

H13P

2276-Sgs1H13P R

SGS1

H13P

2307-W15P F Sgs1

SGS1

W15P

2308-W15P R Sgs1

SGS1

W15P

2607-Rmi1 F63P F

RMI1

F63P

2608-Rmi1 F63P R

RMI1

F63P
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Sequence
GGAATACGAAATCTTTGggTTC
CTGTAAAGTCGCC
GGCTATCCAAAAGCACccCGC
GAACAAAAGGCCTA
TAGGCCTTTTGTTCGCGggGT
GCTTTTGGATAGCC
ATGTGGACCAGGAACAcCAAA
CTTTATAACCAGCA
TGCTGGTTATAAAGTTTGgTGT
TCCTGGTCCACAT
GGCGACTTTACAGGAAGcCAA
AGATTTCGTATTCC
GGAATACGAAATCTTTGgCTTC
CTGTAAAGTCGCC
GGCGACTTTACAGGAAaAgAA
AGATTTCGTATTCC
GGAATACGAAATCTTTcTtTTCC
TGTAAAGTCGCC
TTTCGTATTCCAGGCTgcCCAA
AAGCACATCGCGA
TCGCGATGTGCTTTTGGgcAG
CCTGGAATACGAAA
TTTCGTATTCCAGGCTAAACAA
AAGCACATCGCGA
TCGCGATGTGCTTTTGTTTAG
CCTGGAATACGAAA
GAAGCCGTCACATAACccAAG
AAGGGAGCACAAAT
ATTTGTGCTCCCTTCTTggGTT
ATGTGACGGCTTC
TAACTTAAGAAGGGAGCcCAA
ATGGTTAAAGGAAA
TTTCCTTTAACCATTTGgGCTC
CCTTCTTAAGTTA
AAGAAGGGAGCACAAAccgTTA
AAGGAAACGGCGA
TCGCCGTTTCCTTTAAcggTTT
GTGCTCCCTTCTT
AGACAGAGAACTGTTGccCCA
GGTGTTGATGGTAG
CTACCATCAACACCTGGggCA
ACAGTTCTCTGTCT

Table 2.1: Site-Directed Mutagenesis Primer List (continued)
Primer Name
Gene Mutation
Sequence
2610-Rmi1 P88A R
RMI1 P88A
CCACTTTCTGTTTTTTCGcATC
CAGCTTGGTTTTT
2611-Rmi1 E220P F
RMI1 E220P
ATTTTGTGATTATTTGccATCTA
AATTACAACGTG
2612-Rmi1 E220P R
RMI1 E220P
CACGTTGTAATTTAGATggCAA
ATAATCACAAAAT
2694-Rmi1 A128P F
RMI1 A128P
GGCGGATAACAACTGCcCCAA
GGAAAATAATAGCA
2695-Rmi1 A128P R
RMI1 A128P
TGCTATTATTTTCCTTGGgGCA
GTTGTTATCCGCC
2712-rmi1A139P F
RMI1 A139P
CAACAATAATAGCAGTcCCGC
CAAGAATAAAGCAG
2713-rmi1A139P R
RMI1 A139P
CTGCTTTATTCTTGGCGGgACT
GCTATTATTGTTG
2716-rmi1Y218P F
RMI1 Y218P
TCAGAAATTTTGTGATccTTTG
GAATCTAAATTAC
2717-rmi1Y218P R
RMI1 Y218P
GTAATTTAGATTCCAAAggATC
ACAAAATTTCTGA
3109-Rmi1F63K F
RMI1 F63K
AGACAGAGAACTGTTGaaaCA
GGTGTTGATGGTAG
3110-Rmi1F63K R
RMI1 F63K
CTACCATCAACACCTGtttCAAC
AGTTCTCTGTCT
3111-Rmi1Y218K F
RMI1 Y218K
TCAGAAATTTTGTGATaAaTTG
GAATCTAAATTAC
3112-Rmi1Y218K R
RMI1 Y218K
GTAATTTAGATTCCAAtTtATCA
CAAAATTTCTGA
3113-Rmi1L7P F
RMI1 L7P
ATGTCTTTTTCATCTATCccAaa
ACAGGATATCACAGATG
3114-Rmi1L7P R
RMI1 L7P
CATCTGTGATATCCTGTttTggG
ATAGATGAAAAAGACAT
3115-Rmi1 Y35P F
RMI1 Y35P
GATTGTTTTCAGAGCTccCCAA
AATGAACCTTGGT
3116-Rmi1 Y35P R
RMI1 Y35P
ACCAAGGTTCATTTTGGggAGC
TCTGAAAACAATC
All mutagenic PCRs were transformed into E. coli 5α cells via electroporation and plated
on selective media (all mutations except Sgs1 N1-80 STOP were selected on LBAmpicillin plates; Sgs1N1-80 was selected on LB-Kanamycin). Colonies were selected
from the overnight growth and plasmid was prepped according to the protocol below.
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Mutants were sequenced via MWG operon and results were evaluated via Sequencher
software for integration of the mutation of interest.

Plasmid Isolation from Bacteria
All plasmid minipreps were prepared using the QIAprep miniprep kits from
QIAGEN. Briefly, 5 ml of overnight bacterial culture was spun down at 3400 rpm for 10
min; the pellet was resuspended in QIAGEN buffer P1, followed by lysis with buffer P2,
and protein precipitation with buffer N3. The solution was then spun at 14 000 rpm for
10 min, and the supernatant was harvested. The plasmid was purified on the kitprovided column and eluted in 10 mM Tris, pH 8.

Gross Chromosomal Rearrangement (GCR) Assay
All GCRs were done in strain KHSY1338 (ura3-52, leu2Δ1, trp1Δ63, his3Δ200,
lys2ΔBgl, hom3-10, ade2Δ1, ade8, YEL069C::URA3, sgs1::HIS3). The assay surveys
for the loss of both URA3 and CAN1 genes and is indicative of a high level of genomic
instability. Five to ten colonies of KHSY1338 transformed with a mutant plasmid of
choice were grown in synthetic media lacking leucine (SC-LEU) . From these cultures, a
dilution was plated on SC-LEU and grown to obtain a viable cell count. The remaining
culture was pelleted, resuspended in water, and plated on GCR plates containing
canavanine and 5-FOA as previously described. [1].
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Trichloroacetic Acid (TCA) Extraction
Protocol was adapted from the protocol first described in Wright et al, 1989 [2].
The yeast strain of interest was grown to saturation in liquid media overnight; from this
culture, a culture is set up at OD600= 0.2 and grown to desired OD (varied from 0.5 to
1.0, depending on protein being probed). Five ODs of the culture was then spun and the
supernatant removed. The pellet was washed with water before being spun down again.
The pellet was then resuspended in 20% TCA and

acid-washed glass beads and

beaten in a bead beater. The lysate was drawn off, and the beads were washed with
TCA; this wash was pooled with the lysate. The sample was then spun down and the
pellet was resuspended in laemmli buffer and pH-adjusted with 2M Tris pH 8. The
sample was boiled, and then used in SDS-PAGE.

SDS-PAGE and Western Blot Analysis
Protocol was adapted from protocols in Schagger et al, 1987 and Towbin et al [3,
4]. Samples were loaded into an SDS-PAGE gel with 10%-18% polyacrylamide and run
in tris-glycine buffer (250 mM Tris, 1.9 M glycine, 1% SDS) at 170 V until good
resolution of a protein band can be expected as determined by the protein marker. The
proteins were then transferred to a PVDF membrane in 1x transfer buffer (250 mM Tris,
1.9 M glycine, 20% methanol) for 1 hour and 15 minutes at 300 mV in a Hoefer semi-dry
transfer machine. The membrane was then blocked overnight in 5% milk plus 1x TBST
(150 mM NaCl, 10 mM Tris, 0.1% Triton-X100, pH 7.6). Primary antibody was added to
5 ml of the same milk solution and the blot was incubated for 1 hour at room
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temperature. Following incubation, the blot was washed three times with TBST for 30
min. Secondary antibody (conjugated to horseradish peroxidase) was added to 5 ml
milk solution and incubated for 1 hr at 4°C. The blot was then washed three times with
TBST at 4°C for 30 min. The blot was then probed with 1:1 Amersham ECL prime kit
reagents (GE Healthcare) for 2 min and visualized with film.

Hydroxyurea Sensitivity Assay
Cultures were grown in SC-LEU overnight to saturation. A culture was prepared
from each of these saturations at an OD600 = 0.2 and grown to OD600= 0.5. A volume
equal to 0.5/OD times 50 µl of each culture was spun down at 14,000 rpm for 10 min
and resuspended in 50 µl water. A series of 10-fold dilutions was prepared and 2 µl of
each dilution was plated on YPD and YPD supplemented with 100 mM, 150 mM, or 200
mM HU and grown at 30°C. Plates were monitored for 4-5 days.

Yeast Mating for Diploids
Mating protocols were adapted from [5]. The two haploid strains of interest KHSY
2494 (MATa, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, RAD51.V5.6xHIS.KANMX6, Open
Biosystems)

and

KHSY

2497

(MATα,

ura3Δ0,

leu2Δ0,

his3Δ1,

lys2Δ0,

TOP3.V5.VSV.KANMX6), plus mating strains KHSY1435 (MATa, Δthr4) and 1436
(MATα, Δthr4) were streaked on YPD and grown for 2 days at 30°C. A single colony
from both strains of interest were mixed in 50 µl of water, spotted on YPD, and grown
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overnight at 30°C. From this spot, a small scoop was taken and spread for singles on
YPD and grown for 2 days at 30°C. A colony of tester strain 1435 was then suspended
in 50 µl of water and spread on a warm YPD plate; this was repeated for a separate
plate for tester strain 1436. Sixteen colonies from the mating plate were then suspended
in 30 µl of water, and 2 µl was spotted on a YPD plate, and both tester lawn plates.
Plates were incubated overnight at 30°C. The tester plates were replica plated onto
minimal media (SC-Min) and incubated overnight at 30°C. Diploids were identified as
those that did not grow on either tester plate as neither the tester nor strains of interest
can survive on minimal media without mating with one another. Diploids were frozen
and stored.

Lithium Acetate (LiAc) Transformation
The protocol used was previously described in Gietz and Woods, 2006 [6]. The
strain used for transformation was grown overnight in YPD to saturation. This culture
was then used to inoculate a 25 ml YPD culture to an OD 600= 0.2 and grown to
OD600=0.8± 0.04. The culture was then pelleted at 2000 rpm for 2 min, washed with 25
ml water, and spun down again. The pellet was then resuspended in 1 ml 100 mM LiAc
and spun down at 14,000 rpm for 30 seconds. This pellet was then resuspended in 240
µl 100 mM LiAc and distributed into 4 equal aliquots before being spun down at 14,000
rpm for 1 min. These pellets were then treated with 50% PEG, 36 µl of 1 M LiAc, 75 µl
of plasmid or PCR product plus water, and 10 µl boiled and snap-cooled salmon sperm
DNA and incubated for 30 min at 30 °C. Post-incubation, the cells were heat-shocked at
76

42°C for 15 min. The cells were then spun down at 7000 rpm for 1 min, and the pellet
was resuspended in 100 µl water and plated on selective media for the target gene or
mutation (SC-LEU for point mutants, SC-HIS for Rmi1.myc integrants) and grown for 2
days at 30 °C. Single colonies were restreaked, incubated for 2 days at 30°C, and
single colonies from this streak were frozen and stored post-verification.

Media Types
Media recipes were derived from Sherman, 2002 [5].

YPD liquid media was

made by autoclaving 10 g/l Yeast Extract (US Biological), 20 g/l Bacto-peptone (US
Biological), and 20 g/l glucose (Fisher Scientific). YPD agar uses the same ratios, but
with 20g/L Agar (US Biological). Selective media agar was made by autoclaving 20 g/l
agar and combining it with 2% glucose and a filter-sterilized solution of 6.7 g/l Yeast
Nitrogen base (US Biological) and 2 g/l of a dropout mix lacking the amino acid being
selected for (-LEU, -HIS; US Biological). Liquid selective media was made the same,
but without agar. SC-Minimal media contains only 20 g/l agar and 2% glucose. LB
media consisted of 10 g/l Tryptone (Fisher Scientific), 5 g/l Yeast extract, and 5 g/l NaCl
(Fisher Scientific).
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CHAPTER 3:
A TRANSIENT α-HELICAL MOLECULAR RECOGNITION ELEMENT IN THE
DISORDERED N-TERMINUS OF THE SGS1 HELICASE IS CRITICAL FOR
CHROMOSOME STABILITY AND BINDING OF TOP3/RMI1.
Note to the reader: This chapter has been previously published with permission from the
publisher as Kennedy, JA, Daughdrill, GW, and Schmidt, KH (2013). “A transient αhelical molecular recognition element in the disordered N-terminus of the Sgs1 helicase
is critical for chromosome stability and binding of Top3/Rmi1.” Nucleic Acids Res.,
41(22) 10215-27.
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Abstract
The RecQ-like DNA helicase family is essential for the maintenance of genome
stability in all organisms. Sgs1, a member of this family in Saccharomyces cerevisiae,
regulates early and late steps of double-strand break repair by homologous
recombination. Using nuclear magnetic resonance spectroscopy, we show that the Nterminal 125 residues of Sgs1 are disordered and contain a transient α-helix that
79

extends from residue 25 to 38. Based on the residue-specific knowledge of transient
secondary structure, we designed proline mutations to disrupt this α-helix and observed
hypersensitivity to DNA damaging agents and increased frequency of genome
rearrangements. In vitro binding assays show that the defects of the proline mutants are
the result of impaired binding of Top3 and Rmi1 to Sgs1. Extending mutagenesis Nterminally revealed a second functionally critical region that spans residues 9–17.
Depending on the position of the proline substitution in the helix functional impairment of
Sgs1 function varied, gradually increasing from the C- to the N-terminus. The multiscale
approach we used to interrogate structure/function relationships in the long disordered
N-terminal segment of Sgs1 allowed us to precisely define a functionally critical region
and should be generally applicable to other disordered proteins.

Introduction
The maintenance of genome stability is essential for organismal survival. A
complex and diverse system of proteins has evolved to accomplish this function. Sgs1
of Saccharomyces cerevisiae is a 3–5′ DNA helicase that belongs to the evolutionarily
conserved RecQ helicase family whose members function in the maintenance of
genome stability. Named after the RecQ helicase of Escherichia coli, members of this
helicase family have been identified in all organisms, including five homologs in humans
(RecQ1, BLM, WRN, RecQL4, RecQL5) [1]. Mutations in BLM, WRN and RecQL4 are
associated with Bloom syndrome, Werner syndrome and Rothmund–Thompson
syndrome, respectively, which are characterized by elevated levels of aberrant

80

recombination events, chromosome instability and extraordinary predisposition to
cancer development early in life [1].
Saccharomyces cerevisiae cells that lack Sgs1 exhibit several phenotypes that
are similar to those of cells from persons with Bloom syndrome, most notably
dysregulated homologous recombination, hypersensitivity to DNA-damaging agents,
meiotic defects and cell cycle delay [2,3]. These defects are caused when the helicase
activity of Sgs1 is inactivated by mutations in the ATPase domain or the RecQ Cterminal domain, which together make up the helicase core. Also located in the Cterminal half of Sgs1 is the Helicase and RNAase D C-terminal (HRDC) domain thought
to be involved in DNA substrate binding and protein–protein interactions. These
domains are conserved in most RecQ homologs; they are structurally ordered and
crystal structures of this region have been reported for E. coli RecQ and human RecQ1
[4,5]. In contrast, the N-terminal half of Sgs1 is devoid of conserved catalytic domains
and provides binding sites for proteins with roles in DNA metabolism, including the
topoisomerases Top2 and Top3, replication protein Rpa70, Rad16 and Srs2 [2,6–8].
Interaction with the Top3 homologs has also been shown for human BLM, RecQ1 and
RecQ5, and the RecQ homolog of Schizosaccharomyces pombe, Rqh1 [9–12].
Superhelical relaxation activity and Holliday-junction dissolution activity of these
topoisomerase/helicase complexes is greatly enhanced by interaction with the RecQmediated genome instability 1 (Rmi1) protein [13–15].
One of the most important functions of the Sgs1 N-terminus is the interaction with
the Top3/Rmi1 complex (BLM/Topo IIIα/Rmi1/Rmi2 in humans, Rqh1/Top3/Rmi1 in S.
pombe) [13–16]. The Top3 binding site is within the first 100–158 residues of Sgs1 [17–
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19]. The loss of this region produces more severe phenotypes that exhibit slower growth
and higher sensitivity to DNA damage than those produced by loss of Sgs1 alone [3].
This may be due to toxic intermediates produced by Sgs1 that accumulate during
homologous recombination and require Top3 decatenation for resolution. Despite the
fact that Sgs1 and BLM bind Top3 and its human homolog Topo IIIα, respectively, there
is little primary sequence similarity between the N-terminal regions where these
interactions are predicted to occur. Both N-termini are predicted to be intrinsically
disordered [20], which may help explain their level of sequence divergence [21,22].
Such intrinsically disordered proteins/regions (IDPs/IDRs) are widespread in eukaryotes
and function arises from an ensemble of conformations that contain varying degrees of
secondary structure and rarely form transient tertiary contacts [21, 23–28]. A high
percentage of eukaryotic proteins are predicted to contain significant stretches (>30
residues) of disorder; in S. cerevisiae, 50–60% of the total proteome are IDPs/IDRs,
and a survey of cancer-associated human proteins found that ∼79% of the proteins in
the database are IDPs/IDRs [29,30].
Using multidimensional heteronuclear nuclear magnetic resonance (NMR)
spectroscopy, we have identified a short segment within the first 125 residues of the
intrinsically disordered N-terminus of unbound Sgs1 that has transient α-helical
structure whose integrity is essential for Sgs1 function in vivo. We have rationally
designed single amino acid substitutions that disrupt transient α-helices. Some of these
mutations eliminate Top3 binding to Sgs1, cause DNA damage hypersensitivity and
induce spontaneous chromosomal rearrangements.
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Materials and Methods
Expression and Purification of Peptides for NMR Spectroscopy
Methods were based on a previously described procedure for the expression of
an IDP [31]. Plasmid pKHS443, expressing Sgs11−125, was constructed by inserting the
first 375 bp of SGS1 into pET28a (Novagen) using NdeI and BamHI sites. Plasmid
pKHS463, expressing Sgs11−80, was constructed by introducing a stop codon after 240
bp in pKHS443. pKHS443 or pKHS463 was transformed into E. coli BL21 (DE) cells
and grown at 37°C in 2 l of M9 media (42 mM Na 2HPO4, 22 mM KH2PO4, 8 mM NaCl, 2
mM MgSO4, 11 mM d-glucose, 0.1 mM CaCl2, 10 µM FeCl3, 1 mg of Vitamin B1/L, pH
7.3) plus 200 mg of ampicillin, supplemented with N15 ammonium chloride and C13
glucose. Protein expression was induced at OD600 = 0.6 for 3 h with 1 mM Isopropylbeta-D-thiogalactopyranoside (IPTG) at 37°C. Cells were harvested via centrifugation at
8000 rpm before being resuspended in buffer A1 (50 mM NaH 2PO4, 300 mM NaCl, 10
mM imidazole, pH 8.0) and lysed at 19 000 psi via French press. The lysate was
cleared via centrifugation (18 000 rpm, 1 h, 4°C) and the supernatant was loaded onto a
30 ml Ni-NTA column on an AKTA FPLC. The column was washed with 5 column
volumes of buffer A2 (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), and
the peptide was eluted in buffer B (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole,
pH 8.0). Fractions containing the eluted protein were pooled and dialyzed into 50 mM
Tris (pH 8.0) and 100 mM NaCl. The fractions were treated with 1 ml CleanCleave
thrombin beads (Sigma) at room temperature for 8 h to remove the N-terminal (HIS)6
tag. Cleaved proteins were dialyzed into gel filtration buffer (50 mM NaH 2PO4, 300 mM
NaCl, 1 mM EDTA, 0.02% NaN3, 4 mM DL-Dithiothreitol (DTT), pH 7), then
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concentrated to a volume of 10 ml and loaded onto a 120-ml GE Hiload 16/60 Superdex
70 column via fast protein liquid chromatography (FPLC) and harvested over four 2.5-ml
runs. Fractions containing the peptide were pooled and dialyzed into NMR buffer (50
mM NaH2PO4, 100 mM NaCl, 1 mM EDTA, 0.02% NaN3, 4 mM DTT, pH 6.8) before
being concentrated to 600 µl (150 µM for Sgs1 1−125; 690 µM for Sgs11−80, 160 µM for
Sgs11−80-F30P).

NMR Analysis
NMR data for Sgs11−80 and Sgs11−80-F30P were collected at 25°C on a Varian
VNMRS 800 MHz spectrometer equipped with a triple resonance pulse field Z-axis
gradient cold probe. To make the amide 1H and

15

N as well as

13

C,

13

Cβ and

13

CO

resonance assignments, sensitivity enhanced 1H-15N heteronuclear single quantum
correlation (HSQC) and three-dimensional HNCACB and HNCO experiments were
performed on a uniformly

15

N- and

13

C-labeled sample of Sgs11−80 at 470 µM (or

Sgs11−80-F30P at 160 µM) in 90% H2O/10% D2O, phosphate buffered saline (PBS)
buffer, at a pH of 6.8 (32–34). For the HNCACB experiment, data were acquired in 1H,
13

C and

15

N dimensions using 9615.3846 (t3) × 16 086.4648 (t2) × 2000 (t1) Hz sweep

widths, and 512 (t3) × 128 (t2) × 32 (t1) complex data points. For the HNCO, the sweep
widths were 9615.3846 (t3) × 2000 (t2) × 2000 (t1) Hz, complex data points were
identical to the HNCACB. The sweep widths and complex data points of the HSQC
were 9615.3846 (t2) × 2100 (t1) Hz and 1024 (t2) × 128 (t1), respectively. Processing and
analysis of the HNCACB data resulted in 66 nonproline amide 1H,
resonance assignments plus 8 proline

13

Cα and
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13

15

N,

13

Cα and

13

Cb

Cβ resonance assignments. 1H-15N

steady-state nuclear Overhauser effect (NOE) experiments were recorded at 25°C on a
Varian VNMRS 600 MHz spectrometer equipped with a triple resonance pulse field Zaxis gradient cold probe in the presence and absence of a 120 off-resonance 1H
saturation pulse every 5 ms for 3 s. A total of 512 (t2) × 128 (t1) complex points were
recorded with 128 scans per increment with the sweep widths set to 7225.4335 (t2) ×
1700 (t1) Hz. The 1H-15N heteronuclear Overhauser effect (NHNOE) values were
determined by taking the quotient of the intensity for resolved resonances in the
presence and absence of proton saturation. Three measurements were made on each
protein and the values were averaged. Resonance assignments for Sgs1 1−125 were
carried out at 25°C on a Varian VNMRS 600 MHz spectrometer equipped with a triple
resonance pulse field Z-axis gradient cold probe. To make the amide 1H and 15N as well
as

13

Cα,

13

Cβ and

13

CO resonance assignments, sensitivity-enhanced 1H-15N HSQC and

three-dimensional HNCACB and HNCO experiments were performed on a uniformly
15

13

N- and

C-labeled sample at 150 µM in 90% H2O/10% D2O, PBS buffer, at pH 6.8.

For the HNCACB experiment, data were acquired in 1H,

13

C and

15

N dimensions using

7225.4335 (t3) × 12 064.1295 (t2) × 1499.9813 (t1) Hz sweep widths, and 512 (t3) × 108
(t2) × 32 (t1) complex data points. For the HNCO, the sweep widths were 7225.4335 (t3)
× 1500 (t2) × 1499.9813 (t1) Hz, and 512 (t3) × 74 (t2) × 32 (t1) complex data points. For
the HNCACO, the sweep widths were 7225.4335 (t3) × 12 000 (t2) × 1499.9813 (t1) Hz,
and 512 (t3) × 70 (t2) × 28 (t1) complex data points. Processing and analysis of the data
resulted in 87 nonproline amide 1H,
proline

13

Cα and

15

N,

13

Cα and

13

Cb resonance assignments plus 12

13

Cβ resonance assignments. All NMR spectra were processed with

nmrPipe and analyzed using nmrView software (31,35,36). Apodization was achieved in
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the 1H,

13

C and

15

N dimensions using a squared sine bell function shifted by 70°.

Apodization was followed by zero filling to twice the number of real data points and
linear prediction was used in the 15N dimension of the HNCACB.

Hydroxyurea Hypersensitivity Assay
Yeast strain KHSY1338 (ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom310, ade2Δ1, ade8, YEL069C::URA3, sgs1::HIS3) was transformed with derivatives of
plasmid pRS415-SGS1 (Supplementary Table S1) by standard lithium-acetate
transformation [37] and selected on synthetic complete media lacking leucine (SC-Leu).
Transformants were grown in liquid SC-Leu to OD600 = 0.5, then plated in 10-fold
dilutions on YPD (yeast extract/peptone/dextrose) and on YPD supplemented with 100
mM hydroxyurea (HU). Colony growth at 30°C was documented after 3–5 days.

Top3 and Rmi1 Binding Assay
Plasmid pKHS462, expressing GST-Sgs11−250, was constructed by inserting the
first 750 bp of SGS1 into pGEX-6p-2 (GE Healthcare) using BamHI and XhoI sites. The
Sgs1 fragment was expressed in E. coli BL21 (DE) cells in LB media (10 g/l tryptone, 5
g/l NaCl, 5 g/l Yeast extract) supplemented with 1.5 mg ampicillin for 3 h in the
presence of 1 mM IPTG. The cell pellet was resuspended in 100 µl GST buffer (125 mM
Tris, 150 mM NaCl, pH 8.0) plus HALT protease inhibitors (Pierce) and sonicated for 10
× 3 pulses. Lysate was cleared by centrifugation at 14 000 rpm for 10 min at 4°C.
Glutathione magnetic beads (Pierce) were then incubated with 625 µg of cleared lysate
for 1 h at 4°C, and washed three times with GST buffer. Native yeast whole-cell extract
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containing endogenous levels of Top3 and/or Rmi1 was prepared from a culture of
KHSY2497 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, TOP3.V5.VSV.KANMX6, Open
Biosystems), KHSY4695 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0, rmi1::HIS3,
TOP3.V5.VSV.KANMX6) or KHSY4696 (MATα, ura3Δ0, leu2Δ0, his3Δ1, lys2Δ0,
TOP3.V5.VSV.KANMX6, RMI1.myc.HIS3MX6) grown at 30°C in YPD overnight. To
construct a top3Δ yeast strain that expresses myc-epitope tagged Rmi1, a diploid
generated by mating RDKY3837 (MATa, ura3-52, trp1Δ63, his3Δ200, leu2Δ1, lys2Bgl,
hom3-10, ade2Δ1, ade8, top3::TRP1) and KHSY4696 (MATα, ura3Δ0, leu2Δ0, his3Δ1,
lys2Δ0, TOP3.V5.VSV.KANMX6, RMI1.myc.HIS3MX6) was sporulated (38) to isolate a
top3::TRP1, RMI1.myc.HIS3MX6 haploid (KHSY4741) by genotyping on selective
media. The presence of the top3::TRP1 and RMI1.myc.HIS3MX6 alleles was also
confirmed by polymerase chain reaction. Yeast cells were collected by centrifugation at
2000 rpm for 4 min, washed and resuspended in Top3/Rmi1 buffer (50 mM Tris, pH 7.5,
0.01% NP-40, 5 mM β-glycerol phosphate, 2 mM magnesium acetate, 120 mM NaCl)
plus HALT protease inhibitors (Pierce). The suspension was lysed via French press at
19 000 psi or in a BeadBeater (Biospec Products, Inc.) by beating three times for 1 min.
Lysates were cleared by centrifugation at 14 000 rpm for 15 min at 4°C. Cleared yeast
lysate of 20 (KHSY2497, KHSY4695) or 10 mg (KHSY4696, KHSY4741) was incubated
with Sgs1-bound magnetic beads for 90 min at room temperature on a nutator. Beads
were washed four times with Top3/Rmi1 buffer plus HALT protease inhibitors (Pierce)
and boiled for 10 min in Laemmli buffer (BioRad). Beads were collected by
centrifugation and eluted protein complexes were separated by 10% sodium dodecyl
sulphate-polyacrylamide

gel

electrophoresis
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(SDS-PAGE).

Presence

of

Sgs1

fragments, Top3 and Rmi1 and was determined by western blotting using monoclonal
antibodies against GST (Covance), VSV (Sigma) and myc (Covance) epitopes,
respectively.

Gross-Chromosomal Rearrangement Assay
Accumulation of cells that had undergone simultaneous inactivation of the URA3
and CAN1 genes on chromosome V was determined as previously described [39]
except that cells were grown in the absence of leucine to select for the presence of the
pRS415-derived plasmids expressing the desired sgs1 mutants. Briefly, yeast strain
KHSY1338 was transformed with derivatives of plasmid pRS415-SGS1 containing
proline mutations (Supplementary Table S3.I) and grown to saturation at 30°C in 10 ml
of SC-Leu. Cells were washed in water and plated on selective media containing
canavanine (can) and 5-fluoro-orotic acid (5-FOA) to select for cells with inactive CAN1
and URA3 genes. Cells were also plated on SC-Leu media to obtain a viable cell count.
After incubation at 30°C, viable cell count was determined after 3 days, and colonies on
5-FOA/can were counted after 5 days. Mutation rates and 95% confidence intervals
were calculated from 6 to 16 cultures as previously described [39,40].

Preparation of Yeast Whole-Cell Extracts by Trichloroacetic Acid Extraction
To assess expression levels of Top3 and Rmi1 in rmi1::HIS3 and top3::TRP1
strains, respectively, yeast cultures were grown in YPD with vigorous shaking and 10
ODs were harvested by centrifugation at 2000 rpm for 2 min. To assess expression
levels of sgs1-F30P and sgs1-H13P, the 3′-end of SGS1 in pKHS481 was fused to the
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myc-epitope amplified from pFA6a-13Myc-HIS3MX6 [41] by gap repair of SacIlinearized pKHS481 to generate pKHS596. F30P and H13P mutations were introduced
into pKHS596 by QuikChange mutagenesis (Agilent Technologies) to generate
pKHS598 and pKHS600, respectively. Cell pellets were washed in water and
resuspended in ice-cold 20% trichloroacetic acid (TCA) and vortexed in a cell disruptor
(USA Scientific) with acid-washed glass beads for 4 min at maximum speed. Cell lysate
was cleared at 14 000 rpm for 3 min. The pellet was resuspended in Laemmli buffer,
adjusted to neutral pH and boiled for 2 min before separation by 10% SDS-PAGE.
Presence of Top3.VSV, Rmi1.myc, Sgs1.myc and GAPDH was determined by western
blotting using monoclonal antibodies against VSV (Sigma) and myc (Covance) epitopes,
and against GAPDH (Pierce), respectively.

Results
The First 125 Residues of the Structurally Disordered N-terminus of Sgs1
Contain Two Transient α-helices
Sgs1 is a modular protein containing both ordered and disordered domains. The
ATPase domain, zinc-binding domain, winged-helix domain and the HRDC domain
make up the structurally ordered C-terminal half of Sgs1. In contrast, most of the Nterminal half of Sgs1 (residues 1–654) is predicted to be disordered [20,42]. This is also
the case for other members of the RecQ helicase family, most notably S. pombe Rqh1
and human BLM.
A previous study has shown that the first 158 residues of Sgs1 are sufficient for
binding to the topoisomerase Top3 [18]. It is well established that short segments within
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longer disordered regions will undergo coupled folding and binding in the presence of
protein binding partners [43–45]. Disorder predictors like IUPred [46] will frequently
display short dips into the ordered region (disorder tendency < 0.5) that correspond to
these protein binding sites, and it is expected that these regions will contain some
degree of transient secondary structure. The lowest dips in the IUPred plot of the first
158 residues of Sgs1 correspond to residues E24 and Y102 (Figure 3.1). To determine
whether these small segments within the disordered N-terminus of Sgs1 could adopt
functionally significant secondary structures, we characterized the solution structure of
the first 125 residues of Sgs1 using NMR spectroscopy. Single (15N)- and double
(15N/13C)-labeled samples of Sgs11−125 were overexpressed in E. coli and purified to
apparent homogeneity. The double-labeled sample was used to measure the HSQC
spectrum (Figure 3.2) as well as the triple resonance spectra that were used to make
resonance assignments. The HSQC spectrum shows narrow chemical shift dispersion
in the 1H dimension (7.85–8.5 ppm), consistent with a disordered peptide [47–49]. The
15

N-labeled sample was used to measure the NHNOE. NHNOE values are sensitive to

the rotational correlation time for the residue of interest. In disordered regions, small
positive NHNOE values indicate regions that are less dynamic and typically correlate
with the presence of transient secondary structure, and negative NHNOE values
indicate highly dynamic regions. The NHNOE values observed for Sgs1 1−125 are
consistent with a mostly disordered protein that contains two transiently ordered regions
centered on residues F30 and E92 (Figure 3.3A). Alpha carbon secondary chemical
shifts (CAΔδ) were calculated for every residue by subtracting the amino acid–specific
random coil chemical shift values for CA from the measured values [50]. This is a
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reliable method for identifying the presence of transient secondary structure in IDPs
[51–53]. The presence of transient α-helical secondary structure in Sgs11−125 was
indicated by consecutive positive CAΔδ values for residues 23–34 and 88–97 (Figure
3.3B).
Several clusters of overlapping resonances in the HSQC and HNCACB spectra,
and repeating amino acid motifs (e.g. Thr-Ala-Thr) limited resonance assignments to
77% of the nonproline residues for the Sgs1 1−125 fragment. Several of the residues that
could not be assigned were in or near the two transient α-helical segments preventing
an identification of the helix boundaries. To develop a more complete picture of the first
helical region, NMR analysis of a shorter Sgs1 fragment containing residues 1–80
(Sgs11−80) was performed. Using this fragment, we were able to assign 93% of the
nonproline resonances in the HSQC spectrum (Figure 3.2) and to fill in the gaps in the
secondary

13

Cα chemical shift analysis (Figure 3.3C and D). The overlap between the

HSQC spectra of the Sgs11−80 and the Sgs11−125 peptides indicates that elimination of
36% of the residues of the Sgs11−125 peptide (45 residues) did not affect the solution
structure of the first 80 residues of Sgs1, consistent with this being a disordered region.
Secondary

13

Cα chemical shift analysis indicates the presence of α-helical secondary

structure for residues 25–38 and residues 88–97 within this disordered region (Figure
3B and D). However, as mentioned above, helical states for both regions are transient
because secondary shift values of > 2.6 δppm would be expected for
persistent α-helix [51].
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Functional Mapping of α-helices by Proline Mutagenesis
To determine if the transient α-helical structures for residues 25–38 and 88–97
are important for Sgs1 function, residues with the highest NHNOE and CAΔδ values in
each helical region were replaced with prolines—a known helix breaker. V29 and F30 in
the first helical region and W92 and L93 in the second helical region were changed to
proline in the context of full-length Sgs1. Cells expressing the mutant helicases were
plated on media containing 100 mM of the DNA-damaging agent HU (Figure 3.4). While
the sgs1-V29P and sgs1-F30P mutants were as sensitive to HU as the sgs1Δ mutant,
neither the W92P nor the L93P mutation caused increased sensitivity (Figure 3.4A and
B), indicating that the α-helical structure centered on V29 and F30 contributes to Sgs1’s
role in DNA damage repair, whereas that centered on W92 and L93 does not.
According to the NHNOE and CAΔδ values, the strongest helical region in the
first 125 residues of Sgs1 extends from residues 25 to 38. To determine the functional
distance that this helical region extends on both sides of V29 and F30, residues were
mutated according to the expected i, i + 4 intramolecular hydrogen-bonding pattern of a
typical α-helix. The mutants using V29 as a starting point, therefore, were D25P, I33P
and I37P and those based on F30 were K26P and Q34P. Because proline substitutions
of disordered residues near the ordered region would not be predicted to affect Sgs1
function, a T61P mutation (IUPred disorder score: 0.73) was included as a negative
control. The sgs1-K26P, sgs1-Q34P, sgs1-I37P and sgs1-T61P mutants exhibited wildtype levels of HU sensitivity, whereas the sgs1-D25P and sgs1-I33P mutants were
hypersensitive, with a gradual decrease in functional impairment of Sgs1 being
observed between proline substitutions near the N-terminus of the helix and those near
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the C-terminus (Figure 3.4A). These observations are consistent with the functional αhelix extending from residues 25 to 33.
Whereas the lack of an effect of proline in position 26 argues against K26 being
an internal residue of α-helix, our findings are consistent with K26 being in the first
helical turn, more specifically in the N1 position, where proline is tolerated [54,55],
whereas D25—as the N-cap residue [56]—defines the N-terminal helix boundary.
Indeed, the AGADIR algorithm [57] identified a prominent peak of helical propensity
centering on residue I33, and D25 received the highest N-cap score (Figure 3.5A).
Consistent with the results of the DNA-damage-sensitivity assay, AGADIR predicted
reduced helical content for the D25P mutant, but not for the K26P mutant (Figure 3.5B).
Removing the N-cap by replacing the aspartic acid residue at position 25 with basic
(D25K) or neutral (D25A) residues, which have excellent helical propensity, but are poor
N-cap residues [58], leads to N-terminal extension of the helix in AGADIR (Figure 3.5C).
This increase in helical content in the sgs1-D25K and sgs1-D25A mutants did not impair
Sgs1 function in vivo (Figure 3.4C).
Further extending the proline mutagenesis starting from V29 toward the Nterminus revealed wild-type levels of HU sensitivity for sgs1-T21P, consistent with D25
defining the N-terminal end of the α-helix. In contrast, the sgs1-K17P, sgs1-W15P,
sgs1-H13P and sgs1-L9P mutants were more sensitive to HU than cells expressing
wild-type Sgs1, indicating that this region is also critical for Sgs1 function (Figure 3.4B
and D). The stretch of consecutive positive CAΔδ values for N8 to R11 is consistent
with α-helical propensity and the HU hypersensitivity assay suggests that it extends Cterminally to residue H17. At first sight, the negative CAΔδ value for W15 seems to
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indicate that W15 is not in a transient helical structure (Figure 3.3D). If this is the case
then it suggests that any helical structure in the bound state is not contiguous from
residue 8 to 17. However, the inconsistent CAΔδ value for W15 could be owing to the
inaccuracies associated with the random coil chemical shift library used for calculating
the secondary chemical shifts [50] or related to an anomalous effect on the CA shift that
results from the partial charge of the H13 and H17 side chains. Consistent with W15
being an α-helix, substituting the tryptophan with other residues with good helical
propensity, such as alanine or arginine, did not affect Sgs1 function in the DNA-damage
hypersensitivity assay (W15A, Figure 3.4B) or its ability to induce slow growth in the
sgs1Δ top3Δ strain [59]. However, α-helical content in this region could not be further
assessed as assignments, and therefore NHNOE and CAΔδ values for residues S6,
E12, H13 and K14 were not available owing to overlapping resonances in the HSQC
spectra of both Sgs11−80 and Sgs11−125. That W15 and W92 could be changed to
nonaromatic residues without increasing sensitivity of cells to DNA damaging agents
(Figure 3.4B) also shows that these two residues are not involved in stacking
interactions with each other, with other aromatic residues in the region, or with DNA
[60,61], or at least that such stacking interactions are not important for the role of Sgs1
in suppressing HU hypersensitivity.
To verify that proline mutations that cause HU hypersensitivity indeed disrupt the
α-helix between residues D25 and A38, we analyzed the solution structure of the
sgs11−80-F30P mutant by NMR (Figure 3.6). We found that the resonances that shifted
notably in the HSQC spectrum of the F30P mutant compared with the wild type were
limited to residues F28–A38 (Figure 3.6A, Merged), suggesting that changes induced by
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the F30P mutation are probably localized to the α-helix. Indeed, the consecutive positive
secondary alpha carbon chemical shifts (CAΔδ) between residues D25 and A38 in wildtype Sgs1, which indicate the presence of α-helical secondary structure, were markedly
reduced in the F30P mutant (Figure 3.6B), demonstrating that a proline at position 30 is
sufficient to prevent the formation of the α-helix between residues 25 and 38. We also
confirmed that proline mutations that disrupt α-helical content in the N8–H17 region or
the D25–A38 region and cause the highest HU sensitivity (H13P, F30P) do not affect
Sgs1 expression levels and stability (Figure 3.9).

Disruption of Transient α-helices Impairs Complex Formation Between
Sgs1, Top3 and Rmi1
The disordered region of Sgs1 where the transient α-helices were identified binds
to the Type-1A topoisomerase Top3 [18]. To test if HU hypersensitivity caused by
proline mutations in this region is owing to the disruption of transient helices that are
required for the interaction between Sgs1 and Top3, the ability of various sgs1 mutants
to form a complex with Top3 was assessed in vitro. Because overexpression of fulllength Sgs1 leads to insolubility [62,63], we chose the N-terminal 250 residues of Sgs1
and expressed them as an N-terminal GST fusion in E. coli. This Sgs11−250 fragment
pulled down endogenous Top3 from native yeast whole-cell extract in an Rmi1dependent manner (Figure 3.7A). Similarly, binding of Rmi1 to Sgs11−250 was reduced in
the absence of Top3 (Figure 3.7B), suggesting that Top3 and Rmi1 depend on each
other for binding to the N-terminal 250 residues. Despite the effect on Sgs1 binding,
expression levels of Top3 and Rmi1 were not affected by the absence of Rmi1 and
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Top3, respectively (Figure 3.7C and D). Sgs11−250 binds to Top3 more strongly than
Sgs11−160 and, similar to what has been reported previously for an Sgs1 fragment
comprising residues 107–283 [19], Sgs1125−250 did not bind to Top3 (Figure 3.7E and F).
When we introduced L9P, H13P, K17P, D25P, V29P and F30P mutations into the
Sgs11−250 fragment, its ability to pull down Top3 from cell extracts was diminished,
whereas the T21P and K26P mutants were still able to bind Top3 (Figure 3.7G).
Mutations of Sgs1 that disrupted binding to Top3 also disrupted binding to Rmi1 (Figure
3.7H).

Integrity of Transient α-helices is Critical for Maintaining Chromosomal
Stability
Lack of Sgs1 or disruption of its conserved C-terminal helicase core domain
leads to mitotic hyperrecombination and a moderate increase in the accumulation of
gross-chromosomal

rearrangements

(GCRs),

including

translocations

between

nonallelic sites [39,64,65]. To determine if the inability of Sgs1 to interact with Top3 and
Rmi1 also leads to increased genome instability, we tested the ability of D25P, K26P,
V29P, F30P and I33P mutants of full-length Sgs1 expressed from a CEN/ARS plasmid
to suppress the elevated GCR rate of an sgs1Δ mutant. Mirroring the results of the HU
hypersensitivity assay, D25P, V29P, F30P and I33P were unable to complement the
defects of sgs1Δ cells, whereas cells expressing the K26P mutant accumulated GCRs
at a similar rate as cells expressing wild-type Sgs1 (Table 3.1).
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Discussion
In the prokaryote-to-eukaryote transition, some members of the RecQ helicase
family acquired long N-terminal regions that precede the ATPase domain of the helicase
core. In Sgs1, the only RecQ homolog in S. cerevisiae, this N-terminal region is ∼650
amino acids long, making up ∼45% of the 1447-residue long protein. This entire region
is predicted to be intrinsically disordered and to contain several short segments of
transient secondary structure (Figure 3.1). Using NMR spectroscopy, we have
demonstrated that the first 125 residues of this N-terminal region of Sgs1 are
intrinsically disordered in the unbound solution state with two short segments, between
residues 25–38 and 88–97, that adopt transient α-helical structure. Transient α-helices
in disordered regions of proteins are often stabilized by interactions with a binding
partner [43–45,66,67]. This principle was used to rationally design single residue
substitutions that disrupted the transient α-helical structures of residues 25–38 and 88–
97, and the effects of these mutations on Sgs1 function were tested in vitro and in vivo.
Substitution of residues D25, V29, F30 and I33 with the α-helix breaker proline impaired
Sgs1 function in vivo, as evidenced by increased sensitivity to DNA damage and
increased chromosome instability, and reduced binding of Top3 and Rmi1 to Sgs1 in
vitro. Additional proline mutagenesis following the i, i − 4 α-helix pattern revealed that
L9, H13 and K17 were critical for the same Sgs1 functions as the D25–A38 α-helix.
Our work demonstrates that the integrity of a transient α-helix is required for the in vivo
function of Sgs1 and the binding of Sgs1 to Top3 and Rmi1. This helps explain why
previous attempts to identify functionally critical single residues through alanine
scanning of the region were unsuccessful (K4A, P5A, L9A) [68]. Alanine scanning is
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often useful for identifying residues important for catalytic function, such as the ATPase
activity of Sgs1 (K706A in the Walker A motif). However, the effectiveness of this
approach to detect functionally important structural motifs in disordered segments, such
as transient α-helices, is hampered by the high helical propensity of alanine and will
depend on whether the substitution occurs at a residue that forms part of the binding
interface [58]. Substitution with lysine and valine residues, which also have excellent
helical propensity, also had no effect on Sgs1 function (D25K, Figure 3.4C; D25V [59],
whereas a proline substitution at this same residue disrupted function (D25P, Figure
3.4A). Even amino acid residues that have lower helical propensity and are therefore
not commonly found in α-helices, such as glycine and serine, are not necessarily
successful at disrupting transient α-helices when introduced as single-residue
substitutions. For example, the E12G and H13S mutations by themselves were
insufficient to disrupt the interaction between Sgs1 and Top3, but were effective when
combined [68]. Rationally designing mutations based on residue-specific knowledge of
transient secondary structure provided a direct test of structure/activity relationships for
Sgs1 (and presumably other IDPs) that could only be realized by combining a highresolution structural approach, like NMR, with the in vivo and in vitro functional tests that
can be performed in a model organism like S. cerevisiae. While this type of multiscale
approach has commonly been used to interrogate structure/activity relationships for
ordered proteins, the widespread application of this approach to IDPs/IDRs has been
hampered by a lack of understanding of the general rules that connect their dynamic
structures to their function. We believe our study helps clarify an approach that can be
consistently applied to identify the functionally critical regions of IDPs/IDRs.
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What functional advantages might the long, intrinsically disordered N-terminal tail
provide to Sgs1? One possibility is that it contains multiple protein interaction sites, in
addition to Top3/Rmi1. This hypothesis is supported by multiple dips below the 0.5
threshold in the IUPred plot (Figure 3.1) and the fact that Sgs1 binds Top2, Rad16,
Rpa70, Dna2 and Mre11 at sites that map to the disordered N-terminus, although the
discrete binding sites have not been identified [6–8,13]. Sgs1 may need to bind several
of these proteins, sequentially or concurrently, in the same process. For example, the
Sgs1/Top3/Rmi1 complex is instrumental in DNA resection during double-strand break
(DSB) repair in a reaction analogous to that performed by the RecBCD complex in
bacteria. In this model, which was recently proposed by Cejka et al. [13], the
Sgs1/Top3/Rmi1 complex is first recruited to the DSB by physically interacting with the
Mre11 subunit of the Mre11/Rad50/Xrs2 complex. Subsequently, the Sgs1/Top3/Rmi1
complex physically interacts with Dna2 to stimulate preferential degradation of the 5′end and with replication protein A (RPA) to protect the 3′-end. Still other physical
interactions at the N-terminal tail, including those with Rad16 and Top2, are likely to be
important for roles of the Sgs1/Top3/Rmi1 complex in DNA repair and chromosome
segregation. Conformational flexibility may also be crucial to accommodating the
various structures and sizes of DNA substrates that the Sgs1/Top3/Rmi1 complex acts
on, which range from simple double-stranded or splayed ends to hairpins,
quadruplexes, Holliday junctions and telomeres.
In E. coli, RecQ and Top3 interact functionally, but not physically. One advantage
of gaining physical contact between Sgs1 and Top3 would be the ability of one subunit
in the complex to regulate another subunit’s enzymatic activity. Tight coordination
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between a Type-IA topoisomerase activity, such as exhibited by Top3, and DNAdependent ATPase activity, such as exhibited by the helicase core of Sgs1, can be
seen in the reverse gyrases of thermophile and hyperthermophile bacteria and archaea,
where the two activities are either contained in a single polypeptide [69,70] or are
encoded by two separate genes [71]. In these enzymes, the topoisomerase domain has
been found to reduce the activity of the helicase-like ATPase domain [72] and,
conversely, the ATPase domain has been shown to inhibit the supercoil relaxation
activity of the topoisomerase subunit to induce positive supercoiling [71]. Inhibition of
the helicase activity of the human Werner syndrome helicase WRN by its associated
Type-1B topoisomerase Topo I hints at the possibility of coordination between the two
activities also in RecQ-like helicases. Similarly, in Sgs1, deletion of the Top3 contact
site (sgs1Δ1-158) causes a more severe phenotype than that caused by the absence of
Sgs1 [3], which could be explained by Top3 binding having an inhibitory effect on the
ATPase activity of Sgs1.
The interaction with a Type-1 topoisomerase has been preserved in at least four
of the five human RecQ-like helicases: BLM, WRN, RecQL1 and the long isoform of
RecQL5. Like Sgs1, BLM and WRN interact with Topo IIIα (Type IA) and Topo I (Type
IB), respectively, at the far end of a long N-terminal tail [12]. Human RecQL1 was also
found to interact with Topo IIIα, whereas the long isoform of RecQL5 (RecQL5β) coimmunoprecipitated with Topo IIIα and Topo IIIβ [10,11]. The predicted helical content
of the N-terminus of BLM does not resemble that of the Top3/Rmi1 contact site between
residues 25 and 38 in Sgs1, which appears to be the result of a proline substitution in
BLM at position 30 (Figure 3.8A). Instead, the helAcal content in the segment starting
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with residue L9, which is weak in Sgs1, is predicted to be dominant in BLM. Thus,
although both BLM and Sgs1 interact with topoisomerase 3 at the N-terminus, the
structural elements in the two proteins that mediate this interaction may not be
conserved. This is also supported by the finding that the C-terminal 156 residues of
BLM also bind to Topo IIIα [12], whereas only the N-terminus of Sgs1 interacts with
Top3. Strikingly, the predicted helical content for residues N23 to R36 in WRN is nearly
a perfect match to that of the confirmed α-helix in Sgs1 (Figure 3.8B). However, WRN
has not been shown to interact with Topo IIIα [10], possibly owing to the insertion of the
exonuclease domain just downstream of this site, and it will be interesting to test if
residues N23–R36 of WRN can provide a contact site for the Top3/Rmi1 complex when
placed in Sgs1. In the case of S. pombe Rqh1, the first 322 N-terminal residues are
required for interaction with Top3 [9]. Although helical content is not predicted for the
first 100 residues of this region, noticeable helical content is evident for the 27-residue
region between residues H264 and R291 and the 15-residue region between residues
D112 and Q127, which could be investigated as putative Top3 binding sites (Figure
3.10 ). Although Topo IIIα also binds full-length RecQL1 and RecQL5 [10, 11], the
binding regions in these two human RecQ homologs have not yet been narrowed down.
Applying the same NMR-based structure–function analysis to the remaining 525
residues of the disordered N-terminal tail of Sgs1 (and the tails of the other long RecQlike helicases) will help to identify additional structural elements, either transient or
persistent, that serve as molecular recognition elements for protein partners or DNA,
and allow for the rational design of new separation of function alleles that encode
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mutants of RecQ-like helicases with single residue substitutions that are defective in
discrete cellular functions.
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Figure 3.1: Prediction of intrinsically unstructured regions in Sgs1. Disorder
scores are from IUPred (46) with scores >0.5 predicting disordered residues and scores
<0.5 predicting ordered residues. Residues 1–158 (upper panel) are predicted to be
mostly disordered with two short segments around residues E24 and Y102 dipping into
the ordered region.
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Figure 3.2: HSQC spectra of the first 125 residues of Sgs1 (Sgs1 1–125) and the first
80 residues of Sgs1 (Sgs11–80). Narrow chemical shift dispersion in the 1H dimension
in both the HSQC spectra of the long (Sgs11–125) and short (Sgs11–80) peptide are
consistent with a disordered peptide. The overlay of the long and short peptide
(Merged) shows little discrepancy in the peak assignments between the two proteins,
implying conservation of structural elements, even with the truncation.

108

Figure 3.3: Measurement of NHNOE and secondary alpha carbon shifts (CAΔδ) of
the Sgs11–125 peptide and the Sgs11–80 peptide. Consecutive positive values in the
NHNOE plot for the Sgs11–125 peptide (a) and the Sgs11–80 peptide (c) indicate regions
with a slower rotational correlation time that may adopt secondary structure.
Consecutive positive secondary alpha carbon chemical shifts (CAΔδ) between residues
88 and 97 (b) and between residues 25 and 38 (d) indicate the presence of α-helical
secondary structure in the unbound Sgs1 peptide as compared with standard chemical
shifts in a random coil library (48,50).
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Figure 3.4: HU hypersensitivity of cells expressing sgs1 alleles with mutations in
(a) the α-helical region spanning residues 25–38 and (b) the α-helical region
spanning residues 88–97. The wild-type phenotype exhibited by cells expressing
W15A and W92A mutants of Sgs1 also demonstrates that these aromatic residues are
not involved in stacking. T61P was included as a control for a disordered residue. (c)
Replacing the N-cap residue D25 with basic (D25K) or neutral (D25A) residues that are
poor N-caps, but have strong α-helical propensity, does not affect Sgs1 function. (d)
Extending proline mutagenesis N-terminally of the first α-helical region reveals
additional functional residues (L9, H13, H17).
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Figure 3.5: AGADIR (57) prediction of the helical content of the N-terminus of
Sgs1. (a) In wild-type Sgs1 (dotted line), a prominent peak of helical propensity is
predicted at residue I33 and a smaller peak at residues R10–E12. Residue D25
received the highest N-cap score (open columns). (b) The deleterious D25P mutation is
predicted to reduce the helical content of the D25–A38 region, whereas the
nondeleterious K26P mutation is not. (c) Replacing the N-cap residue D25 with residues
that have excellent helical propensity, but are poor N-cap residues (lysine, alanine), is
not predicted to reduce helical content of the D25–A38 region, but predicts an Nterminal extension of the helical region with a new peak of helical content at residue
Q23 in the D25A mutant and at residue L22 in the D25K mutant.
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Figure 3.6: HSQC spectra and secondary chemical shift (CAΔδ) analysis of the
first 80 residues of Sgs1 with a proline substitution at residue 30 (sgs1 1–80-F30P).
(a) The overlay (Merged) of the HSQC spectra of wild-type Sgs1 (blue) and the sgs1F30P mutant (red) reveals shifts in the peak assignments for residues F28, V29, Q31,
A32, I33, Q34, I37 and A38, which form a transient α-helix in wild-type Sgs1. (b)
Consecutive positive secondary alpha carbon chemical shifts (CAΔδ) between residues
D25–A38 in wild-type Sgs1 (open blue columns), which indicate the presence of αhelical secondary structure in the unbound Sgs1 peptide, are markedly reduced in the
Sgs1-F30P mutant (red filled columns).
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Figure 3.7: Loss of function of Sgs1 proline mutants is due to loss of Top3 and
Rmi1 binding. Sgs1 proline mutants were expressed as N-terminal GST fusions in E.
coli and purified by binding to glutathione beads. Top3 and Rmi1 were obtained from
native whole-cell extracts of yeast strains KHSY2497 (RMI1), KHSY4695 (rmi1Δ) or
KHSY4696 (RMI1.MYC), KHSY4741 (top3Δ), which express epitope-tagged Top3
and/or Rmi1 from their chromosomal loci under their native promoters. (a) Binding of
Top3 to the Sgs11–250 peptide is Rmi1-dependent. (b) Binding of Rmi1 to the Sgs11–250
peptide is Top3-dependent. (c) Deletion of RMI1 does not lead to loss of Top3
expression. (d) Deletion of TOP3 does not lead to loss of Rmi1 expression. (e) The
Sgs11–250 peptide binds Top3 more strongly than the shorter Sgs1 1–160 peptide. (f) The
Sgs1125–250 peptide does not bind Top3, indicating that critical residues for Top3 binding
are located in the first 125 residues of Sgs1. (g) Proline mutations at L9, H13, K17, D25,
V29 and F30, but not at T21 and K26, reduce binding of Sgs1 1–250 to Top3. (h) Proline
mutations at H13 and F30, which reduce binding of Sgs11–250 to Top3, also reduce
binding to Rmi1.
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Table 3.1. Effect of proline substitutions in the transient α-helix between residues
D25 and A38 of Sgs1 on the rate of accumulating GCRs

Relevant
genotype
SGS1
sgs1-D25P
sgs1-K26P
sgs1-V29P
sgs1-F30P
sgs1-I33P


Plasmid
pKHS481
pKHS494
pKHS500
pKHS492
pKHS482
pKHS496

GCR rate (Canr 5– 95% CIa (Canr 5FOAr × 10−8)
FOAr × 10−8)
58
34–73
334
260–789
71
39–132
320
189–352
704
194–996
211
165–255

Increase over wild
type (SGS1)
1
6
1
6
12
4

↵a95% confidence intervals were calculated according to Nair (40), with
nonoverlapping confidence intervals indicating statistically significant differences
(α < 0.05) between median GCR rates.
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Figure 3.8. Helical content prediction for the N-termini of Sgs1, WRN and BLM
(57). (a) In human BLM, which binds to the human Top3 homologue Topo IIIα, a
prominent peak of helical content is predicted at residues Q12 and L13, which
corresponds to the small R10–E12 peak in Sgs1. A peak corresponding to that at
residue I33 in Sgs1 is not predicted in BLM, in part because of a proline residue at
position 30. (b) The distribution of predicted helical content for the N-terminus of human
WRN, which binds to Topo I, but has not been shown to bind to Topo IIIα, is similar to
Sgs1, with two prominent peaks at residues E10 and A30, corresponding to similar
peaks at R10–E12 and I33 in Sgs1.

115

Table 3.2: Plasmids used in this study

Plasmid

Description

pRS415

CEN/ARS, LEU2

pKHS443

pET28a-Sgs1N1-125

pKHS463

pET28a-Sgs1N1-80

pKHS481i

pRS415-SGS1

pKHS482

pRS415-SGS1-F30P

pKHS484

pRS415-SGS1-W92PL93P

pKHS485

pRS415-SGS1-L93P

pKHS489

pRS415 -SGS1-K26P

pKHS492

pRS415-SGS1-V29P

pKHS494

pRS415-SGS1-D25P

pKHS496

pRS415-SGS1-I33P

pKHS497

pRS415-SGS1-Q34P

pKHS546

pGEX-6p-2-SGS1N1-250-K26P

pKHS547

pGEX-6p-2-SGS1N1-250-V29P

pKHS548

pGEX-6p-SGS1N1-250-F30P

pKHS582

pRS415-SGS1-L9P

pKHS583

pRS415-SGS1-H13P

pKHS584

pGEX-6p-2-SGS1N1-250-L9P

pKHS585

pGEX-6p-2-SGS1-250-H13P

pKHS586

pGEX-6p-2-SGS1N1-250-T21P

pKHS587

pGEX-6p-2-SGS1N1-250-K17P
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Table 3.2: Plasmids used in this study
(Continued)
Plasmid

Description

pKHS588

pRS415-SGS1-L181P

pKHS589

pRS415-SGS1-L215P

pKHS590

pRS415-SGS1-T61P

pKHS591

pRS415-SGS1-L176P

pKHS592

pRS415-SGS1-W15P

pKHS594

pRS415-SGS1-I37P

pKHS595

pGEX-6p-2-SGS1N1-250-D25P

pKHS596

pRS415-SGS1.MYC

pKHS598

pRS415-SGS1.MYC-F30P

pKHS600

pRS415-SGS1.MYC-H13P

pRS415 is a gift from Dr. Steven Brill (Rutgers University)
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Figure 3.9: Proline substitutions in Sgs1 that cause hypersensitivity to the DNA
damaging agent hydroxyurea do not affect expression levels of the sgs1 mutant
proteins. The sgs1Δ mutant KHSY1338 was transformed with plasmids pKHS596
(Sgs1.myc), pKHS598 (sgs1-F30P.myc) or pKHS600 (sgs1-H13P.myc). Whole cell
extracts were prepared by TCA extraction from mid-log phase cultures and separated
by 10% SDSPAGE. Wildtype Sgs1 and the sgs1-F30P, sgs1-H13P mutants were
detected by Western blotting with monoclonal antibody against the C-terminal mycepitope. GAPDH was detected by a monoclonal antibody against GAPDH.

118

Figure 3.10: Helical content prediction for the N-terminus of S. pombe
Rqh1 by AGADIR (57). The distribution of helical content for the first
322 residues, which are required for interaction with Top3 (9), are
shown. The first prominent peak is predicted at residue M117 within a
15-residue segment spanning from D112 to Q127, and a second peak at
I286 within a 27-residue segment spanning from H264 to R291.
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CHAPTER FOUR:
THE ROLE OF PROTEIN DISORDER IN CHROMATIN PROCESSES OF S.
CEREVISIAE
Introduction
Classically, proteins have been defined by three dimensional structure—function
is dictated by the shape a protein takes. Recent developments, however, suggest that
Intrinsically Disordered Proteins/Regions (IDP/Rs) play a large role in the sometimes
complex functions of many proteins. Disordered proteins are found in the regulation of
transcription/translation, cell signaling, phosphorylation, and small molecule storage [16]; given this wide range of duties, it should be unsurprising that this class of proteins is
well-represented in many organisms. Studies using disorder prediction software have
suggested that bacterial proteomes can be expected to be between 7-33% disordered,
and Archaea 9-37% [7]. This percentage increases with organism complexity. In
Saccharomyces cerevisiae, up to 60% of the total proteome is predicted to have some
degree of disorder spanning at least 30 consecutive residues, the minimum definition for
an IDR [8]. Approximately 6% of the proteome estimated to be wholly disordered [9].
Biologically, these proteins appear to be enriched in functions including the stress
response, cell cycle, and electron transport [9]. Up to 25% of the total human proteome
is predicted to be disordered, and include proteins with a wide range of functions,
including Securin, Calpastatin, Caldesmon, and Tau [8-10]. As a class, IDRs are
characterized by a large degree of polar and charged residues, a deficiency in large,
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bulky, hydrophobic residues, a lack of persistent secondary and tertiary structure, little
sequence complexity, a low degree of compactness, and a high degree of open,
random-coil “shape,” existing as an ensemble of dynamic conformations [1, 11-13]. A
lack of hydrophobic residues may prevent the protein from adopting structure as it
prevents the formation of a hydrophobic core, but there are known instances of
“induced-folding” models, whereupon disordered proteins assume structure once they
are bound by a specific ligand [14-19].

Such disordered regions may have small

pockets of persistent or transient secondary structure that may facilitate initial binding
[20]. Because the proteins do not commit to one particular structure, a common theory
of “binding promiscuity” in disordered proteins means that open conformation becomes
a boon to proteins needed in several biological pathways, as the same area could serve
as a binding site to several different proteins. A well-studied example is the
Transactivation Domain of p53, which mediates interactions between several proteins,
including p300/CBP and MDM2/MDM4 [21]. In addition to this benefit, IDP/Rs are also
good sites for post-translational modifications, since the protein’s flexible nature allows
for easy access to modification sites by a wide range of effectors [22]. Flexibility in the
protein can also favor faster interaction rates between protein and ligand, as the open
conformation’s larger target size may eliminate the restrictions of orientation present in
the rigid “lock-and-key” models of structured proteins. IDRs provide easy access for
kinases and phosphatases, thus making them ideal with regards to biological processes
that have time constraints and the need for transient modification events [7]
IDP/Rs can exist as either entropic chains—which provide elasticity or act as
“linker” regions between structured domains—or a second major functional class that is
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comprised of “display sites” (sites for post-translational modification by modifying
enzymes), “chaperones,” “effectors” (modifiers of binding partners), “assemblers”
(responsible for binding several proteins, possibly in large complexes) and “scavengers”
that store small molecules [23]. As proteins can have multiple disordered regions, it is
not impossible that one protein can serve several of these functions. A look at the 356
wholly disordered proteins of S. cerevisiae reveals this complexity—142 are unidentified
reading frames with no known function; truly, these proteins may serve in many
capacities, and this level of complexity may make elucidation of some functions difficult
[8]. Difficulty assigning a function to the protein products of these genes may also arise
from the lack of structure that the proteins are hypothesized to assume; with no known
folds and domains, it becomes difficult to make comparisons to proteins with similar
structure and known function. Disordered regions can also adopt different structures
upon binding to different ligands which further complicates the identification of relevant
biochemical pathways and protein/protein interaction in that the same disordered area
can serve as a functionally different hub for several different partners. For instance, the
tumor suppressor p53 C-terminus has been found to adopt different types of secondary
structure when bound to different partners, and the HIF-1α activation domain adopts
either alpha helical or extended structures depending on whether it is binding coactivator p300 or transcriptional mediator FIH [1].

This caveat is important when

considering conservation of certain structural motifs between homologs; since
disordered proteins can undergo induced folding upon partner binding, the use of X-ray
crystallography as a means to study these regions coupled with a partner may be
misleading.

In addition to perhaps underestimating the degree of disorder in a
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proteome based on tandem purification and crystallization [8], the conformation of the
protein that is disordered in apo formation may vary substantially depending on which
partner it is coupled with in the 3d analysis. Hence, there are many other tools in use to
study disordered proteins in both complexed and unbound form, including nuclear
magnetic resonance, small-angle x-ray scattering, atomic force microscopy, and
paramagnetic spin labelling [24].
When DNA damage in S. cerevisiae occurs, DNA repair proteins in several
different pathways receive signals from DNA damage sensor proteins via mediator
proteins and kinases in an effort to modify the chromatin in such a way that facilitates
repair such as homologous recombination, non-homologous end joining, and excision
repair. Depending on the type of damage, proteins involved in detecting and properly
repairing damage can include several checkpoint proteins and kinases [25-27] (e.g.
Mec1, Rad53), which require modification from and interaction with upstream and
downstream protein elements, and enzymes for functions ranging from break resection
[28-30] (e.g. Exo1, Sgs1, MRX proteins), base excision [31] (e.g. Rad27) nucleotide
excision [32] (e.g.. Rad16), and ligation of DNA breaks [33] (e.g. Lig4), which require
the ability to themselves be modified, as well as interact with other proteins that may be
found at DNA breaks, unusual DNA structures, or stalled replication forks. Given this
complex network of interaction and modification, we hypothesized that S. cerevisiae
DNA repair proteins may contain an enrichment of functional disorder, since this type of
non-structure facilitates these protein functions well. Study into some yeast proteins
have indeed found that these proteins have predicted or confirmed regions of disorder
important for proper protein function [34, 35].
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Given that the proteins of DNA repair

and related chromatin processes are, overall, highly prone to interaction and
modification, and since one of the major roles of disordered regions is to facilitate these,
we asked whether or not disorder is overrepresented in the S. cerevisiae proteins, and,
if so, which of these points seems to be a driving force in the occurrence of functional
disorder. To this end, we have conducted a survey of 160 proteins classified in the
protein database, Uniprot, as DNA repair proteins and analyzed them using PONDRVLXT[36] and PONDRFIT [37], software that can predict both the presence of disorder
and putative protein binding sites. Analysis established the degree to which disorder
plays a role in budding yeast DNA repair, and how this disorder may be a function of
protein/protein interaction and phosphorylation. Our analysis gives some insight into
the role of functional disorder in this protein subset, and can be used as a source for
experimental design beyond classical approaches like sequence alignments.

Methods
Formulation of protein data set
Our protein data set was manually constructed by searching the S. cerevisiae
Uniprot (European Bioinformatics Institute) database for the term “DNA repair.” The top
160 non-repetitive hits were selected and their FASTA sequence files were obtained
from the Saccharomyces Genome Database (SGD) at http://www.yeastgenome.org/.

124

Disorder prediction and interaction site prediction
Disorder prediction was provided by PONDR-VLXT [36], and interaction site
prediction

was

analyzed

using

PONDRFIT

[37]

software,

provided

at

http://www.disprot.org/pondr-fit.php and http://www.pondr.com/index.

Repair classification and phosphorylation
Repair classifications for all protein in the data set were manually determined by
using the GO terms provided in the Saccharomyces Genome Database (SGD).
Phosphorylation sites were manually evaluated by using the SGD Phosphogrid
database on the “protein” section of each entry. Phosphogrid can be found at
www.phosphogrid.org.

Results
PONDR-VLXT predicts disorder based on a protein’s likelihood to form a folded
core. Analysis using PONDR-VLXT in human cancer-associated proteins found that
these proteins, as well as regulatory and cytoskeletal proteins were two-fold as likely to
contain disordered regions >30 residues than proteins involved in metabolism,
biosynthesis and degradation [3]. Hub proteins, those with >10 binding partners, were
found to be significantly more disordered than non-hubs in protein sets from C. elegans,
S. cerevisiae, D. melanogaster, and H. sapiens [35]. A study of the yeast transcriptional
network showed that within yeast transcriptional proteins, transcriptional hubs contained
the greatest amount of disorder [38]. In addition to binding, functional disorder can be
used to modulate post-translational modifications, as flexible linker regions, as a
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stimulus for protein degradation, and as scaffolding regions for protein complexes [7,
39, 40]. Given the prevalence of IDRs, and given that proteins in the chromatin
processes are often subject to roles that disorder facilitates, we asked whether or not S.
cerevisiae chromatin processes proteins were more prone to disorder than the whole S.
cerevisiae proteome. We evaluated proteins in the chromatin processes data set for the
presence of at least one IDR as predicted by PONDR-VLXT; in the data set, 72.5% of
the proteins contained disorder (Figure 4.1A), versus the predicted 60% in the total
proteome [9]. In order to further investigate the function of this overrepresentation, we
first considered the possibility of increased number of protein/protein interaction sites in
chromatin processes proteins, since IDRs are prone to modulate several interactions.
PONDRFIT has the capability to predict interaction sites on a protein by evaluating
whether a stretch of amino acids will be chemically fit for burial into a partner protein. Of
the 160 proteins in our set, PONDRFIT predicted at least one interaction site in 110 of
the proteins, with an expected decrease in the number of proteins found with an
increasing number of predicted sites (Figure 4.1B). To further investigate the role of
disorder in protein/protein interaction of chromatin processes proteins, we asked what
fraction of these interaction sites occurred in proteins with an IDR (Figure 4.1C).
Interestingly, the proteins with no predicted interactions sites were overwhelmingly
proteins without IDRs (20% ordered vs. 11% disordered), while proteins with one or
more interactions were overwhelmingly proteins with at least one predicted IDR.
Perhaps even more striking, proteins with 3 or more predicted interaction sites are
exclusively proteins with IDRs, suggesting a primary role for protein/protein interaction
with regards to disorder in the chromatin processes data set. When evaluating the data
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for predicted interaction sites, we further focused on the proteins in the top 5% with
regards to number of predicted interactions. These proteins contained a large number of
interaction sites (8-13 sites). In order to establish a connection between number of
interaction sites and biological function, we researched the putative physical binding
partners for the proteins in this top 5%, including Mrc1, Rad9, Slx4, Sgs1, Zip1, Rad2,
and Xrs2 (Figure 4.1D), using the SGD database, and found that all seven have been
found to interact with a large number of protein partners (Table 4.1).
With these proteins in mind, we hypothesized that the high occurrence of
disorder in the chromatin processes proteins was a result of disorder facilitating the
predicted interaction sites. We then mapped the PONDRFIT data to the disorder
prediction from PONDR-VLXT in an effort to ascertain to what degree disorder and
interaction sites are connected. For the top 5%, there is a clear bias toward interaction
sites located in disordered regions; for all proteins in this set, anywhere between 50 and
75% of the predicted interaction sites occurred in areas of disorder. There was also a
large overall number of disordered regions in these proteins, with anywhere from 4 to 10
total regions ≥30 residues identified (Figure 4.2A). These regions vary in length
between 30 residues in Rad2 and 304 residues in Sgs1; for the most part, however,
there is little variation in average region length, with a mean range of 65-119 residues
for the 7 proteins (Figure S4.2). Also of note was the location of the majority of those
residues predicted by PONDR-VLXT to be disordered; for the top 5% of interactors,
there was little difference between the percent of disordered residues found within IDRs
and the overall percentage of disordered residues in the total protein, implying that the
majority of disordered residues are in longer stretches of disorder, and suggesting that
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the disorder is functional (Table 4.3). In an effort to understand the biological role that
these interaction sites in disorder may play, we looked at the DNA damage signaling
cascade, which contains 3 of the 7 proteins in the top 5%. The adaptors of the pathway,
Rad9 and Mrc1, contain the greatest number of predicted interaction sites, and a large
percentage (64% and 69%, respectively), are predicted in disordered regions. Because
these proteins mediate several up and downstream partners, it is possible that the
increased number of binding sites in disorder serves to accommodate all partners over
the smallest amount of primary structure possible, as has been seen in other IDRs (e.g.
p53) [41]. Another protein from the top 5%, Xrs2, is not a mediator of the signaling
response, but is a member of an upstream complex whose partners contain small
numbers of predicted interaction sites. Thus, Xrs2 presents another function for
increased disorder and protein interaction in the chromatin processes set; Xrs2 can
contain a large number of interaction sites, freeing the remaining complex members,
Mre11 and Rad50, for other functions, particularly catalytic nuclease and ATPase
activities; we discuss this function further below (Figure 4.2B).
Given that the top 5% had a large number of interactions predicted in IDRs, and
given that a large number of predicted interactions seemed to connect well with a
biological function requiring disorder modulating protein/protein interaction in the
signaling cascade, we asked whether or not there were other traits of disorder in these
proteins that correlated with an increased number of protein interaction sites. We first
evaluated the data set for overall percentage of disordered residues per protein as
predicted by PONDR-VLXT. No proteins in the set contained all residues with a disorder
probability < 0.5, and one protein, Sml1, was 100% disordered. Sml1 is an inhibitor of
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ribonucleotide reductase, and is degraded in response to DNA damage to increase
dNTP pools needed for repair [42]. This degradation is regulated by post-translational
modifications, which are easily accessed in IDRs. In addition, it has been suggested
that there is a weak correlation between disorder and increased degradation rate; given
Sml1’s need to be overturned in the presence of DNA damage, the prevalence of
disorder in this protein could have a functional role [43]. Overall, the proteins in the data
set were skewed toward being 40% or less disordered, with 20% of the proteins
exhibiting 1-10% total disorder, 26% exhibiting 11-20% total disorder, 24% exhibiting
21-30% disorder, and 14% exhibiting 31-40% disorder (Figure 4.3A). We predicted a
relationship between the overall percentage of disordered residues and number of
interactions predicted by PONDRFIT, but found little correlation between the two values
(R2= 0.3149) (Figure 4.3B). Extreme examples like Sml1 and Slx8 reveal why this
correlation is so poor; the two proteins are 100% and 76% disordered, but contain two
and zero predicted interaction sites, respectively. This could imply that the prevalence of
disorder in these proteins is the result of an increased need for modification rather than
protein/protein interaction. It is possible, too, that the PONDRFIT analysis is insufficient
to detect binding if a protein is in a “fuzzy complex.” These binding events are often
more dynamic than those seen in induced-fit models [44], and may be overlooked in the
algorithm, since they do not normally form a structural state that requires specific (likely
hydrophobic) chemistry that the program accounts for when predicting binding sites.
When we evaluate the checkpoint cascade, we saw little overall difference in percent
disorder amongst most of the proteins in the cascade, despite differences in predicted
interaction sites seen in Figure 2B (Figure 4.4). Thus, we suggest that while the high
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degree of chromatin processes protein with IDRs is likely a result of need for
protein/protein interaction, overall disorder is a poor indicator of increased protein
interaction. We then reevaluated the distribution of disorder within the protein set by
taking into account only the percentage of the protein residues that have both PONDRVLXT scores ≥ 0.5 and are located in IDRs. This changed the protein profile from that
seen in Figure 4.3A; almost 28% of the proteins contained no residues with PONDRVLXT scores > 0.5 in IDRs (Figure 4.5A). This shift suggests that a considerable
amount of the overall disorder in some proteins in the set are distributed in smaller
regions, which may be less likely to be functionally protein-binding than a larger region
exceeding 30 residues. We considered that not overall disorder, but rather the number
of disordered regions a data set protein contains is a good predictor of protein/protein
interaction propensity.

When we compared this value to predicted interaction sites, a

stronger correlation resulted (R2= 0.6026) (Figure 4.5B). Looking back at the checkpoint
cascade, we see that the proteins in the cascade with the highest number of disordered
domains, Xrs2, Rad9, and Mrc1, are also the proteins identified as having a the largest
number of putative interactions (Figure 4.6). Rad50 bucks this trend with 4 disordered
domains (like Rad9 and Xrs2), but only 3 predicted interaction sites. One suggestion is
that because Rad50 may play a role in binding DNA at double strand break ends, and
because disorder has been found to be prevalent in proteins that bind DNA [45] . We
propose that overall number of disordered domains, then, is a better indicator of
increased protein/protein interaction, and that biological function, particularly as a
binding hub or central binding protein in a complex, is highly connected to a greater
number of disordered domains.
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While evaluating the connectivity between biological function in the checkpoint
cascade with protein interaction, we noticed Xrs2 as the sole member in its complex
with Mre11 and Rad50 with a high number of predicted interaction sites versus the
partners (10, versus 3 for both Mre11 and Rad50). We asked whether this pattern was
also repeated in other complexes that had two or more members in our data set. When
we compared the number of predicted interaction sites between complex protein
members, we noticed that, in general, most complexes, including Mre11/Rad50/Xrs2,
Slx4/Slx1,

Rad55/Rad57,

Slx5/Slx8,

Lif1/Lig4

Sgs1/Rmi1,

and

Rad2/Tfb1/Tfb2/Rad3/Ssl1 contained a complex member that had 3 or more predicted
interaction sites and a complex member with little or no predicted interaction (Figure
4.7A). This observation correlates well with the complex member with the highest
number of predicted interactions also being the complex member with the greatest
number of disordered domains, with Mre11/Rad50/Xrs2 and Rad55/Rad57 being the
two notable exceptions (Figure 4.7B). Conservation of those proteins in complex with
the most protein interaction and disorder is often the most poor of all complex members.
Slx4 is so poorly conserved that BLAST analysis only returns hits for Saccharomyces
species [46]. Xrs2 is poorly conserved when compared to Mre11 and Rad50, and is only
found in eukaryotes [47]. The human homolog, Nbs1, only has 29% homology to Xrs2 in
the structured N-terminal region, and no significant homology in the C-terminus, which
is predicted to be disordered in both proteins [48]. As disordered regions tend to tolerate
evolution better than ordered regions [49], it suggests an evolutionary advantage to
these complex members with regards to chromatin processes. Evolution can occur in
one protein more neutrally to account for increasing organismal complexity, while the
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others, often with catalytic domains or specialized folds, can evolve more
conservatively.
Another major role of functional disorder in proteins is post-translational
modification. The “open” conformation of disordered regions provides a more accessible
area for modifiers like kinases to apply modifications to residues than those seen in
folded proteins, which bury a large percentage of its primary structure [50]. Posttranslational modification like phosphorylation is also used as a means of enthalpy
compensation for the entropy loss incurred when disordered regions undergo folding in
response to protein/protein interaction; thus, modification and interaction at disordered
sites are sometimes tied [51, 52]. Protein/protein interaction is clearly a driving force for
increased need in disorder in the chromatin processes proteins over the yeast proteome
at large, but since several of these proteins undergo post-translational modification in
response to cellular signal for chromatin modification, we also considered that
modification played a role in the disorder overrepresentation in our data set.
Phosphorylation is one of the most closely studied modifications in S. cerevisiae, and
high-throughput studies of the phosphoproteome have been conducted [53, 54]. Thus,
we decided to use phosphorylation as an indicator of the role of disorder in modification
of chromatin processes proteins. We used phosphogrid to acquire phosphorylation sites
for all proteins and began by accessing whether phosphorylation tended to occur more
often in proteins with or without disorder. In our set, 14% of the proteins have no IDRs
or any phosphorylation sites; 11% were completely ordered, but contained at least one
phosphorylation event. The most represented group in the set, however, were proteins
both containing disorder and at least one phosphorylation site, which comprised 64% of
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the total chromatin processes data set (Figure 4.8A). We decided to look at this
particular group more closely to ascertain if this increase in phosphorylation was
actually occurring in IDRs in these proteins. When we looked at proteins with at least a
single phosphorylation event and mapped the site to disordered regions as predicted by
PONDR-VLXT, we established that a small percentage (19%) had no known
phosphorylation occurring in disorder. The overwhelming majority of proteins had at
least one of the known phosphorylation events occurring in disorder, and 32% of the
proteins had all known phosphorylation events occurring in disordered regions (Figure
4.8B). Given these results, it can be surmised that disorder in the chromatin processes
proteins exists to accommodate both increased protein/protein interaction and
phosphorylation events.

Discussion
In this study, we evaluated the role of disorder in the Chromatin Process
proteome, and established that disorder is overrepresented in these proteins, likely as a
result of the need for extensive protein/protein interactions and sites for modification via
phosphorylation. We identified a subset of Chromatin Process proteins that are highly
connected in the number of predicted interaction sites and the location of these sites in
disorder. Based on other studies in disorder, the overrepresentation of disorder in DNA
repair is consistent with other findings; it has been reported that biological function with
a high need for regulation, signaling, and complex formation [55], all roles that are
highly prevalent in DNA repair. While our analysis in the checkpoint cascade clearly
shows that there is not a need for disorder at all steps, those proteins with the highest
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orders of disordered domains are the mediators/adaptors of the cascade response, and
have a larger number of substrates. A large number of disordered interaction areas
allow the protein to accommodate the various proteins in downstream interaction
without the need for the protein being too large or adding large, bulky domains over the
course of evolutionary history as species and DNA damage response becomes more
complex. Proteins in the cascade like the kinases, however, do not have a need to be
extensively disordered if their downstream substrates are; indeed, the kinases in the
cascade (Mec1, Tel1, Dun1, Chk1, Rad53), all display low orders of disorder. In the
case of Mec1 and Tel1, the immediate substrates are rich in disordered domains, and in
the complete data set, there is a high variability in disorder in the effector proteins; it is
not beyond reason that a good deal of these will be disordered or in complex with a
disordered protein, as approximately half of kinase substrates are highly unstructured,
while only 19% are not, and 85% of kinases with 50% or more of substrates with a high
level of disorder (>30% of the protein) are implicated in response to a particular stimulus
or stress, such as DNA damage [56].
It is interesting that greater number of protein/protein interactions is not a function
of total protein disorder, as a great deal of flexibility may imply a greater deal of binding
promiscuity possible, allowing for several interactions over one large area via an
induced-fit folding model. However, the role of linear motifs, short, sometimes wellconserved stretches often found in disordered regions can explain why we see a greater
number of interaction in proteins with several smaller disordered domains; linear motifs
are interaction areas that are a subset of induced-fit interactors, and are implicated in
transient and low-affinity binding events, such as modification by kinases [57]. Using
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the profiles of the high-number interactors as an example, one can see that there are
several “dips” in the disorder prediction plots that cover short spans of residues (Figure
4.9). It is possible that these are linear motifs that break up what would otherwise be a
long disordered domain, thereby increasing the number of domains, but decreasing the
overall percentage of disorder, especially in shorter proteins. These motifs can work
alone or in tandem with other motifs, and can acquire post-translational modifications
that can change the target of the motif. In total, the presence of these motifs may serve
as anchoring points for several protein/protein interactions and the disorder flanking
them may serve to further facilitate binding. A large number of disordered domains with
a large number of surrounding linear motifs are a likely explanation for the higher order
interactions; in fact, we have already studied the presence of one motif in Sgs1
extensively using NMR [34]. The transient alpha-helix in the N-terminus of the protein
facilitates the binding of the Top3/Rmi1 complex, and the downstream disorder has
been shown to accommodate the binding as well, as the optimal binding domain
extends well beyond the indispensable docking structure. There may, in fact, even be a
second motif that facilitates binding as well, as we found that a longer 250 residue
peptide bound Top3 and Rmi1 better than a shorter 160 residue peptide [34]. There is
a notable dip in the disorder profile in Sgs1 in the region the shorter peptide lacks; while
it is larger than one would expect from a linear motif, it is possible that there are several
small structures that make up the region, skewing interpretation of the profile, but
implying further binding events over the same length.
The finding that phosphorylation in DNA repair proteins has a strong bias in
disorder is something that has been described in whole proteomes previously; a study
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of the human proteome revealed that proteins described in GO terms as
“phosphorylation” targets was one of the categories investigated most enriched in
disordered proteins [58].

An intensive study of the residue composition flanking

phosphorylated residues showed an enrichment of “surface exposed” residues around
all 3 types of phosphorylated residues and the sequence complexity of these flanking
regions were relatively low [59]; both qualities are used to define disordered proteins.
p53 is a well-studied example of how phosphorylation provides versatility in disordered
regions often not afforded in folded regions; the phosphorylation status of p53 changes
the affinity of different protein interactions and some regions have been shown to adopt
a different three-dimensional form depending on the partner bound to it, thus this
important protein can regulate the protein/protein interactions in time and cover several
interactions over a smaller distance needed than seen in a folded protein by utilizing
disorder [16, 60, 61].

Because several of the proteins in chromatin processes

participate in several different interactions and/or types of repair, the degree of disorder
and phosphorylation overrepresented in the chromatin processes protein set is to be
expected; in an effort to keep the proteins involved from becoming so large that they are
metabolically draining on the cell, the addition of disorder in the transition from bacteria
to yeast allows one protein to accommodate several binding events over one region and
be modified by signaling proteins as a means to regulate when and where these
interactions take place. The DNA damage checkpoint response and facets of DNA
repair require interactions that are transient in nature, and disorder that is easily
modified accommodates this need, as it tends to be high in specificity, low in affinity,
and easily accessed by regulating enzymes. Biochemically, phosphorylation is likely
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also biased to these areas in order to accommodate extended protein/protein interaction
as the modification can sometimes be sufficient to drive the enthalpic penalty that is
incurred when the disordered region undergoes a transition from disorder to order [61].
Since we hypothesize that many of these disordered regions in Chromatin Process
proteins, especially in higher order interactors, contain recognition elements to facilitate
binding and eventually undergo extensive folding, it is likely that, in some cases,
modification of these proteins may be a function of providing the necessary energy for
the folding of the element and its flanking disorder to occur.
Because we have shown that disorder is predicted to occur in a large percentage
of chromatin processes proteins, and because there is a role for interaction and
modification in these regions, we offer a warning to those studying these proteins using
classical methods like primary sequence alignment. While it is possible that sequence
conservation can exist in areas of conserved disorder, it is more likely that the sequence
can vary substantially so long as disorder and the overall chemistry of the region does
not change [62, 63]. It is possible, then, to miss areas of functional binding and
modification if one relies solely on sequence identity as a means of studying homologs.
We suggest that the presence of disordered regions in chromatin processes protein be
considered in the future when trying to solve pertinent functional domains and when
comparing regions of binding and modification between orthologs.
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Figure 4.1: Prevalence of disorder and predicted interaction sites in Chromatin
Processes proteins. A) Proteins in the Chromatin Processes data set were evaluated
using PONDR-VLXT for at least one stretch of disordered residues (VLXT value ≥ 0.5)
greater than or equal to 30 residues (proteins with disorder). B) PONDRFIT was used to
predict the protein/protein interaction sites of the proteins in the data set. C) Proteins
were divided into proteins with and without at least one disordered region with regards
to number of predicted interactions. Interaction prediction is most prevalent in proteins
with at least one disordered region. D) Identity of the top 5% of proteins in the set with
the highest number of predicted interaction sites.
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A)

B)

Figure 4.2: Predicted interaction in disorder for top 5% of highest-number
interactors and role in checkpoint cascade. A) The top 5% of interacting proteins
were evaluated by location of PONDRFIT-predicted interaction in disordered regions
predicted by PONDR-VLXT ≥30 consecutive residues. B) The role of 3 of 7 of the
top5% in a simplified model of the DNA damage checkpoint cascade. Mediators of the
response have the highest number of predicted interaction sites, while the kinases upand downstream have few or no interactions predicted.
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Figure 4.3: Percentage of disordered residues is not an indicator of a large number of predicted interactions. A)
Overall protein disorder (residues with value ≥ 0.5) as predicted by PONDR-VLXT versus percent of the protein. B)
Correlation between percentage of overall disordered residues and number of PONDFIT-predicted interaction sites.
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Figure 4.4: Evaluation of percent disordered residues in damage checkpoint response pathway. There is no
correlation between role of a protein and/or the number of predicted interactions and percentage of overall disorder.
Percent disorder is noted next to the protein.

146

Figure 4.5: Number of disordered domains is the best indicator of a large number of predicted interactions. A)
Percent of disordered residues in IDRs as predicted by PONDR-VLXT (residues with value ≥ 0.5). B) A moderate
correlation exists between number of total IDRs in a Chromatin Processes protein and the number of predicted interaction
sites.
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Figure 4.6: Evaluation of number of disordered domains in damage checkpoint response pathway. There is a
correlation between role of a protein and/or the number of predicted interactions and number of IDRs as predicted by
PONDR-VLXT. Mediators of the checkpoint appear to have the greatest number of IDRs; large numbers are also present
in complexed proteins, usually in conjunction with one or more proteins with few IDRs. The number of domains is noted
next to the protein.
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Figure 4.7: Protein complexes in Chromatin Processes proteins have one member with a large number of
predicted interactions and disordered domains. PONDR-VLXT predicted disordered domains and PONDRFIT
predicted interactions were compared between protein complex members who had at least two members in the data set.
The number of predicted sites or domains is indicated next to the protein.
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A)

B)
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Figure 4.8: Phosphorylation in chromatin processes proteins occurs most
frequently in disordered domains. A) Phosphorylation sites for the protein set were
taken from PHOSPHOGRID; proteins without a disordered domain dominated the group
of proteins in the set with no phosphorylation events, while almost 70% of the data set
was both phosphorylated and had at least one disordered domain. B) Phosphorylation
occurs completely in disorder in nearly 35% of all proteins with at least one disordered
domain.
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Table 4.1: Known interacting partners of top 5% highest-number interactors in the
Chromatin Processes data set
Total # of
Predicted
Protein Interaction
Name
Sites Known Interacting Proteins

Mrc1
Rad9

Sgs1

Xrs2

Zip1
Slx4

Rad2

13

Cdc45, Cmk2, Cse4, Csm3, Ctf4, Dia2, Dpb2, Gwt1, Hht1,
Hht2, Hog1, Mcm2, Mcm3, Mcm4, Mcm6, Mec1, Pol2, Prp9,
Psf2, Rad53, Rpn3, Sld5, Smt3, Spt7, Stb2, Taf9, Tof1, Tye7,
Ubi4

11

Cdc14, Cdc28, Cdc5, Chk1, Clb2, Dpb11, Dun1, Hta1, Hta2,
Mec1, Nab2, Rad17, Rad52, Rad53, Rad9, Smt3, Ubi4

10

Bud27, Cdc28, Cmr1, Dna2, Frk1, Gis1, Ksp1, Mec1, Mlh1,
Mlh3, Mre11, Msh6, Prp45, Rad16, Rad51, Rad53, Rfa1,
Rmi1, Rtt107, Smt3, Srs2, Stu2, Swd3, Top3, Ubc9, Yck2

10

Ahp1, Cdc16, Cmr1, End3, Erg20, Hmt1, Htb1, Htb2, Ino4,
Lif1, Mre11, Nab2, Pch2, Pst2, Rad50, Rec107, Rif2, Smt3,
Tek1, Xrs2, YBR063C

9

Apl1, Atg1, Bli1, Cdc28, Cmr1, Cnl1, Cst9, Did2, Eto1, Far10,
Gyp5, Hhf1, Hhf2, Htb1, Htb2, Kar3, Kin3, Lhs1, Mad1, Met4,
Mps3, Myo2, Nam7, Nnf1, Nnf2, Not3, Nuf2, Pan1, Red1,
Sec9, Smt3, Smy1, Spra2, Spc24, Spc72, Spr3, Tae2, Tpk3,
Tpm2, Ubi4, Yaf9, YHR080C, Yta6

8

Ahp1, Bmh2, Cdc27, Cpr1, Dpb11, Gus1, Hxk1, Rad1,
Rad10, Rtt107, Slx1, Smc5, Smt3, Ssz1, Tdh1, Yef3

8

Cmk2, Dhh1, Frk1, Gal4, Msh2, Nab2, Pat1, Pex15, Puf3,
Rad3, Rpo21, Sat4, Sen1, Slf1, Smt3, Srb4, Srs2, Ssl1, Ssl2,
Tfb1
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Table 4.2: Characterization of disordered domains in top 5% highest-number
interactors in the Chromatin Processes data set
Protein
Name

Length of Disordered
Regions (# of residues)

Average
Region
Length

38, 41, 43, 51, 56, 63, 67, 81,
Mrc1
120, 155

72

Zip1

41, 42, 44, 49, 59, 69, 182

69

Slx4

36, 62, 88, 102

72

Rad9

61, 73, 134, 201

117

Sgs1

48, 56, 59, 129, 304

119

Rad2

30, 44, 76, 85, 105

68

Xrs2

44, 66, 70, 79

65

Table 4.3: Characterization of disordered residues in top 5% highest-number
Interactors in the Chromatin Processes data set
% disordered
%
Total residues in disordered
Protein Protein domains ≥30 residues in
Name Length
residues
protein
Mrc1

1096

65

75

Zip1

875

55.5

67

Sgs1

1447

41

47

Slx4

748

38.5

39

Rad9

1309

35.8

56

Rad2

1031

33

44

Xrs2

854

30

39
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Figure 4.1: IUPRED plots of high-level interactors with putative binding sites. Binding sites predicted by PONDRFIT
are highlighted in yellow. A disorder probability > 0.5 suggests a disordered section of the protein. Mrc1 phosphorylation
are
mapped
in
red
as
described
.
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Table 4.4: Proteins in the Chromatin Processes data set

Protein

%
Residues
≥.5

% in
Disordered
Domains
≥30
Residues

Apn1

24

Apn2

Interactions

#
Disordered
Domains

#
Phosphorylation
sites

Pathways
(GO terms)

19

1

1

3

BER

24

9

0

1

0

Bre1

40

31

4

3

2

BER
HR,
Checkpoint

Cdc25

38

34

7

7

29

Checkpoint

Cdc28

7

0

0

0

6

Cdc45

23

16

1

2

2

Cdc7

16

6

3

1

5

Cdc9

24

19

1

2

5

Checkpoint
HR,
Checkpoint
HR,
Checkpoint,
Replication
HR, NER,
BER

Chk1

6

0

0

0

8

Checkpoint

Chl1

16

8

0

1

3

SCC

Csm1

23

0

1

0

0

HR

Csm3

35

10

2

1

1

Replication

Ctf18

20

0

1

0

4

HR, SCC

Ctf4

17

11

2

3

7

Ddc1

30

22

5

3

7

HR, SCC
HR,
Checkpoint

Din7

12

0

1

0

0

Replication

Dmc1

8

0

1

0

0

HR

Dna2

23

18

5

2

9

Dot1

33

25

4

2

3

Dpb11

33

19

2

2

5

HR
HR, NER,
Checkpoint
MMR,
Replication

Dun1

20

16

1

2

25

Checkpoint

Eco1

25

13

1

1

1

Esc2

61

53

3

2

9

SCC
HR,
Checkpoint

Est1

12

7

0

1

2

Misc

Exo1

39

31

2

2

5

HR, MMR

Hmi1

5

0

0

0

2

Misc

Hnt3

14

0

0

0

0

Misc

Hsm3

9

0

0

0

1

MMR

Htb1

53

43

0

1

1

Misc
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Table 4.4: Proteins in the Chromatin Processes data set (Continued)
% in
Disordered
%
Domains
#
#
Residues
≥30
Disordered Phosphorylation
Protein
≥.5
Residues
Interactions
Domains
sites

Pathways
(GO terms)

Irc20

17

12

3

4

1

HR, NHEJ

Ku70

13

0

0

0

3

HR, NHEJ

Ku80

17

5

2

1

0

HR, NHEJ

Lif1

57

49

3

3

1

NHEJ

Lig4

7

0

0

0

3

NHEJ

Mag1

10

0

1

0

2

BER

Mcd1

43

29

4

2

8

SCC

Mcm10

42

37

4

2

9

Mcm2

32

28

3

2

8

Mcm3

26

20

3

2

20

Mcm4

28

25

3

2

24

Replication
HR,
Replication
HR,
Replication
HR,
Replication

Mcm5

19

4

0

1

4

Replication

Mcm6

30

22

2

3

16

Mcm7

16

9

1

2

9

Mec1

2

0

0

0

4

Replication
HR,
Replication
Checkpoint,
Replication

Mec3

36

12

1

1

2

Checkpoint

Mgm101

29

20

0

1

1

Misc

Mgs1

18

11

2

1

0

Replication

Mgt1

13

0

0

0

0

Misc

Mhr1

17

0

0

0

0

HR

Mlh1

20

15

2

2

3

MMR

Mlh2

20

13

5

2

0

MMR

Mlh3

5

0

0

0

0

HR, MMR

Mms1

5

0

0

0

2

Replication

Mms2

27

0

1

0

1

Replication

Mms21

14

0

1

0

1

Replication

Mms22

22

14

6

3

0

Replication

Mms4

29

15

2

2

8

Mph1

20

16

3

3

2

Mrc1

75

65

13

10

31

Mre11

35

30

3

2

2

HR
HR,
Replication
Checkpoint,
Replication
HR,
Checkpoint

Msh1

11

5

0

1

2

HR, MMR
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Table 4.4: Proteins in the Chromatin Processes data set (Continued)
% in
Disordered
%
Domains
#
#
Residues
≥30
Disordered Phosphorylation
≥.5
Residues
Interactions
Domains
sites

Pathways
(GO terms)

Msh2

3

0

0

0

1

HR, MMR

Msh3

14

11

3

1

0

HR, MMR

Msh4

14

11

3

1

0

HR

Msh5

7

0

1

0

0

HR

Msh6

25

24

6

1

16

MMR

Mus81

26

13

2

2

2

HR

Nej1

27

23

2

1

3

NHEJ

Nhp10

56

42

3

2

4

Misc

Nse1

7

0

0

0

0

Replication

Nse4

45

37

1

3

2

Replication

Ntg1

13

9

0

1

0

BER

Ntg2

8

0

1

0

0

BER

Ogg1

11

0

0

0

0

BER

Pan2

6

0

0

0

1

Replication

Pan3

32

23

3

1

8

Replication

Pap2

35

34

4

3

3

Misc

Pds1

79

60

7

3

19

Misc

Phr1

6

0

0

0

4

Misc

Pif1

31

26

4

3

5

HR

Pms1

26

23

3

4

6

MMR

Pol1

24

18

6

4

21

Replication

Pol2

6

3

0

2

3

Replication

Pol30

9

0

0

0

0

Replication

Pol31

13

0

0

0

2

Replication

Pol32

67

64

2

1

9

Replication

Pol4

14

9

0

1

0

Pph3

7

0

0

0

0

NHEJ
HR,
Checkpoint

Pri1

9

0

0

0

2

Replication

Psf1

9

0

0

0

0

Replication

Pso2

28

19

1

2

2

Rad1

22

19

2

4

5

Rad10

44

42

2

1

0

Misc
HR, NER,
MMR
HR, NER,
MMR

Rad14

56

42

3

2

2

NER

Rad16

22

20

2

1

6

NER
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Table 4.4: Proteins in the Chromatin Processes data set (Continued)
% in
Disordered
%
Domains
#
#
Residues
≥30
Disordered Phosphorylation
≥.5
Residues
Interactions
Domains
sites

Rad17

24

17

1

1

4

Pathways
(GO terms)
HR,
Checkpoint

Rad18

64

53

3

4

9

Replication

Rad2

44

33

8

5

7

NER

Rad23

63

55

1

3

15

Rad24

28

24

4

2

4

Rad27

24

8

1

1

2

NER
HR, NER,
Checkpoint
BER, NHEJ,
Replication

Rad3

8

0

1

0

0

NER

Rad30

11

6

0

1

0

Replication

Rad34

17

13

2

1

0

NER

Rad4

27

25

3

2

0

NER

Rad5

25

18

4

4

7

Rad50

37

26

3

4

3

Replication
HR,
Checkpoint

Rad51

23

19

2

1

0

HR

Rad52

55

49

6

2

6

HR

Rad53

26

16

5

3

36

Checkpoint

Rad54

18

8

2

1

2

HR

Rad55

20

0

3

0

5

HR

Rad57

17

7

0

1

1

HR

Rad59

12

0

0

0

0

Rad6

37

37

1

2

1

HR
Checkpoint,
Replication

Rad7

31

25

3

1

7

Rad9

52

36

11

4

45

NER
NER,
Checkpoint

Rdh54

25

14

2

2

3

HR

Rev1

11

4

3

1

1

Replication

Rfa1

12

9

1

1

2

Replication

Rfa2

28

15

1

1

7

Replication

Rfa3

23

0

0

0

1

Replication

Rfc1

31

23

3

2

7

Replication

Rfc2

6

0

1

0

0

Replication

Rfc3

7

0

0

0

0

Replication

Rfc4

7

0

0

0

0

Rmi1

30

14

0

1

1

Replication
HR,
Checkpoint

Protein
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Table 4.4: Proteins in the Chromatin Processes data set (Continued)
% in
Disordered
%
Domains
#
#
Residues
≥30
Disordered Phosphorylation
≥.5
Residues
Interactions
Domains
sites

Pathways
(GO terms)

Rrm3

33

32

5

1

1

Replication

Rsc2

41

28

4

3

15

Misc

Sae2

35

21

4

2

7

HR

Sae3

53

45

0

1

1

Sgs1

47

41

10

5

2

HR
HR,
Checkpoint
HR,
Replication

Shu2

8

0

0

0

0

Sir2

20

13

2

1

4

Sld2

80

62

6

5

8

Sld3

47

41

5

4

60

Replication
HR,
Replication
HR,
Replication

Sld5

28

14

0

1

0

Replication

Slx1

9

0

0

0

0

HR

Slx4

56

39

8

4

13

HR

Slx5

52

47

6

4

2

Misc

Slx8

76

72

0

1

4

Misc

Smc1

27

7

6

2

2

Misc

Smc5

18

9

2

1

0

Misc

Sml1

100

100

2

1

2

Misc

Snf5

57

52

7

3

3

Misc

Srs2

33

24

4

5

9

Ssl1

21

18

1

1

2

Ssl2

24

16

4

2

1

HR, NHEJ
NER,
Replication
NER,
Replication

Tah11

18

12

1

1

4

Replication

Tdp1

14

9

1

1

0

Misc

Tel1

1

0

0

0

2

Checkpoint

Tfb1

31

20

2

2

2

NER

Tfb2

14

8

0

1

2

NER

Tfb5

38

0

0

0

1

Tof1

15

13

2

2

12

NER
SCC,
Checkpoint,
Replication

Ubc13

16

0

0

0

0

Replication

Ung1

16

0

0

0

0

Xrs2

39

30

10

4

9

Misc
HR,
Checkpoint
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Table 4.4: Proteins in the Chromatin Processes data set (Continued)
% in
Disordered
%
Domains
#
#
Residues
≥30
Disordered Phosphorylation
≥.5
Residues
Interactions
Domains
sites

Pathways
(GO terms)

Yen1

39

32

3

5

4

HR

Zip1

67

56

9

7

6

HR
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CHAPTER 5:
BIOINFORMATICALLY GUIDED MUTAGENESIS IN RMI1, THE NONCATALYTIC
SUBUNIT OF THE S. CEREVISIAE SGS1/TOP3/RMI1 COMPLEX, REVEALS TWO
FUNCTIONAL MOTIFS

Introduction
The RecQ-like DNA helicase family is evolutionarily conserved and necessary for
genomic stability from bacteria to humans. In yeast the RecQ-like DNA helicase Sgs1
forms a complex with Top3/Rmi1 (STR) and facilitates both early and late stage DNA
break repair [1]. Early in double strand break (DSB) repair, STR resects the ends of the
DSB to facilitate the formation of a single-strand 3’ overhang to which Rad51 binds [25]. This Rad51 filament is then able to initiate a genome-wide search for sequence
homology (strand invasion), eventually leading to the formation of Holliday Junctions
(HJs) that need to be resolved prior to cell division. Resolution can be achieved by the
HJ-specific endonuclease Yen1, randomly leading to crossover and noncrossover
products, or HJs can be dissolved by STR in a process involving HJ migration and
decatenation of the single strands that yields noncrossover products [6]. STR has also
been implicated in the reversal of strand invasion after extension of the invading 3’end
by DNA synthesis to promote DSB repair by synthesis-dependent strand annealing, as
well as reversal of strand invasion prior to 3’end extension (D-loop reversal) [7].
Through these functions, STR promotes noncrossover outcomes of HR and regulates
160

HR levels. Hence, yeast cells that lack the helicase activity of the STR complex (sgs1)
are

prone

to

hyperrecombination,

increased

chromosomal

instability,

gross

chromosomal rearrangement (GCR) formation, hypersensitivity to DNA-damaging
agents and, in the case of top3 and rmi1 single mutants, very poor growth [8-11].
Despite the severe growth phenotype of the rmi1 mutant, the functional
contribution of Rmi1 to the STR complex is still poorly understood. Rmi1, was first
discovered in S. cerevisiae in a screen for components of the Sgs1/Top3 pathway [9].
Yeast cells lacking Rmi1 were found to be hypersensitive to hydroxyurea (HU) and
methylmethanesulfonate (MMS), have an increased rate of spontaneous DNA damage
as indicated by an increase in Rad52 foci, an increase in GCRs, and deficiency in
Rad53 phosphorylation [9, 11]. Diploids lacking Rmi1 are defective in meiosis, and
deletion of genes with roles in the checkpoint response to replication stress, such as
Mrc1, Tof1, Csm3, lead to synthetic lethality, implying a diverse role for Rmi1 in several
chromatin processes [9, 11]. Despite the severity of rmi1 phenotypes, Rmi1 has no
known catalytic function. It has been shown to stimulate the catalytic functions of
Sgs1/Top3, particularly the decatenation of HJs [12-14]. This function is conserved in
the BLM/TopoIIIα/Rmi1/Rmi2 (BTR) complex, the human variant of STR, and studies in
human cell lines imply a role for Rmi1 in TopoIIIα stability and expression [14-16].
The N-terminus of human Rmi1 has been crystallized, providing some clues to its
role in catalytic enhancement and BTR complex stability [17, 18]. The N-terminus of
human Rmi1 is most closely related to the S. cerevisiae Rmi1, is capable of binding
BLM and TopoIIIα, and contains a central oligonucleotide-binding (OB) fold that is
similar in structure to that of the replication protein A subunit RPA70, though it is
161

suggested that it is incapable of binding DNA like RPA [18, 19]. Human Rmi1 contains a
disordered loop needed for dHJ dissolution enhancement of TopoIIIα [17]. Cocrystallization of the Rmi1 N-terminal lobe peptide with TopoIIIα reveals that the OB-fold
of Rmi1 lies opposite of the ssDNA-binding domain of TopoIIIα, and the loop of Rmi1
physically interacts with the topoisomerase by inserting itself into the topoisomerase
gate. It has been hypothesized that this loop may be what facilitates the catalytic
enhancement of TopoIIIα by regulating opening and closing of the topoisomerase gate
[17, 18].
In an effort to better understand the molecular basis of Rmi1 function, we have
combined bioinformatics tools with an in vivo mutational analysis of RMI1 function in
yeast. This approach has identified short, N- and C-terminal structural motifs that are
essential for Rmi1 function and are conserved in human Rmi1. We propose hypotheses
for how these motifs contribute to Rmi1’s role in maintaining the functional integrity of
the STR complex.

Experimental Procedures
Bioinformatics analysis
The 241 residues of S. cerevisiae Rmi1 and the N-terminal 240 residues of the
625-residue human Rmi1 were analyzed for helical propensity, structural disorder, and
amino acid sequence similarity [20-24].
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Plasmids
The open reading frame of RMI1 plus 500 bp up- and downstream was amplified
by PCR from the endogenous RMI1 locus of KHSY1338 (ura3-52, leu21, trp163,
his320,0 lys2-Bgl, hom3-10, ade21ade8, YEL069C::URA3, sgs1::HIS3). The
fragment was inserted into XbaI-digested pRS415 by gap-repair cloning using the nonhomologous-endjoining deficient yeast strain KHSY2331 (ura3-52, leu2Δ1, trp1Δ63,
his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1, ade8, YEL069C::URA3, lig4::loxP-G418-loxP)
and standard lithium-acetate transformation [25]. The integrity of RMI1 and the promoter
region in the resulting pRS415-RMI1 plasmid (pKHS 621) was verified by sequencing.
Point mutations were introduced into pKHS 621 by QuikChange site-directed
mutagenesis (Agilent Technologies). The list of plasmids used in this study is provided
in Table 5.1.

Yeast strains
To construct yeast strains with chromosomally integrated rmi1 mutants that are
expressed as C-terminally myc-epitope-tagged proteins, pKHS 621 was linearized with
BoxI and the HIS3-linked myc-coding sequence from pFA6a-13MYC-HIS3MX6 [26] was
inserted by gap-repair cloning.

Point mutations were introduced into the resulting

plasmid (pKHS630) using the QuikChange protocol (Agilent Technologies). Fragments
spanning MYC-tagged RMI1 and rmi1 mutant alleles were amplified from pKHS 630
and its derivatives by PCR and used to replace the endogenous RMI1 locus in the
BY4711-derived

yeast

strain

MATa,

ura30,

leu20,

his31,

lys20,

TOP3.V5.VSV.KANMX6. Integrity of RMI1 and the mutant alleles was confirmed by
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sequencing and expression verified by Western blot analysis with c-myc monoclonal
antibody (Covance).

Hydroxyurea hypersensitivity assay
Derivatives of pKHS621 were transformed into KHSY4695 (MATα, ura30,
leu20, his31, lys20, rmi1::HIS3, TOP3.V5.VSV.KANMX6), grown to OD600 = 0.5 in
synthetic complete media lacking leucine (SC-Leu), and spotted in 10-fold dilutions on
yeast extract/peptone/dextrose (YPD) and on YPD supplemented with 150 mM HU.
Growth was documented after 3 to 5 days of incubation at 30°C.

Cycloheximide chase
Yeast cultures were grown overnight to OD600 = 1.0. Cells were synchronized by
addition of 2 µg/µl alpha factor for 1 hour, followed by addition of 1 µg/µl alpha factor for
an additional 1 hour. Cells were washed twice with warm YPD and resuspended in YPD
to reach OD600 = 1.0. Cycloheximide was added to the culture at a final concentration of
50 µg/ml and the culture was incubated with vigorous shaking at 30 °C. Aliquots
equivalent to 2 ODs were removed at the indicated intervals over a 24-hour time course.
Whole cell extracts were prepared as previously described [27]. Briefly, washed cell
pellets were resuspended in 20% trichloroacetic acid and vortexed in a cell disruptor
with glass beads for 10 minutes at maximum speed. Lysate was cleared by
centrifugation at 14000 rpm for 2 min. The pellet was resuspended in Laemmli buffer,
the pH adjusted with 2 M Tris, pH 8.3, and boiled. Extracted proteins were separated by
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SDS-PAGE and transferred to PVDF membrane before being probed for Rmi1 and rmi1
mutants using a c-myc monoclonal antibody (Covance).

Results
Determining functionally important residues in S. cerevisiae Rmi1 has been
challenging as there, are no known catalytic domains, no crystal structure, and only
minimal conservation of primary sequence (~35% between yeast genera, 18% between
S.cerevisiae and human Rmi1) and length, ranging from 241 residues in S. cerevisiae to
625 in humans. We reasoned that combining structural prediction tools [23, 24, 28] in
such a way that they detect ‘order within disorder’ could reveal functionally important
motifs in Rmi1. We focused our analysis on the N- and C-terminal tails flanking the
predicted OB-fold, and an apparent disordered loop emerging from the OB-fold (Figure
5.1A). We identified two regions of increased helical propensity, spanning residues 5869 and residues 212-228, as well as two regions of lesser helical propensity between
residues 126-131 and 138-145 (Figure 5.1B). We had previously determined that
disruption of an α-helix was most effective when a residue with high helical propensity
near the peak or in the N-terminal half of the helix was replaced with the helix breaker
proline. Therefore, we constructed F63P, A128P, A139P and E220P mutations (Fig.
5.1A) to determine the importance of these regions for Rmi1 function in vivo. These
proline substitutions led to marked decreases in helical propensity in these regions
(Figure 5.1C-F). We also noted that the proline at position 88 seemed to disrupt what
might otherwise be a region with high helical propensity, and hypothesized that this
native break was helping to maintain a degree of flexibility in what would otherwise be a
165

persistent, structured region. We considered that replacing P88 with a residue with high
helical propensity that was otherwise benign, such as alanine, would restore helicity to
this region. Indeed, the P88A mutation is predicted to lead to an extraordinary increase
in helical propensity not seen in any region of the wildtype forms of yeast or human
Rmi1 (Figure 5.1G). We exploited the HU hypersensitivity of yeast cells lacking
Rmi1[11] to assess the functional impact of these proline substitutions in vivo. We found
that rmi1 cells expressing rmi1-A128P and rmi1-A139P exhibited the same HU
sensitivity as the rmi1 mutant complemented with wildtype RMI1, whereas rmi1-P88A
was able to partially suppress the HU hypersensitivity of rmi1 (Figure 5.1H). The rmi1F63P mutant caused the same degree of HU hypersensitivity as a deletion of RMI1,
indicating that it was a null allele (Figure 5.1H). We considered the possibility that the
phenotype of the F63P mutation could also be due to the loss of a strong hydrophobic
interaction via the aromatic residue, and decided to evaluate the importance of the
chemical composition of this predicted helical region. We chose to replace F63 with a
hydrophilic residue with high helical propensity, such as lysine, that would be predicted
to maintain the structural integrity of the motif, but change its chemical characteristics.
We found that the F63K mutation caused the same hypersensitivity to HU as the F63P
mutations (Figure 5.1G), implicating that this residue maps to an α-helical structure that
must conserve both its shape and hydrophobic character in order to maintain wildtype
function of Rmi1. Similarly to F63, substitution of E220 with proline abolished Rmi1
function (Figure 5.1H).
Next we analyzed primary sequence alignments of S.c. Rmi1 to identify
conserved residues and regions of conserved chemical character that could also be
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indicative of a functional role. We found that the 241-residue long S.c. Rmi1 is ~85%
identical to Rmi1 of other Saccharomyces species, but identity markedly decreased to
~30% when compared to yeast species outside of the genus (e.g., K. lactis, C.
glabrata), and to ~18% when compared to the N-terminal 241 residues of human Rmi1.
Because of this low level of sequence conservation we decided to analyze an alignment
of twelve closely related Rmi1 sequences from fully sequenced Saccharomyces and
non-Saccharomyces yeast species in PhylomeDB v4 [22] (Figure 5.2C, Supplemental
Figure 5.1). This alignment revealed that the chemical characteristics of the α-helical
region centered on residue E220 were conserved, with a short stretch of hydrophobic
residues surrounded by charged residues. Whereas neither E220 nor the acidic or
hydrophilic character of the residue was conserved outside of the Saccharomyces
genus, the hydrophobic residues were, including a tyrosine at position 218 (Figure
5.2C). We hypothesized that this residue was not only part of the functional α-helical
structure we had inferred from the E220P mutant, but was also a key residue for binding
in an otherwise fairly charged α-helix. Indeed we found that either breaking the helix
(rmi1-Y218P) or increasing its hydrophilicity (rmi1-Y218K) abolished Rmi1 function
(Figure 5.2D). Although S.c. Rmi1 and human Rmi1 are only 18% identical, we found
that they share regions of similar helical propensity, including the region that surrounds
Y218 in yeast and Y201 in human Rmi1 (Figure 5.2A,B).
When we extended the computational analysis to the N-terminus of human Rmi1,
we identified three regions of increased helical propensity (Figure 3B), which have been
shown to form three α-helices in the crystal structure [17, 18]. Comparisons of helical
propensity and primary sequences of S.c. Rmi1 and the N-terminus of human Rmi1
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suggest a structural equivalence between the predicted sole α-helix in yeast and 3 in
human Rmi1, with a potential equivalent of F63 at residue F50 in human Rmi1 (Figure
5.3A,B; Figure 5.5). The lack of helical propensity in the first 57 residues of S.c. Rmi1
suggests that this region does not form α-helices in the apo form as human Rmi1 does.
However, we noticed two discrete regions in the yeast sequence alignment (residues
S2-T16 and E28-E38) that contain hydrophobic residues in the i+4 pattern typical of an
α-helix and are separated from each other by residues with the lowest helical
propensity, proline and glycine (Figure 5.3C). To test the possibility that these two mildly
hydrophobic regions could become helical upon binding to another protein, possibly
Sgs1, or could be analogous to α1 and α2 in human Rmi1 we replaced L7 and Y35 with
proline (Figure 5.3C). Expression of either mutant, however, was sufficient to fully
restore wildtype growth to the rmi1 mutant on HU (Figure 5.3D), suggesting either that,
unlike in human Rmi1, this region in S.c. Rmi1 does not adopt α-helical structures or
that any helical structure or binding-induced folding in this region is not required for
Rmi1’s role in tolerating HU-induced DNA-damage.

Discussion
In this study, we have used three bioninformatic tools – disorder prediction,
helical propensity prediction and phylome alignments – to elucidate structure/function
relationships in the N- and C-terminal regions of S.c. Rmi1 that surround it’s postulated,
central OB-fold.
Short structured motifs are common in areas of disorder, and are often Molecular
Recognition Features (MoRFs), which are short sequences of marginal order used for
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protein binding that induces further disorder-to-order transition [29-31]. PONDR-VLXT
[32] and IUPRED [33] predict order for residues 134-227, the majority of which likely
form the OB-fold observed in the crystal structure of human Rmi1. This ordered region
contains a disordered loop (residues 120-136) that seems to be equivalent to the
disordered insertion loop in the OB-fold of human Rmi1 [17]. Deletion of this loop in
human Rmi1 eliminates complex formation with BLM and TopoIIIα [18] whereas
replacement of the equivalent loop in S.c. Rmi1, as estimated by sequence alignment
with a scrambled version of equal chemistry, showed that Rmi1 was able to bind Sgs1
and Top3, but was unable to stimulate Top3 catalytic activity and dHJ dissolution [17].
Our proline mutagenesis (A128P, A139P) suggests that the adoption of helical structure
in this disordered loop is not required for Rmi1’s function in tolerating HU-induced DNA
damage.
The N- and C-terminal regions flanking the OB-fold contain many disordered
residues and short ordered segments. In these regions, we have identified three
mutations (F63P/K, Y218P/K, E220P) that display rmi1-like defects during chronic
exposure to HU, and one mutation, P88A, that exhibits an intermediate growth defect on
HU. To date, only one other point mutant in S.c. Rmi1 has been reported, E69K [34]. At
the permissive temperature of 25°C the sensitivity of this mutant to DNA-damaging
agents resembles that of wildtype, but at 35°C it exhibits the defect of an rmi1. That
E69K appears to be better tolerated than F63P/K can be explained by the location of
E69 at the C-terminus of the predicted helical region (residues 58-69), where mutations
appear to have less functional impact [27], whereas F63 maps closer to the center and,
in contrast to E69, is conserved in other yeast species (Figure 5.3C).
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At the C-terminus, E220P and Y218P/K mutations caused the same HU
hypersensitivity as F63P/K mutations at the N-terminus, leading us to propose that
residues 58-69 and 212-228 of S.c. Rmi1 form functionally critical α-helices that must
retain a certain degree of hydrophobic character for full functionality. Based on the
hydrophobicity of the α-helices we hypothesize that they function as interaction sites,
with the F63 and Y218 residues part of the binding interfaces. This type of small binding
motif paired with disorder has been seen in other proteins, including the yeast protein
Adr1, which contains two small zinc finger domains in a disordered domain [35];
interestingly, the disordered components of this domain undergo extensive folding when
contact is made between the zinc fingers and DNA. We tested if binding-induced helix
formation was also a function of the extended unstructured N-terminus of yeast Rmi1,
but found that introducing proline residues at positions (L7, Y35), where prospective
helices might form, did not impair Rmi1 function as assessed by growth on HU.
Regarding the binding events that the F63 helix and Y218 helix may be engaged
in, we present two possibilities: First, one or both of the helices may be stabilizing the
OB-fold of Rmi1 as seen in other proteins containing this fold type [36]. Crystallography
of human Rmi1 suggests that the three alpha helices in the N-terminus (α1-3) mediate
protein stabilization via L57 and T59 in the third helix and K166 in the OB fold via
hydrogen bonding [18]. If the predicted α1 (58-69) in S.c. Rmi1 is analogous to α3 in
human Rmi1, it is possible that F63P eliminates the structural element needed for
stabilizing stacking interactions, and F63K induces an electrostatic repulsion strong
enough to prevent the packing between the strands of the central fold and the Nterminal α-helix.
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The functional impairment of S.c Rmi1 by the P88A mutation is consistent with
the role of the putative N-terminal α-helix in stabilizing the OB-fold. We propose that the
helix-breaking property of the proline at position 88 (Figure 5.1G) contributes to the
flexibility of a linker between the α-helix and the first -sheet of the OB-fold.
Replacement of this proline with alanine, which has excellent helical propensity, is
predicted to make this linker helical. The resulting rigidity may weaken the interactions
between the N-terminal α-helix and the first -sheet of the OB-fold, leading to a
destabilization of the OB-fold, but not as severe as that resulting from disrupting the
integrity of the α-helix itself by F63P/K. Crystallography of human Rmi1 supports this
role for the N-terminal α-helix and, by extension, the flexible linker, with the
corresponding residues being in close proximity to the central OB-fold. F50 in α3 of
human Rmi1, which we propose to be equivalent to F63 in the predicted α1 of S.c.
Rmi1, is in close proximity to β1 and β4 of the OB-fold (Figure 5.4). Similarly, at the Cterminus, Y201, the equivalent of Y218 of S.c. Rmi1, appears close to the rear of the
OB-fold, also in proximity to β1 (Figure 5.4) [17].
Second, one or both of the α-helices in Rmi1 may mediate physical interactions
between the Rmi1/Top3 complex and Sgs1. Crystallography of the human
Rmi1/TopoIIIα complex shows that the central OB-fold of Rmi1 is the primary interactor
with TopoIIIα [17]. This suggests that aside from stabilizing the OB-fold, it is unlikely that
the putative helices at F63 and Y218 play a role in Top3 binding. Where the RecQ
helicase interacts with the Rmi1/topoisomerase complex is still unknown, but the
location of the α helices at the N- and C-terminal ends of S.c Rmi1, their hydrophobic
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faces, and their conservation in human Rmi1 may make the α-helices at F63 and Y218
candidates for Sgs1 binding.

Future Directions
In an effort to test the hypothesis that the structures destroyed by proline
mutation are providing stability to the protein at large, a cycloheximide chase will be
employed to compare the stability of the wildtype Rmi1 protein to the mutant proteins.
Upon introduction of cycloheximide, all protein synthesis ceases, and the degradation
time of a protein can be probed. To date, the wildtype protein has been evaluated via
chase as described in the method section; preliminary results suggest that protein levels
reach near zero around 7-8 hours following cycloheximide exposure. It is hypothesized
that both F63P and Y218P are contributing to protein instability that yields the sick
phenotypes seen on HU; thus, it is expected that the chase results will show that the
proteins degrade much more quickly than the wildtype protein. A128P is being used as
a positive control, and is expected to have a similar stability profile to wildtype Rmi1.
Future directions also include P88A protein stability with the cycloheximide chase.
Considering that the phenotype on HU is intermediate to the wildtype and F63P/Y218P
phenotypes, it is possible that the protein will be intermediate in stability and time to
complete degradation. It is also possible that P88A plays no role in stability of Rmi1
itself, but rather prevents some other sort of binding event or function that requires the
flexible linker that P88 maintains. To test this possibility, we may test the ability for the
mutant protein to bind its only known partners, Sgs1 and Top3. This could be
accomplished via in vitro pulldown, as previously described [27]. In this case, it is
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hypothesized that Sgs1 binding is more likely to be mediated by this flexible loop, as
previous crystallography of the human orthologs puts the binding of Top3 out of reach of
the region [17].
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FIGURE 5.1: Sites of directed mutagenesis predicted by Agadir software. A)
Residues F63, A128, A139, and E220 are residues near the peak of the helical
prediction. P88 is predicted to be responsible for the sudden loss in helical prediction in
the area just N-terminal of it. B-F) Wildtype and Mutation Agadir profiles show
dissolution of predicted structure when proline mutants are introduced to these areas or
induction of structure when proline is removed. G) Plasmids containing the ORF of
RMI1 and rmi1 mutants were transformed into a Δrmi1 strain and challenged with HU.
F63P and F63K are phenotypically like the empty vector negative control; E220P and
P88A have intermediate phenotypes.
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FIGURE 5.2: Yeast Rmi1 and human Rmi1-N have comparable predicted structure
in the far C-terminus. A) The Agadir profile of yeast Rmi1 predicts an alpha helix at
the end of the protein. B) An equivalent helix is predicted at the end of human Rmi1-N,
which is the only region of the human protein with sequence similarity to the yeast
ortholog. C) Phylome DB alignment of yeast species reveals a highly conserved
tyrosine at position 218. This residue is in the same predicted helix as E220 and has a
potential equivalent in Y201 in humans. D) Y218P and Y218K rmi1 plasmids cannot
complement Δrmi1 strains on HU.
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FIGURE 5.3: Yeast and human Rmi1 have potentially comparable predicted
structure and “proto-structure” in the far N-terminus. A) Agadir profile of S.
cerevisiae Rmi1 N1-80. B) Agadir profile of H. sapiens Rmi1 N1-80. The profile predicts
three helices, as labeled. The estimated human equivalent to yeast F63, F50, is
highlighted. C) Phylome DB alignment of yeast species illustrates clusters of conserved
residue chemistry about L7 and Y35, which are themselves highly conserved. The
predicted threshold of the yeast Rmi1 helix is plotted in the red box; the thresholds of
two hypothesized proto-helices, which may assume structure upon a binding event, are
plotted in the red hashed boxes. The human Agadir prediction (light blue boxes) and
actual crystal structure helical thresholds [79] (dark blue boxes) are included for
comparison. D) Mutagenesis in L7 and Y35 meant to prevent the induction of alphahelical structure does not affect growth on HU.
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FIGURE 5.4: Structural hypotheses for proline mutant phenotypes based on
disorder prediction and crystal structure. Mapping the equivalent human residues to
F63 (light blue helix) and Y218 (dark blue helix) in the human Rmi1-N crystal structure
(PDB database: 4CGY) [65] shows a close proximity of these residues and their
accompanying structures to the central barrel of the OB fold , suggesting a role for
these structures in protein stabilization. Both residues are removed in space from Top3α
(green), suggesting that they are not important for direct Top3α/Rmi1 interaction.

F
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FIGURE 5.5: Alignment between S.c. Rmi1 and H.s. Rmi1N. Human equivalents to
yeast F63 and Y218 are highlighted in red boxes.
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Table 5.1: Plasmids used in this study
Plasmid

Description

pKHS 621

pRS415-Rmi1

pKHS 622

pRS415-Rmi1-F63P

pKHS 623

pRS415-Rmi1-E220P

pKHS 624

pRS415-Rmi1-A128P

pKHS 625

pRS415-Rmi1-A139P

pKHS 626

pRS415-Rmi1-P88A

pKHS 627

pRS415-Rmi1-Y218P

pKHS 628

pRS415-Rmi1-L7P

pKHS 629

pRS415-Rmi1-Y35P

pKHS 630

pRS415-Rmi1.myc

pKHS 631

pRS415-Rmi1.myc- F63P

pKHS 632

pRS415-Rmi1.myc-A128P

pKHS 633

pRS415-Rmi1.myc-Y218P

pRS415 is a gift from Dr. Steven Brill (Rutgers University)
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APPENDIX A:
SGS1 TRUNCATIONS INDUCE GENOME REARRANGEMENTS BUT SUPPRESS
DETRIMENTAL EFFECTS OF BLM OVEREXPRESSION IN SACCHAROMYCES
CEREVISIAE

Note to the reader: This chapter has been previously published with permission from the
publisher as Mirzaei, H, Syed, S, Kennedy, JA, and Schmidt KH (2011). “Sgs1
Truncations Induce Genome Rearrangements but Suppress Detrimental Effects of BL
Overexpression in Saccharomyces cerevisiae.” J Mol Biol., 405(4); 877-891.
Research was designed by K. Schmidt. Sgs1 Truncations and experiments were
performed by S. Syed. BLM diploid experiments and chimera protein construction was
done by H. Mirzaei. Point mutations and experiments on the zinc-binding domain were
done by H. Mirzaei and J. Kennedy. Corresponding author: Kristina Schmidt,
Department of Cell Biology, Microbiology and Molecular Biology, University of South
Florida, 4202 E. Fowler Avenue, ISA2015, Tampa, FL 33620. Phone: (813) 974-1592.
Fax: (813) 974-1614.; E-mail: kschmidt@usf.edu

Abstract
RecQ-like DNA helicases are conserved from bacteria to humans. They perform
functions in the maintenance of genome stability, and their mutation is associated with
cancer predisposition and premature aging syndromes in humans. Here, a series of Cterminal deletions and point mutations of Sgs1, the only RecQ-like helicase in yeast,
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show that the HRDC and Rad51 interaction domain are dispensable for Sgs1’s role in
suppressing genome instability, whereas the zinc-binding domain and the helicase
domain are required. BLM expression from the native SGS1 promoter had no adverse
effects on cell growth, but also was unable to complement any sgs1Δ defects. BLM
overexpression, however, significantly increased the rate of accumulating GCRs in a
dosage dependent manner and greatly exacerbated sensitivity to DNA-damaging
agents. Co-expressing sgs1 truncations of up to 900 residues, lacking all known
functional domains of Sgs1, suppressed HU sensitivity of BLM overexpressing cells,
suggesting a functional relationship between Sgs1 and BLM. Indeed, protein disorder
prediction analysis of Sgs1 and BLM was used to produce a functional Sgs1-BLM
chimera by replacing the N-terminus of BLM with the disordered N-terminus of Sgs1.
The functionality of this chimera suggests that it is the disordered N-terminus, a site of
protein binding and post-translational modification, that confers species-specificity to
these two RecQ-like proteins.

Introduction
RecQ-like DNA helicases, named after the DNA repair protein RecQ of E. coli [13] are evolutionarily highly conserved. These 3’- to 5’-helicases function at the interface
between DNA replication and recombination to maintain genome integrity. Sgs1 is the
only known member of this helicase family in Saccharomyces cerevisiae [4]. Sgs1deficient cells show increased sensitivity to the DNA-damaging agents hydroxyurea
(HU) and methylmethane sulfonate (MMS), missegregate chromosomes, accumulate
gross-chromosomal rearrangements (GCRs) and have a shortened lifespan [5-8]. In
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contrast, five RecQ-like helicases (RecQL1, BLM, WRN, RecQL4 and RecQL5) are
known in humans, and mutations in the BLM, WRN and RECQL4 genes are associated
with the rare, cancer-prone Blooms syndrome, Werner syndrome and Rothmund
Thompson syndrome, respectively [9-13]. All RecQ-like helicases share a seven-motif
helicase domain with Walker A and DEAH motifs. The RQC (RecQ-helicase-conserved)
domain, located C-terminal to the helicase domain, is thought to be involved in DNA
binding and conferring specificity of binding to DNA structures, such as G4-tetrads 14;
[15-17]. The HRDC (Helicase and RNaseD C-terminal) domain is the most C-terminal of
the conserved domains and resembles domains in other proteins that are involved in
nucleic acid metabolism, such as RNase D and UvrD; but, like the RQC domain, it is not
found in all RecQ-like helicases [18; 19]. The HRDC domain has been implicated in
binding and resolving DNA structures, such as Holliday junctions, and in mediating
protein-protein interactions [18; 20-23]. Two acidic regions have also been identified Nterminal of the helicase domain and may be involved in mediating protein-protein
interactions [10; 24; 25]. Sgs1 is found in a complex with Top3 and Rmi1, and there is
also evidence of physical interactions of the N-terminal half of Sgs1 with
Top2, Srs2 and Rad16, and interactions of the C-terminus with Mlh1 and Rad51 [26; 27]
[28-31].
Defects in BLM, the human RecQ-helicase considered to be most closely related
to Sgs1 cause Bloom’s syndrome (BS), an autosomal recessive disorder characterized
by chromosome gaps and breaks, elevated sister chromatid exchange, mitotic
hyperrecombination, and aberrant DNA replication events [32-34]. Affected individuals
suffer from a high incidence and wide variety of cancers, infertility and dwarfism
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(reviewed in reference 33). BLM catalyses ATP-dependent 3' to 5' DNA unwinding with
a preference for DNA structures that may arise spontaneously during DNA replication or
as a result of homologous recombination (HR) [35]. For example, by unwinding unusual
secondary DNA structures, BLM may aid replication fork progression, prevent
illegitimate recombination during replication and assist in restarting stalled forks [36-39].
Evidence supporting a role of BLM in maintaining genome integrity has been
accumulating. For example, BLM-defective cells exhibit a retarded rate of strand
elongation during DNA replication 40, accumulate abnormal replication intermediates
[41] and are hypersensitive to agents that impair DNA replication [42]. BLM physically
interacts with several proteins that play important roles during DNA replication and
repair, such as replication protein A (RPA), the flap-endonuclease FEN-1, chromatin
assembly factor CAF-1, the mismatch repair protein Mlh1, HR factor Rad51 and
topoisomerase III α [43-49]. BLM peaks in S phase and it localizes to replication foci,
most likely through its physical interaction with a subunit of DNA polymerase δ [50-54].
Here we have determined the role of C-terminal domains and protein interaction
sites of Sgs1 in suppressing GCR accumulation by expressing point mutants and
truncations of Sgs1 lacking as few as 20 and as many as 1428 residues. To investigate
BLM’s ability to complement sgs1Δ defects, such as increased genome instability and
sensitivity to HU and MMS, human BLM cDNA was expressed under control of the
native SGS1 promoter and overexpressed from a galactose-inducible promoter,
revealing that BLM could suppress sgs1Δ defects neither in haploid nor in diploid cells.
However, using computational protein disorder prediction tools, we have designed a
yeast/human chimera that consists of two nonfunctional segments of BLM and Sgs1.
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The ability of this chimera to suppress all sgs1Δ defects that we tested suggests a
functional relationship between BLM and Sgs1, which is also supported by our finding
that short N-terminal fragments of Sgs1, which are devoid of all known functional
domains for helicase activity and DNA binding, suppress severely detrimental effects of
BLM overexpression in yeast.

Materials and Methods
Yeast Strains and Media
All strains are derived from KHSY802, a derivative of S288C. Yeast strains
expressing

truncations

of

Sgs1

helicase

were

constructed

by

homologous-

recombination-mediated integration of PCR products, replacing the desired 3’-segment
of SGS1 on chromosome VIII with a myc-epitope coding sequence (from pFA6a13Myc.His3MX655, gift from Mark Longtine, University of Washington) in frame with the
SGS1 coding sequence. Expression of all truncation alleles and the myc-epitope-tagged
wildtype allele of SGS1 was confirmed by western blot analysis. All gene replacements,
insertions and truncations were performed by the standard LiAc protocol [56], using
PCR products with at least 50-nucleotides on each end that matched the chromosomal
target locus. To express BLM from the native SGS1 promoter (PSGS1), a PCR
fragment containing BLM cDNA (Open Biosystems) and a HIS3 cassette was amplified
by PCR from plasmid pKHS293 using primers that include 50-nt homology to the
chromosomal SGS1 locus. This PCR product was fused to the native chromosomal
SGS1 promoter by homologous-recombination-mediated integration [56]. A PCR
fragment coding for a 13Myc epitope tag was amplified from pFA6a-13Myc-kanMX6 55
186

and integrated in-frame at the 3’end of cDNAs or sgs1 alleles for detection of protein
expression by western blot analysis. In strain KHSY3350 and KHSY3218, galactoseinducible promoters amplified from plasmids pFA6a-kanMX6-PGAL1 or pFA6a-TRP1PGAL155, respectively, were used to replace the native SGS1 promoter. To construct
KHSY3355, the 3’-terminal 2313 bp of BLM cDNA linked to a HIS3 cassette were
amplified by PCR from plasmid pKHS293 and used to replace the 3’-terminal 2400 bp of
SGS1 in KHSY802. The accuracy of PCR-derived SGS1 or BLM integrations was
confirmed by sequencing. Amino acid changes C1047F and F1056A in Sgs1 were
made by sitedirected mutagenesis (QuikChange, Stratagene) of pKHS360 and
integrated at the sgs1::HIS3 locus in KHSY1338. All yeast strains used in this study are
listed in Table S1 (Supplementary Information). Cells were grown in YPD consisting of
10g/l yeast extract (Fisher Scientific), 20 g/l Bacto-peptone (BD Diagnostic Systems),
2% glucose (Fisher Scientific), unless indicated otherwise. For plates, agar (BD
Diagnostic Systems) was added at a concentration of 20 g/l.
Western blot analysis
To confirm expression of myc-epitope tagged BLM and SGS1 alleles, cells were
grown to OD600 = 0.5 in YPD and whole cell extracts were prepared from 5 ml of
culture (~ 3.5 × 107 cells) by standard trichloroacetic acid (TCA, Fisher Scientific)
extraction [57]. Five microliters of TCA extract were separated on 10% polyacrylamide
gels, transferred to a PVDF membrane (BioRad), probed with anti-c-myc monoclonal
antibody (9E10, Covance Research Products) and visualized by chemiluminescence
(ECL Plus, GE Healthcare). To confirm expression of SGS1 and BLM from the GAL1
promoter the same western blot procedure was used, but cells were grown overnight in
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YP ((10g/l yeast extract (Fisher Scientific), 20 g/l Bacto-peptone (BD Diagnostic
Systems)) supplemented with 2% sucrose (Fisher Scientific), then diluted to OD 600 = 0.2
either in YP supplemented with 2% sucrose (uninduced sample) or 2% galactose
(induced sample) and harvested for TCA extraction when cultures reached OD600 = 0.5.
Molecular weight marker (Broad Range) was from BioRad.

Sensitivity to DNA damaging agents HU and MMS
Cell cultures were grown in YPD to OD600 = 0.5 and 10-fold serial dilutions were
spotted on YPD supplemented with 0.05% methyl-methanesulfonate (MMS, Sigma
Aldrich) or hydroxyurea (HU, US Biologicals) at 50 mM or 100 mM, as indicated. For
experiments that included strains expressing BLM or Sgs1 from the GAL1 promoter
(Figure 5), cultures were grown in YP-2% sucrose instead of YPD, and spotted on YP-1
% sucrose + 1% galactose (to induce gene expression) supplemented with 100 mM HU,
or without HU as the growth control.

GCR rate measurements
Rates of accumulating gross-chromosomal rearrangements (GCRs) in YPD were
determined as previously described [58]. For GCR rate measurements of yeast strains
expressing BLM or Sgs1 from the GAL1 promoter the same procedure was followed,
except that media was supplemented with 2% galactose to induce gene expression.
Briefly, 10 ml of YP-2% galactose were inoculated with a single colony, which had been
grown on YPD agar for 3 days. After 3 days of growth in liquid media at 30° C with
vigorous shaking, cells were plated on GCR plates 58 supplemented with 2% galactose
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instead of 2% glucose, and 10−6 dilutions were plated on YPD to obtain the viable cell
count. Colonies on GCR plates were counted after 5 days of incubation at 30° C. For
GCR rate measurements in the presence of varying BLM expression levels (Table 2),
0.1% or 0.5% galactose was added to liquid YP media and to GCR plates instead of 2%
galactose, and sucrose was supplemented to reach a total of 2% sugar in the media.
95% confidence intervals were calculated according to Nair [59].

Random Spore Analysis
Diploids heterozygous for the desired mutant alleles were grown overnight at
30°C in YPD, washed, transferred to 0.1% potassium acetate (Fisher Scientific) and
incubated for 5 days at 30°C with vigorous shaking. Asci were incubated in the
presence of zymolase (MP Biomedicals, 500 μg/ml) in 1 M sorbitol (Fisher Scientific) for
20 min at 30°C and enriched for haploid spores as previously described [60]. Spores
were plated on YPD, incubated at 30°C and genotyped by spotting on synthetic dropout media (US Biologicals) to detect the presence of TRP1 and HIS3 marker cassettes
linked to the mutant alleles. Presence of mutant alleles linked to the kanMX6 cassette
was detected by the ability of haploids to grow on YPD supplemented with 200 μg/ml
G418 (Axxora LLC, San Diego, CA).
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Results
Requirement of the RQC domain of Sgs1, but not the HRDC domain, for
GCR suppression
Sgs1 contains a conserved DEAH helicase domain, a conserved helicase and
RNaseD Cterminal (HRDC) domain, two acid regions (AR1, AR2) and a RecQconserved (RQC) domain composed of zinc-binding and winged-helix domains. Several
protein interaction sites have also been located in the 1447-amino-acid long protein
(Figure A.1A). To determine the role of these domains in the maintenance of genome
stability, systematic deletions to the 3’ end of the chromosomal SGS1 gene were
generated, such that truncations of the C-terminus of Sgs1, ranging from 20 to 1428
amino acids, were expressed as fusions to a myc epitope. Truncations of up to 80
amino acids were constructed to not affect any known functional domain of Sgs1 while
ΔC100 and ΔC200 deletions partially or completely, respectively, removed the HRDC
domain and ΔC300 and ΔC400 deletions partially or completely removed the RQC
domain. The largest deletions (ΔC700, ΔC800, ΔC900, ΔC1000 and ΔC1100) eliminate
the entire helicase domain, including the Walker A motif (803–812 aa), with the ΔC800ΔC1100 deletions also affecting the part of the N-terminal half of Sgs1 that contains
protein interaction sites (e.g., Rad16, residues 421–792; Top2, residues 432–724; Srs2,
residues 422–722) and two acid regions (AR1, residues 321–447; AR2, residues 502–
648), whereas ΔC500 and ΔC600 deletions partially remove the helicase domain while
leaving the Walker A motif intact (Figure 1A). All truncation alleles were stably
expressed from the chromosomal SGS1 locus under control of the native SGS1
promoter (Figure A.1B). C-terminal fusion to the myc-epitope did not adversely affect
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Sgs1 function, as indicated by equal sensitivity to HU and MMS of strains expressing
tagged and untagged Sgs1 (wildtype) (Figure 2A). The largest deletion, leaving intact
only the 19 N-terminal amino acids of Sgs1 (sgs1ΔC1428), was as sensitive to HU and
MMS as a complete SGS1 deletion (sgs1Δ), thus behaving like a null allele (Figure
A.2A). Loss of up to 200 C-terminal amino acids did not increase sensitivity to HU or
MMS, whereas loss of 300 or more amino acids led to sensitivity similar to that of the
sgs1ΔC1428 and sgs1Δ mutants (Figure A.2A). The construction of additional 20amino-acid truncations extended the C-terminal region that is dispensable for HU/MMS
resistance to 240 amino acids (Figure A.2B).
It was previously shown that cells lacking the DNA helicase Srs2 (srs2Δ) depend
on functional Sgs1 for their viability [61]. To assess the ability of sgs1 truncation alleles
to support growth of the srs2Δ mutant, we constructed diploid strains heterozygous for
the srs2Δ deletion and heterozygous for the sgs1ΔC200, sgs1ΔC260 or sgs1ΔC300
alleles. The meiotic products of the sporulated diploids were spread on nonselective,
rich media (YPD), allowing all spores to grow (Figure A.2C). Diploids heterozygous for
the srs2Δ deletion and the sgs1ΔC200 truncation yielded spores that grew into colonies
of the same size, suggesting that the C-terminal 200 amino acid residues of Sgs1,
which harbor the HRDC domain and an interaction site with the homologous
recombination factor Rad51, are not required for the viability of the srs2Δ mutant. In
contrast, sporulation of diploids heterozygous for the srs2Δ deletion and sgs1ΔC260 or
sgs1ΔC300 alleles yielded mixtures of normal-sized and small colonies. Genotyping
revealed that the small colonies were srs2Δ sgs1ΔC260 or srs2Δsgs1ΔC300 mutants
whereas the normal-sized colonies corresponded to wildtype spores or single mutants.
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Thus, Sgs1 that lacks 260 or more C-terminal residues and therefore does not contain a
complete RQC domain cannot support normal growth of cells lacking Srs2. When we
tested the effect of the C-terminal deletions on the accumulation of GCRs, we found that
the C-terminal 240 amino acids were dispensable for maintaining genome integrity,
whereas deleting as little as an additional 20 amino acids (sgs1ΔC260) caused the
GCR rate to increase to that exhibited by the null mutant without a discernable
intermediate phenotype (Table A.1). Combining the sgs1ΔC300 truncation allele with a
deletion of the DNA-damage checkpoint sensor MEC3 led to a synergistic GCR rate
increase, while, as expected, combining the sgs1ΔC200 allele with a mec3Δ mutation
did not. Thus, these findings show that the HRDC domain and the previously reported
C-terminal interaction with Rad51 are not required for Sgs1’s role in preventing the
accumulation of GCRs and supporting normal growth of the srs2Δ mutant, whereas the
integrity of the RQC domain, which has been suggested to span amino acids 1075 to
1207 based on the alignment of three-dimensional structures 62, is essential.

Bloom’s Syndrome Associated RQC Domain Mutations Cause Loss of Sgs1
Function in vivo
Of the 32 exonic base substitutions that are causative of Bloom’s syndrome,
thirteen are missense mutations [9; 13; 63; 64], with six of these mutations affecting
conserved residues that have been shown in vitro to participate in zinc binding and Gtetrad DNA binding activity (Figure A.3A). Studies, however, have been limited to
biochemical and biophysical analyses of mutant proteins and were hampered by the
inability to purify some mutant BLM proteins [16; 17; 65]. Since the cysteine residues
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are highly conserved between RecQ-like helicases, including Sgs1, we replaced the
corresponding cysteine residue in Sgs1 with the BS-associated mutation (sgs1C1047F). Unlike BLM with mutations in any of the three conserved cysteine residues
C1036, C1063 or C1066, which degraded upon purification and could therefore not be
characterized [65], the sgs1-C1047F mutant allele was stably expressed in vivo from
the native SGS1 locus (Figure A.3B). The sgs1-C1047F mutant showed increased HU
and MMS sensitivity, which, however, did not reach the level of the sgs1Δ allele, and
exhibited levels of GCR accumulation comparable to the sgs1Δ mutant, demonstrating
that the C1047F mutation severely impairs Sgs1 function (Figure A.3C, Table A.1). In
addition to conserved cysteine residues and immediately adjoining arginine (R1037)
and aspartic acid (D1064) residues, ClustalW2 alignments showed F1056 to be the only
other fully conserved amino acid residue in the zinc-binding domain of Sgs1 (Figure
3A). Although the corresponding residue in BLM (F1045) is not associated with a BS
mutation, the BLMF1045A mutation has been shown to cause a severe helicase defect
and ssDNA binding deficiency in vitro [65]. When we introduced the corresponding
mutation into Sgs1 (F1056A), however, the mutant was no more sensitive to HU and
MMS than wildtype cells (Figure A.3C), but instead appeared fully functional with a
wildtype GCR rate (Table A.1).
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Expression of human BLM cDNA from the endogenous SGS1 promoter
does not complement Δsgs1 defects
RecQ-like DNA helicases are evolutionarily conserved from bacteria to humans.
Since cells from BS patients share defects seen in sgs1Δ cells, including increased
sensitivity to DNA-damaging agents, increased levels of aberrant genetic exchange and
reduced life-span, it has been suggested that RecQ-like DNA helicases from different
phyla or even kingdoms might complement each other, thus allowing the development
of simple model organisms for the functional and mutational characterization of diseaseassociated human RecQ-like helicases, such as BLM and WRN [66]. Thus, to assess
the ability of BLM to suppress genome instability in the sgs1Δ mutant, BLM cDNA was
inserted in-frame with the start codon of SGS1 at its chromosomal locus (PSGS1BLM).
We reasoned that insertion at the wildtype SGS1 locus would promote cell-cycledependent regulation of BLM expression and expression levels similar to those
previously shown for Sgs1 [67]. Stable expression of BLM was confirmed by western
blot analysis, using a yeast strain expressing myc-tagged BLM (Figure A.4A); however,
all subsequent experiments were carried out with untagged BLM. Expression of a single
copy of BLM (PSGS1 BLM ) did not lead to a statistically significant difference in the
GCR rate compared to the sgs1Δ mutant (Table A.1, Table A.2), or alleviate HU
sensitivity (Figure A.4B), demonstrating that BLM can be successfully expressed in
yeast under control of the native SGS1 promoter without detrimental effects on cell
growth, but is unable to complement the tested sgs1Δ defects to any extent.
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Overexpression of BLM leads to increased sensitivity to DNA damaging
agents and rapid accumulation of GCRs
Since a single copy of BLM (PSGS1BLM) did not complement Δsgs1 defects, we
examined the effect of increasing BLM expression levels on sgs1Δ mutant phenotypes.
For this purpose, the native SGS1 promoter was replaced with a GAL1 promoter and
galactose-dependent expression of BLM was verified by fusing BLM to a myc-epitope
tag (Figure A.4A). Overexpression of BLM did not compensate for the lack of Sgs1
when cells were exposed to HU, but instead led to a further increase in sensitivity to HU
compared to the sgs1ΔC1428 cells or cells expressing BLM under the SGS1 promoter
(Figure A.4B). We found that maximum induction of BLM expression led to a 1665-fold
increase in the GCR rate compared to wildtype and a 34-fold increase compared to the
sgs1Δ mutant assayed under the same conditions (Table A.2). In contrast,
overexpression of Sgs1 from the GAL1 promoter did not lead to GCR accumulation
(Table A.2). The GCR rate increase upon BLM overexpression was dependent on
induction levels, with the GCR rate gradually decreasing to that of the sgs1Δ mutant as
the galactose concentration in the media decreased (Table A.2). Thus, sgs1Δ defects
cannot be complemented by any level of BLM expression; in fact, increasing BLM
expression levels induce higher sensitivity to DNA damaging agents and significantly
higher genome instability compared to the sgs1Δ mutant.
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N-terminus of Sgs1 suppresses detrimental effects of BLM overexpression
Since Sgs1 is important for the suppression of illegitimate recombination
between identical sequences, such as those found in related genes, on homologous
chromosomes and sister chromatids, we tested HU sensitivity of diploid strains
expressing truncated sgs1 alleles in the presence or absence of the SGS1 wildtype
allele (Figure A.5). HU sensitivity was fully suppressed for all alleles if a single copy of
wildtype SGS1 was expressed from the other allele (Figure A.5A), demonstrating that
the sgs1 truncation alleles did not have a dominant effect. As in haploid cells, only the
sgs1ΔC200 allele complemented HU sensitivity of the sgs1Δ diploid completely (Figure
A.5B); however, cells expressing the sgs1ΔC300 to sgs1ΔC900 alleles were less
sensitive than diploids that expressed larger truncations or the sgs1ΔC1428 null allele
(Figure A.5B). This ability of sgs1Δ300 to sgs1ΔC900 truncation alleles to at least
partially suppress HU sensitivity indicates that there may be N-terminal segments in
Sgs1 that contribute to HU resistance.
Diploids expressing BLM from native SGS1 promoters on both alleles
were as sensitive to HU as diploids not expressing Sgs1, whereas diploids
overexpressing BLM from one allele or from both alleles were severely HU-sensitive,
with the highest expression level lacking any growth on 100 mM HU (Figure A.5C),
reflecting the severe HU sensitivity of haploid cells expressing the PGALBLM allele
(Figure A.4B). Diploids overexpressing BLM also appeared to grow more slowly than
any other diploid tested here (Figure A.5C). Remarkably, expression of a single copy of
SGS1 from its endogenous promoter (SGS1/PGALBLM) completely eliminated the
severe HU sensitivity conferred by overexpression of BLM. To determine if full-length
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Sgs1 was required for this suppression, we crossed the haploid strain overexpressing
BLM with haploids expressing various Sgs1 truncations. We found that a single copy of
the sgs1ΔC200 allele was as sufficient as wildtype Sgs1 in suppressing HU sensitivity
and slow growth of the BLM overexpressing strain, and as few as the N-terminal 547
amino acids remaining in the sgs1ΔC900 allele were sufficient for significant
suppression of HU sensitivity and slow growth caused by BLM overexpression (Figure
A.5C). These findings suggest that none of the known enzymatic activities or functional
and conserved domains are required for suppressing the HU sensitivity of the BLM
overexpressing diploids, but that the N-terminal 547 amino acids are sufficient for
suppressing the detrimental effects of BLM overexpression in a diploid. That the
sgs1ΔC1000 and sgs1ΔC1100 alleles were clearly less effective at suppressing HU
sensitivity shows that the N-terminal 447 amino acids, which contain the Top3
interaction site, are necessary but not sufficient for complementation.

Design of a functional Sgs1-BLM chimera
Sgs1 and BLM share about 21% of their amino acid residues in a pair-wise
alignment of the full-length proteins (ClustalW2), with most of the identical residues in
the helicase domain. In fact, the N-terminal segment of Sgs1 expressed by the
sgs1ΔC800 allele, which is able to suppress the HU sensitivity of BLM-overexpressing
diploids, shares only 11% with the corresponding N-terminal segment of BLM. Devoid of
conserved domains and known enzymatic activities, the N-terminus of Sgs1 has been
shown to be required for physical interactions with Top3, Top2, Srs2 and Rad16 [6; 2630]. Using IUPred, an algorithm for the prediction of intrinsically disordered proteins, we
197

found that the N-terminal 650 residues contain a similar distribution of ordered and
intrinsically disordered segments (Figure A.6A, B). In disorder prediction algorithms,
such as IUPred [68; 69], a score of > 0.5 predicts a disordered amino acid residue and a
score of < 0.5 predicts an ordered residue, with 30 consecutive disordered amino acids
commonly being used as a lower limit for detecting disorder in whole proteome
searches [68-71]. The helicase domains of Sgs1 and BLM coincide with the predicted
ordered regions in both proteins, starting at around residue 648, and are surrounded by
a long N-terminal and a short C-terminal segment, which contain mostly disordered
residues. In fact, using the IUPred output scores, 83% of the 648 N-terminal residues of
Sgs1 (538/648) are disordered, with 70% of all 648 residues being located in segments
of more than 30 consecutive disordered residues, whereas only 16% of the C-terminal
800 residues of Sgs1 are predicted to be disordered, with only a single disordered
segment that is longer than 30 residues (residues 1396–1447).
Based on the IUPred prediction, BLM can also be divided into a disordered Nterminus and an ordered C-terminus (Figure A.6A, B). For BLM, 52% of the N-terminal
648 residues are predicted to be disordered but only 15% of these residues are found in
stretches of more than 30 disordered residues. The difference in the pattern of disorder
predicted for the N-terminal segments of Sgs1 and BLM led us to hypothesize that this
region may be involved in conferring species-specificity to BLM and Sgs1 function and,
thus, prevent BLM from functioning in yeast. This hypothesis is supported by the fact
that the N-terminus of Sgs1 is sufficient for complementation of the HU sensitivity
induced by overexpression of BLM. To test this hypothesis, we constructed a yeasthuman chimera in which the N-terminal 647 residues of BLM were replaced by the N198

terminal 647 residues of Sgs1 (sgs1ΔC800- blmΔN647) (Figure A.6C). To express this
chimera from the native SGS1 promoter we replaced nucleotides 1941 to 4344 of the
endogenous SGS1 gene with nucleotides 1941 to 4254 of BLM cDNA (Figure A.6E).
Remarkably, the chimera was nearly as effective as wildtype SGS1 in conferring
resistance to HU, whereas the N-terminal segment of Sgs1 by itself was ineffective
(Figure A.6D). Moreover, when we combined the chimeric allele with a mec3Δ mutation,
GCRs accumulated at a significantly lower rate than in the mec3Δ mutant carrying the
GCR-deficient sgs1ΔC300 or sgs1ΔC800 alleles, albeit not at the low rate of the mec3Δ
mutant carrying the GCR-proficient sgs1ΔC200 allele, signifying partial functionality of
the chimerical protein in the suppression of chromosomal rearrangements (Table A.1).
Finally, besides Srs2, the sgs1Δ mutant also requires the DNA helicase Rrm3 for
viability. Synthetic lethality between sgs1Δ and rrm3Δ mutations is suppressed by
disrupting HR factors such as Rad51 and Rad55, suggesting that the lethality is due
accumulation of aberrant HR intermediates [72-74]. To assess if the Sgs1-BLM chimera
was capable of preventing the accumulation of lethal levels of aberrant recombination
intermediates we constructed a diploid heterozygous for the rrm3Δ mutation and
heterozygous for the sgs1ΔC800-blmΔN647 allele, expressing the Sgs1-BLM chimera.
Spreading of spores from this diploid on YPD, which allows all spores to grow, showed
that the rrm3Δ mutant expressing the chimera grows normally with the diameter of
double mutant colonies measuring approximately 90% of that of the single mutants
(Figure A.6F). These findings indicate that the Sgs1-BLM chimera is functional and,
while not capable of fully suppressing chromosomal rearrangements, prevents the
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accumulation of lethal levels of aberrant recombination intermediates when Rrm3
helicase is absent.

Discussion
Yeast cells that lack Sgs1 exhibit upregulated and aberrant recombination in
mitosis, increased sensitivity to DNA damaging agents, accumulation of GCRs,
synthetic lethality with mutations in other DNA metabolic genes, such as the SRS2 and
RRM3 helicase genes, and meiotic defects that lead to poor spore viability [8; 30; 61;
67; 73; 75-79]. Sgs1 contains several conserved domains (DEAD-helicase, RQC,
HRDC, AR1 and AR2) and protein interaction sites (Top2, Top3, Srs2, Rad16, Rad51,
Mlh1) have been identified by two-hybrid screens [27; 29; 30; 46; 80]. How the integrity
of these conserved motifs and protein-protein interaction sites affects the role of Sgs1 in
suppression of aberrant genome rearrangements has not been determined. The
requirement of some domains and/or protein interaction sites, but not others, may shed
light on the poorly understood mechanism(s) by which Sgs1 contributes to the
maintenance of genome integrity in yeast. Here, we find that the C-terminal 240 aminoacid segment, which contains Rad51 and Mlh1 interaction sites as well as the
conserved HRDC domain thought to be involved in DNA binding and in recognition and
processing of double Holliday junctions [20; 23], is dispensable for Sgs1’s role in
suppressing GCRs. The integrity of the RQC domain, however, is essential for GCR
suppression. That zinc-binding is crucial for Sgs1 activity, and loss of function of the
Cterminal truncation allele was not due to disruption of protein structure/function
because of such a large deletion, was further confirmed by the finding that the point
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mutation of a conserved zinc-coordinating cysteine, which has also been observed in
BS patients 64, led to loss of Sgs1’s ability to suppress HU sensitivity and GCR
accumulation. This loss of function was not due to degradation of the mutant protein as
had been previously observed for some cysteine mutants of BLM during attempts at
overexpression and purification from E. coli. However, we cannot exclude the possibility
that the loss of function resulted from intracellular mislocalization of the mutant protein.
Previously, modeling of the zinc-binding domain of BLM and instability of purified mutant
proteins had indicated that hydrogen bonds between three conserved residues, Y1029
(Y1040 in Sgs1), R1037 (R1048 in Sgs1) and D1064 (D1070 in Sgs1), are required for
folding of the zinc-binding domain and overall protein stability 17. Although F1056 of
Sgs1 does not appear to be involved in this zinc-domain stabilization and the Sgs1F1056A mutant protein appears stable in this study, F1056 is the only other fully
conserved residue in the zinc-binding domain of RecQ-like helicases, suggesting
functional significance. However, introduction of the F1056A mutation had no effect on
Sgs1 function in vivo when we assessed HU sensitivity, consistent with a previous study
81, or GCR accumulation. That in a previous in vitro study 65 the corresponding BLM
mutation (F1045A) had severely impaired helicase and ssDNA binding activities could
either be due to differences in the importance of this residue for enzymatic activity of
BLM and Sgs1 or, more likely, be due to the fact that only the helicase-core segment of
BLM, lacking 769 residues of N- and C-termini, was purified. The in vitro function of this
isolated domain could be more strongly affected by a mutation than the in vivo function
of the full-length Sgs1 mutant protein assessed here. Although nearly half of all BLM
alleles that are associated with single-amino-acid changes (7 of 17 alleles) in BS
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patients are located in the RQC domain [9; 13; 63; 64] none affect F1045, consistent
with our finding that mutation of this conserved residue may not be associated with
significant loss of function in vivo.
We find that Sgs1 retains partial functionality even when it lacks the HRDC, RQC
and DEAH helicase domains, as demonstrated by the greater HU resistance of diploids
that only express the N-terminal 547 amino acid residues compared to those alleles
expressing fewer than 447 residues of Sgs1. One explanation for this finding could be
that protein-protein interactions conferred by the N-terminus could contribute to the
structural stability of multi-protein complexes, such as the Sgs1/Top3/Rmi1 31 complex
or, even more relevant to HU resistance, DNA-damage-specific complexes with Srs2
and Mre11 [29]. In these multi-protein complexes, enzymatic activity of Sgs1 may be
dispensable. Indeed, sgs1 alleles with point mutations in the helicase domain have
been shown to be capable of performing some functions of the wildtype allele, including
those carried out during meiosis and checkpoint activation [79; 82].
In contrast to two previous reports [66; 83], which both used the same yeast
strain that constitutively expressed BLM from a GAPDH promoter and showed partial
suppression of some sgs1Δ defects, including HU sensitivity, we found that neither BLM
expression under control of the natural SGS1 promoter nor varying levels of BLM
expression under control of a galactose-inducible promoter had any positive effect on
the sgs1Δ mutant. That a single copy of BLM, when expressed under control of the
native SGS1 promoter, cannot alleviate sgs1Δ defects initially suggested to us that BLM
had no functionality in yeast. In fact, the strong increase in genome instability,
accompanied

by severe

HU

sensitivity
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and

some

growth

retardation

upon

overexpression of BLM, indicated that BLM expression is detrimental to yeast cells. The
absence of any GCR accumulation upon Sgs1 overexpression suggests that increased
accumulation of GCRs in BLM overexpressing cells is not simply due to increased
unwinding. Rather, we propose that BLM may possess helicase activity in yeast, leading
to increased unwinding upon overexpression, but fails to elicit proper downstream
responses, for example due to lack of proper N-terminal protein-protein interactions,
which ultimately leads to an overabundance of aberrantly repaired lesions. That
endogenous levels of N-terminal segments of Sgs1 as short as 547 residues
suppressed the slow growth phenotype and the severe HU sensitivity of BLMoverexpressing cells argues in favor of a functional relationship between Sgs1 and
BLM. For example, co-expression of Sgs1 and BLM could alleviate HU sensitivity in
BLM overexpressing cells by acting as a bridge between BLM and Top3 (and/or other
protein complexes interacting with the Sgs1 N-terminus), thereby linking enzymatic
activity to appropriate upstream and downstream events. Remarkably, even relatively
short N-terminal fragments of Sgs1 are sufficient for the suppression of the increased
HU sensitivity of BLM-overexpressing cells, further supporting the importance of the
Sgs1 N-terminus with its role in mediating interaction with other DNA metabolic factors.
HU resistance comparable to wildtype cells and significantly reduced GCR
accumulation of cells expressing a chimeric fusion of the Sgs1 N-terminus, which is
devoid of enzymatic function and dispensable for helicase activity and ssDNA binding in
vitro, and the BLM C-terminus, which contains helicase/RQC and HRDC domains, is
consistent with helicase activity of BLM in yeast and a biologically significant, functional
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interaction between BLM and Sgs1. That not only fusion of the Sgs1 and BLM
segments provides HU resistance, but also co-expression of BLM and Sgs1
polypeptides from separate alleles in the same cell may indicate that the N-terminus of
Sgs1 can physically interact with BLM. Our findings also suggest that it is the inability of
the N-terminus of BLM to interact with or be modified by yeast proteins that leads to the
inability of BLM to function in yeast. A previous report that BLM expression in yeast
alleviates several sgs1Δ phenotypes, including partial suppression of HU sensitivity
[66;83], could be explained by the fact that in the earlier study BLM was expressed from
a GAPDH promoter, whereas here it was expressed either from the native SGS1
promoter or from a galactose-inducible promoter. However, in light of the findings
presented here, there could also be an alternative explanation. Since the GAPDHpromoter-BLM construct appears to have been inserted into the middle of the wildtype
SGS1 gene, an N-terminal segment of Sgs1 could have been expressed from the native
SGS1 promoter in addition to BLM being expressed from the GAPDH promoter. As
shown here for haploids expressing the chimera and for diploids coexpressing the Nterminus of Sgs1 and full length BLM, such co-expression of an Sgs1-N-terminal
segment from the native SGS1 promoter and BLM from the GAPDH promoter could be
the an explanation for the reported increase in HU resistance of BLM-expressing cells
compared to sgs1Δ cells.
Of the five human RecQ-like DNA helicases, BLM is considered to be most
closely related to Sgs1. Even though we show here that BLM cannot suppress any
defects of the sgs1Δ mutant, the functional chimera does provide evidence for a
functional relationship between the two RecQ-like helicases and provides a model
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system for the further characterization of BLM functional domains in yeast. In fact, all
BS-associated missense mutations and numerous polymorphisms are located within the
770-residue C-terminal fragment of BLM that is part of the chimera, so that they are now
accessible to further functional and mutational characterization in yeast. The in vivo
functionality of the Sgs1-BLM chimera also demonstrates the remarkable utility of
protein disorder prediction as a tool for the construction of functional mutants. It will be
interesting to see whether domains of any of the other human RecQ-like helicases will,
like BLM, be able to form functional chimeras with the Sgs1 N-terminus.
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Figure A.1. C-terminal truncations of Sgs1 used in this study. (A) Full-length Sgs1
contains a DEAH helicase domain, an RQC domain and an HRDC domain in its Cterminal half and acidic regions AR1 and AR2 in its N-terminal half; interaction sites with
Top3, Top2, Srs2, Rad51 and Rad16 are indicated. C-terminal truncations ranging in
size from 200 residues to 1428 residues were constructed by fusion to a myc-epitope
tag. All truncations were introduced at the endogenous SGS1 locus on chromosome
VIII. (B) Expression of wildtype Sgs1 and truncation alleles from the endogenous SGS1
promoter (PSGS1) was confirmed by western blotting, using a myc-antibody. Molecular
weights (MW) are indicated on the left.
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Figure A.2. Sensitivity of cells expressing Sgs1 truncation alleles to the DNA
damaging agents HU and MMS. Ten-fold dilutions of exponentially growing cultures
(OD600 = 0.5) were spotted on YPD for viable cell count and on YPD containing
100mM HU or 0.05% MMS, followed by incubation at 30° C. (A) Haploid cells
expressing sgs1 alleles lacking 300 or more residues from the C-terminus are as
sensitive to HU and MMS as the null allele. (B). Additional incremental 20-amino-acid
deletions reveal that cells expressing sgs1 alleles lacking up to 240 residues are as
resistant to HU and MMS as wildtype cells whereas those lacking 260 or more residues
are as sensitive as the sgs1Δ mutant. (C) Spores from diploids heterozygous for an
srs2Δ deletion and heterozygous either for the sgs1-ΔC200, sgs1Δ-C260 or sgs1ΔC300 were spread on YPD to allow for growth of spores of all possible genotypes.
Similar sized colonies obtained from the spores of the diploid heterozygous for
sgs1ΔC200 and srs2Δ mutations (left) indicate that the sgs1ΔC200 srs2Δ mutant grows
as well as the single mutants, suggesting that deletion of the C-terminal 200 amino acid
residues does not negatively affect growth of the srs2Δ mutant. In contrast, spores from
diploids heterozygous for the srs2Δ mutation and the sgs1ΔC260 allele (middle) or the
sgs1ΔC300 allele (right), grew into a mixture of normal-sized colonies (corresponding to
single mutants and wildtype) and small-sized colonies (corresponding to srs2Δ
sgs1ΔC260 or srs2Δ sgs1ΔC300 mutants as determined by genotyping), demonstrating
that an intact RQC domain in Sgs1 is required for the viability of the srs2Δ mutant.
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Figure A.3. Effect of zinc-binding domain mutations on Sgs1 function in vivo. (A)
Zinc-binding domain is conserved from bacterial to human RecQ-like DNA helicases.
Protein sequences were aligned with ClustalW2 84. The alignment of RecQL1 was
manually adjusted. Amino acid residues identical in all sequences are highlighted in
gray and indicated by '*' below the alignment, conserved substitutions are indicated by
':' below the alignment, and cysteine residues thought to be involved in zinc-binding are
shown in red. At least six different missense mutations in the zinc-binding domain are
associated with Bloom’s syndrome. (B) C1047F and F1056A mutations were introduced
into Sgs1 and expression was confirmed by western blot using antibody against the Cterminal myc-epitope. Molecular weights (MW) are indicated in kDa to the left. (C)
Mutation of the highly conserved F1056 does not impair Sgs1 function whereas the
C1047F mutation leads to an increase in sensitivity to HU and MMS, but not to the level
seen in the sgs1Δ mutant.
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Figure A.4. BLM expression does not suppress sgs1Δ defects and BLM
overexpression is detrimental to yeast cells. (A) Expression of myc-epitope tagged
Sgs1 (lane 1) and BLM (lane 2) from the native chromosomal SGS1 locus or galactoseinducible overexpression of myc-epitope tagged Sgs1 (lane 4) and BLM (lane 6) in
yeast cells grown in YP supplemented with 1% sucrose and 1% galactose (to induce
expression, lanes 4 and 6) or without galactose (lanes 3 and 5). Both BLM and Sgs1
show signs of degradation upon overexpression (lanes 4 and 6) whereas expression
from the native SGS1 promoter is stable (lanes 1 and 2). Molecular weights (MW) are
indicated in kDa on the left. (B) Cells expressing BLM from the SGS1 promoter on
chromosome VIII are as sensitive to HU as cells lacking Sgs1 (Δsgs1). Replacement of
the natural SGS1 promoter with a galactose-inducible GAL1 promoter induces BLM
overexpression and leads to increased HU sensitivity. Ten-fold dilutions of cells were
spotted on media containing 1% sucrose and 1% galactose (to induce BLM
overexpression) with and without 100 mM HU.
214

Figure A.5. HU sensitivity of diploid cells expressing BLM and mutant alleles of
SGS1. (A) Ten-fold dilutions of exponentially growing diploids expressing truncation
alleles of SGS1 in the presence of a wildtype allele were spotted on YPD media with
and without 100 mM HU. (B) Ten-fold dilutions of exponentially growing diploids
expressing truncation alleles of SGS1 in the absence of a wildtype allele were spotted
on YPD media with and without 100 mM HU. (C) Ten-fold dilutions of exponentially
growing diploids overexpressing BLM from a GAL1 promoter inserted at the native
SGS1 locus and expressing truncation alleles of SGS1 under control of the native SGS1
promoter on the other allele were spotted on media containing 1% galactose (to induce
gene expression) and 1% sucrose with or without 100 mM HU.
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Figure A.6. Construction of a functional chimerical protein composed of the Nterminus of Sgs1 and the C-terminus of BLM. (A – B) Protein disorder prediction of
Sgs1 (red) and BLM (black) using the IUPred algorithm. Values above 0.5 indicate a
disordered residue whereas values below 0.5 indicate ordered residues; amino acid
residue numbers (1–1447) are indicated on the abscissa. Black lines above the graph
show a simplified order and disorder distribution along the length of the protein with
values above 0.5 being assigned a “1” and values below 0.5 being assigned a “0”. The
vertical red line indicates the site in Sgs1, BLM and the chimera where the disordered
N-terminal segment transitions into the ordered helicase domain at residue 647/648.
This site was chosen as the fusion site for the chimera. The approximate location of
Sgs1 domains is indicated above panel A. (C) Disorder prediction for the Sgs1-BLM
chimera in which the N-terminal 647 residues of BLM (black) were replaced with the Nterminal 647 residues of Sgs1 (red). (D) Ten-fold dilutions of exponentially growing
haploids were spotted on YPD with or without 100 mM HU. (E) The C-terminus of the
Sgs1-BLM chimera was fused to a myc-epitope tag and expression was confirmed by
western blotting. Molecular weight marker bands (kD) are indicated on the left (F) A
diploid heterozygous for the rrm3Δ mutation and the sgs1ΔC800-blmΔN647 allele
expressing the chimera was sporulated and random spores were plated on YPD to
allow all spores to grow. An open circle indicates the haploid double mutant, and the
open square and pentagon indicate haploid sgs1ΔC800-blmΔN647 and rrm3Δ single
mutants, respectively.
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Table A.1.
Accumulation of GCRs in cells expressing mutant alleles of SGS1
GCR rate (Canr 5-FOAr × 10− 95% CIb (Canr 5-FOAr ×
10
Relevant Genotype
)
10− 10)
Wild type
1.1
< 1–6.2
sgs1Δ
251
80–310
sgs1ΔC200
7
< 6–23
sgs1ΔC220
31
5–41
sgs1ΔC240
10
< 6–27
sgs1ΔC260
159
85–362
sgs1ΔC280
244
166–387
sgs1ΔC300
145
76–204
sgs1ΔC400
106
60–180
sgs1ΔC500
102
53–252
sgs1ΔC600
152
26–283
sgs1ΔC700
189
49–271
sgs1ΔC800
133
71–225
sgs1ΔC1428
206
97–273
sgs1-C1047F
64
35–131
sgs1-F1056A
< 16
< 10–26
mec3Δsgs1ΔC200
11
< 7–22
mec3Δsgs1ΔC300
1003
691–1500
mec3Δsgs1ΔC800
758
645–895
mec3Δsgs1ΔC800blmΔN647 c
361
330–419
i
All sgs1 truncations (sgs1ΔC) are C-terminally fused to a myc-epitope tag.
ii
95% confidence intervals (CI) were calculated according to Nair [59].
c
The sgs1ΔC800-blmΔN647 allele expresses a chimeric protein that consists of the Nterminal 647 residues of Sgs1 and the C-terminal 770 residues of human BLM.
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Table A.2.
Effect of BLM expression on GCR accumulation in the sgs1Δ
mutant
Galactose
GCR rate (Canr 95% CIb (Canr
concentration in
5-FOAr × 10−
5-FOAr × 10−
Relevant genotype
media (%)
10)
10)
Wild type
0
1.1
< 1–6.2
PSGS1BLM
0
70
56–151
PGALBLM
0
61
30–153
PGALBLM
0.1
335
233–576
PGALBLM
0.5
382
170–777
PGALBLM
2
1832
1090–2910
PGALSGS1
2
< 11
< 9–12
sgs1Δ
2
54
23–104
1
Human BLM cDNA was inserted at the endogenous SGS1 locus, fused to the native
SGS1 promoter (PSGS1) or fused to a galactose-inducible promoter (PGAL). In
PGALSGS1, the native SGS1 promoter region was disrupted by fusing the SGS1 ORF
to a galactose-inducible promoter. If strains expressing BLM or SGS1 genes from the
galactose-inducible GAL1 promoter were grown in less than 2% galactose (to lower
protein expression levels) media was supplemented with sucrose to reach a total sugar
concentration of 2%.
2
95% confidence intervals (CI) were calculated according to Nair [59].
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TABLE A.3: Yeast strains used in this study
Strain

Genotype

KHSY802

MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3

KHSY1338 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1::HIS3
KHSY1705 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::ura3::TRP1, sgs1::BLM.HIS3
KHSY2341 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, mec3::kanMX6, sgs1ΔC200.MYC.HIS3
KHSY2347 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, mec3::kanMX6, sgs1ΔC300.MYC.HIS3
KHSY2599 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3
KHSY2602 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::ura3::TRP1/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1::kanMX6
KHSY2726 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1C200.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY2828 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1C200.MYC.HIS3
KHSY2837 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1C300.MYC.HIS3
KHSY2880 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC300.MYC.HIS3
KHSY2883 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC400.MYC.HIS3
KHSY2886 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC500.MYC.HIS3
KHSY2889 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC600.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY2892 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC700.MYC.HIS3
KHSY2895 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC800.MYC.HIS3
KHSY2898 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1428.MYC.HIS3
KHSY2928 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC400.MYC.HIS3
KHSY2931 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC500.MYC.HIS3
KHSY2934 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC600.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY2937 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC700.MYC.HIS3
KHSY2940 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC800.MYC.HIS3
KHSY2943 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC1428.MYC.HIS3
KHSY2970 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1.MYC.HIS3
KHSY2972 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC200.MYC.HIS3
KHSY2973 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC300.MYC.HIS3
KHSY2974 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC400.MYC.HIS3
KHSY2975 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC500.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY2976 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC600.MYC.HIS3
KHSY2977 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC700.MYC.HIS3
KHSY2978 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC800.MYC.HIS3
KHSY2979 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC1428.MYC.HIS3
KHSY3181 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1100.MYC.HIS3
KHSY3218 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, TRP1.PGAL1.SGS1
KHSY3332 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1::BLM.HIS3
KHSY3346 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::ura3::TRP1, BLM.MYC.kanMX6.HIS3
KHSY3350 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.HIS3
KHSY3353 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY3355 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC800-blmΔN647.HIS3
KHSY3363 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC800-blmΔN647.HIS3, Δmec3::kanMX6
KHSY3372 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, sgs1::BLM.HIS3/sgs1::BLM.HIS3
KHSY3409 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/SGS1.MYC.HIS3
KHSY3410 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC200.MYC.HIS3
KHSY3412 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC300.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY3414 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC400.MYC.HIS3
KHSY3416 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC500.MYC.HIS3
KHSY3417 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC600.MYC.HIS3
KHSY3419 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC700.MYC.HIS3
KHSY3420 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC800.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY3422 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC900.MYC.HIS3
KHSY3423 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1000.MYC.HIS3
KHSY3424 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1100.MYC.HIS3
KHSY3425 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/sgs1ΔC1428.MYC.HIS3
KHSY3426 ura3-52/ura3-52, leu2Δ/leu2Δ , trp1Δ63/ trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ys2ΔBgl, hom3-10/hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3,
kanMX6.PGAL1.BLM.HIS3/kanMX6.PGAL1.BLM.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY3429 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC1100.MYC.HIS3
KHSY3470 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC220.MYC.HIS3
KHSY3473 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC240.MYC.HIS3
KHSY3476 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC260.MYC.HIS3
KHSY3479 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC280.MYC.HIS3
KHSY3500 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC900.MYC.HIS3
KHSY3502 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC1000.MYC.HIS3
KHSY3504 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1ΔC1100.MYC.HIS3
KHSY3510 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, TRP1.PGAL1. SGS1.MYC.HIS3
KHSY3512 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1-C1047F.TRP1
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Table A.3: Yeast strains used in this study (Continued)
KHSY3516 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1-F1056A.TRP1
KHSY3517 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1-C1047F.MYC.HIS3
KHSY3520 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, sgs1-F1056A.MYC.HIS3
KHSY3523 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8, YEL069C::URA3, kanMX6.PGAL1.BLM.MYC.TRP1.HIS3
KHSY3528 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC1000.MYC.HIS3
KHSY3534 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::ura3::TRP1,
sgs1::kanMX6/sgs1ΔC900.MYC.HIS3
KHSY3536 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC1000.MYC.HIS3
KHSY3539 ura3-52/ura3-52, leu2Δ1/ leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200,
lys2ΔBgl/ lys2ΔBgl, hom3-10/ hom3-10, ade2Δ1/ade2Δ1, ade8/ade8,
YEL069C::URA3/YEL069C::URA3, SGS1/sgs1ΔC900.MYC.HIS3
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Table A.3: Yeast strains used in this study (Continued)
KHSY3543 MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2ΔBgl, hom3-10, ade2Δ1,
ade8. YEL069C::URA3, sgs1ΔC800-blmΔN647.MYC.TRP1
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APPENDIX B:
NMR DATA

Table B1: Peak assignments for Sgs1 N1-125 peptide
Residue
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Residue
M
V
T
K
P
S
H
N
L
R
R
E
H
K
W
L
K
E
T
A
T

22
23
24
25

L
Q
E
D

H

HN

CA

CB

8.21988
8.22853
8.33585
N/A
8.36899

122.3445 62.3294 32.91862
119.026 61.76092 69.8252
125.4552 54.21737 32.62978
N/A
63.02
32.21
115.9146 58.29224 63.82262

8.19468
8.28251

122.5807 55.48658 42.32477
122.1783 56.49396 30.52714

7.90041
8.06267

123.5679 55.17055 42.47335
121.7686 56.57215 32.96658

8.04
8.2848
8.042
8.20142
124.57117
8.329

114.57
62.1205 69.6257
126.2067 52.82452 19.27114
113.5352 62.00811 69.79695

8.335
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124.5712 55.31136 42.28904
121.3023 56.0418 29.3875
56.8542 30.5093
121.6091 54.5717 41.1865

Table B1: Peak assignments for Sgs1 N1-125 peptide (Continued)
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64

K
D
F
V
F
Q
A
I
Q
K
H
I
A
N
K
R
P
K
T
N
S
P
P
T
T
P
S
K
D
E
C
G
P
G
T
T
N
F
I

8.2065
8.26583
7.96111
7.83837
8.13081
8.10104
8.0602
7.95223
8.20301

121.5207
120.1133
120.5838
121.8131
122.8441
121.0846
124.3929
119.4848
122.9763

57.0863
54.91777
58.7914
63.23366
58.80898
56.29585
53.1189
61.86297
56.26645

32.7918
41.10337
39.41052
32.5935
39.36015
29.31666
18.90968
38.55723
29.1325

7.98315
8.26634

56.6091 30.5955
122.1882 61.41187 38.63476
127.0843 52.79229 19.19498

8.12
8.26615
N/A
8.47766
8.14235

121.49
56.2169
32.95
123.4053 54.00874
N/A
63.01
32.31
122.0044 56.45931 33.05701
115.244 61.56435 69.71656
52.83696 38.78605
56.50993 63.42659

8.16
N/A
8.44744
8.43197
8.2693
8.2659
8.33404
8.2578
N/A
8.51983
7.9646

118.78
N/A
116.8972
123.4124
120.9317
121.222
119.5746
110.8407
N/A
109.4864
113.204

8.0905
8.0588

120.8059
122.8569
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54.59
41.2
63.04
39.01
58.21897 63.95412
56.67553 32.972
54.6034 41.1861
56.6222 30.2675
58.50417 28.30785
44.69437
63.56
32.1
45.40379

53.1974
57.8361
61.0498

38.7329

Table B1: Peak assignments for Sgs1 N1-125 peptide (Continued)
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104

T
S
I
P
A
S
G
P
T
N
T
A
T
K
Q
H
E
V
M
Q
T
L
S
N
D
T
E
W
L
S
Y
T
A
T
S
N
Q
Y
A
D

8.13716
8.19
8.14958
N/A

118.0419 61.6789 69.62651
118.5
57.96791 64.03301
124.2996 58.65614 38.70634
N/A
63.17
32.11

8.22905
8.16959
N/A
8.28

114.6649 58.1819 64.03219
110.6062 44.67143
N/A
113.97
61.86
69.7

8.1234
8.26019
8.06419
8.26435

114.4951
126.4146 52.79309 19.33326
113.6282 62.13061 69.70393
123.6846 56.3553 32.92902

8.17

121.25

56.728
62.6101

30.5256
56.728

8.17685
8.25404
8.23658
8.41612
8.30018
8.03624
8.32668
8.01026
7.83456
7.95789
7.96941
7.92071
8.12105
8.01092

115.9563
124.6848
116.2874
120.698
120.5722
113.6258
123.086
120.9964
122.8286
115.3333
121.879
115.502
126.2384
112.2691

61.94339
55.16385
58.19368
53.35475
54.77021
62.31408
57.37228
57.7331
55.60242
58.62363
58.30853
61.87001
52.8683
61.84889

69.68748
42.39013
63.84549
38.95899
41.1655
69.52244
29.98405
29.16892
42.37008
63.59823
38.75819
69.80556
19.27598
69.65426

8.23843
8.22509
8.07296
7.93554
8.22067

117.7062 53.1433 38.91206
120.3727 56.30673 29.22771
120.253 57.5453 38.5643
124.7221 52.4258 19.67012
119.5048 54.25103 41.13511
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Table B1: Peak assignments for Sgs1 N1-125 peptide (Continued)
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125

V
P
M
V
D
I
P
A
S
T
S
V
V
S
N
P
R
T
P
N
G

7.90708
N/A
8.21988
8.02629
8.31981

121.1807
N/A
122.3445
120.714
123.9739

59.67993
62.5757
56.36728
61.93245
54.21426

32.80018

N/A
8.4098
8.30954
8.1277
8.1623
8.11231
8.17994
8.33011

N/A
124.753
114.9381
115.3548
117.4504
122.2318
124.1036
119.8839

63.09
52.59244
58.36703
61.7155
58.3601
62.34681
62.21606
58.13893

32.15
19.25044
63.77139
69.656
63.7295
32.73477
32.7663
63.73322

N/A
8.38416
8.08281
N/A
8.4193
7.84815

N/A
120.6465
116.708
N/A
118.3227
115.3577

63.27
32.14
56.16673 30.7691
59.55571 69.56049
63.66
32.11
53.33006 39.16951
46.22267
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32.91862
33.12821
41.31996

Table B2: Peak assignments for Sgs1 N1-80 peptide
Residue
Number

Residue

1

M

2

V

8.21

3

T

8.23151

119.0454 61.7235909

4

K

8.33908

125.4415 54.1603394 32.6217995

5

P

N/A

6

S

8.37255

7

H

8

N

9

L

8.19247

10

R

8.25

121.46

56.1738

30.5

11

R

8.27

122.21

56.26

30.68

12

E

13

H

14

K

15

W

8.01492

121.0278 57.1287804

16

L

7.89708

123.5431 55.1884117 42.4949112

17

K

8.05774

121.7429

56.566761

32.9739304

18

E

8.41845

121.5595

56.8657

30.219

19

T

8.03966

114.5798 61.9319115 69.7065277

20

A

8.28776

126.295

21

T

8.04672

113.706

22

L

8.20583

124.5754

23

Q

8.33352

121.3175 55.8962097

H

HN

122.31

N/A

CA

CB

55.3785

32.8186

62.28

32.87

63.0794182

69.80896

83.009697

115.8686 58.2680206 63.7881699

53.3577805 38.7228394
122.5594 55.4583092 42.2596207

32.7890816
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52.65

29.399929

19.2876396

61.9318314 69.7565918
55.31213

42.2676888
29.42

Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued)
24

E

8.43

121.98

56.63

30.45

25

D

8.34

121.64

26

K

8.20896

121.5487 57.0044098 32.8010292

27

D

8.26834

120.1106

28

F

7.96073

120.5829 58.7588997 39.3948593

29

V

7.8332

121.7531 63.1692696 32.5655403

30

F

8.13168

122.9027 58.7493401

39.359169

31

Q

8.0996

121.1583

29.3470402

32

A

8.06327

124.4081 53.1120911 18.0088692

33

I

7.94951

119.468

61.8188896 38.5292702

34

Q

8.21003

123.063

56.2424812 29.1556606

35

K

8.1676

121.789

36

H

37

I

7.96672

122.2637 61.3540916 38.6244011

38

A

8.26951

127.1183 52.7955513 19.1597309

39

N

8.2482

117.7394

53.2123

38.8374

40

K

8.1294

121.5962

56.1281

32.9709015

41

R

8.27519

123.4202 54.0261688

42

P

N/A

43

K

8.48149

122.0392 56.4200401 33.0219688

44

T

8.15418

115.3279 61.4978905 69.9117432

45

N

8.32

121.0177

53.08

38.94

46

S

8.24

117.72

56.57

63.14

47

P

N/A

N/A

48

P

N/A

N/A

54.5437508 41.1975098

54.9319

56.244709

56.89

41.0997314

32.9058

56.6144295 30.5993195

N/A
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62.956459

30.1029
32.2294

63.0189781 32.0674896

Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued)
49

T

8.23617

114.3647

50

T

8.16683

118.8081 59.6694298 69.7886505

51

P

N/A

52

S

8.44991

116.8439 58.2057915 63.8908081

53

K

8.43316

123.4211 56.6177711 32.9634895

54

D

8.27

120.98

54.6

41.2

55

E

8.27

121.13

56.64

30.33

56

C

8.34

119.62

57

G

8.26367

58

P

N/A

59

G

8.52181

109.4896 45.3688393

60

T

7.96866

113.2012 61.8311691 69.9331436

61

T

8.18

62

N

63

F

8.09147

64

I

8.064

65

T

8.13863

66

S

8.2

67

I

8.15659

68

P

N/A

69

A

8.41648

124.7613 52.5667801 19.2261391

70

S

8.2387

114.7023 58.1207008 64.0062027

71

G

8.1787

110.6324

72

P

N/A

N/A

73

T

8.29179

N/A

61.68

69.8253784

63.0924911 32.2289505

58.4585609 28.2946396

110.7965 43.9230804
N/A

115.94

63.5016594 32.0774689

61.9390488 69.6863632
53.1432495

120.8253 57.8064499 39.4358597
122.95

61.06

38.63

118.1441 61.7212601 69.6549683
118.54

58.05

63.7762413

124.3697 58.6881409 38.7136688
N/A

63.1273804 32.1472511

83.009697

63.99

63.2068481 32.2116318

114.0037 61.8410492 69.7118683
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Table B2: Peak assignments for Sgs1 N1-80 peptide (Continued)
74

N

8.43

121.4487

75

T

8.12689

114.5378 61.9174118 69.5784836

76

A

8.29

126.4438 52.7818794 19.3586197

77

T

8.07365

113.5912 61.8951683 69.7438736

78

K

8.25609

124.0322 56.1994705 33.1184387

79

Q

8.39793

122.5607 55.9633102

29.68297

80

H

7.9755

125.3586

30.5982
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53.1906

57.1394

38.7594

APPENDIX C:
PERMISSIONS

Figure C3: Permissions for text content from chapter 3.
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Figure C4: Permission for figures/tables in chapter 3.
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Figure C5: Permissions for content in appendix A.
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